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ABSTRACT:	
	
Cul3	 forms	E3	ubiquitin	 ligase	 complexes	 that	 regulate	a	variety	of	 cellular	
processes.		This	dissertation	describes	Cul3‘s	role	in	several	of	these	pathways	and	
provides	 new	 mechanistic	 details	 regarding	 the	 role	 of	 Cul3	 in	 eukaryotic	 cells.		
Cyclin	E	 is	 an	example	of	 a	protein	 that	 is	 regulated	 in	a	Cul3-dependent	manner.		
Cyclin	E	 is	 a	 cell	 cycle	 regulator	 that	 controls	 the	beginning	of	DNA	 replication	 in	
mammalian	 cells.			 Increased	 levels	 of	 cyclin	 E	 are	 found	 in	 some	 cancers,	 in	
addition,	proteolytic	removal	of	the	cyclin	E	N-terminus	occurs	in	some	cancers	and	
is	associated	with	tumorigenesis.	Cyclin	E	levels	are	tightly	regulated	and	controlled	
in	 part	 through	 ubiquitin-mediated	 degradation	 initiated	 by	 one	 of	 two	 E3	 ligase	
complexes,	 Cul1	 and	 Cul3.		 Cul1	mediated	 degradation	 of	 cyclin	 E	 is	 triggered	 by	
cyclin	E	phosphorylation,	however	the	mechanism	Cul3	uses	to	ubiquitinate	cyclin	E	
is	poorly	understood.		In	order	to	gain	a	better	understanding	of	how	Cul3	mediates	
cyclin	E	destruction	we	 identified	 the	degron	on	cyclin	E	 that	 is	 important	 in	Cul3	
dependent	degradation.		In	addition,	we	show	this	degron	is	lacking	in	LMW	cyclin	E	
(found	in	abundance	in	breast	cancer),	providing	a	novel	mechanism	for	how	these	
cyclin	 E	 modifications	 result	 in	 increased	 cyclin	 E	 levels	 by	 avoiding	 the	 Cul3	
degradation	pathway.	
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GLOSSARY	
	
Apical	membrane:		The	apical	membrane	is	found	in	the	nephron	where	it	contacts	
the	urine.		AQP2	is	localized	to	the	apical	membrane.	
AQP2:	 	Aquaporin	2	is	a	water	channel	protein	that	resides	in	the	apical	surface	of									
the	 collecting	 duct.	 	 AQP2	 helps	 to	 maintain	 blood	 pressure	 via	 the	 re-
absorption	of	water.		
ATP1Β1:	 	 A	 subunit	 of	 the	 Na+/K+	 ATPase.	 	 This	 subunit	 was	 identified	 as	 a	
possible	binding	partner	of	Klhl3	(Chapter	3).	
Basolateral	membrane:	 	The	basolateral	membrane	contacts	 the	 interstitial	 fluid	
in	the	nephron.	
BTB:		A	domain	found	in	proteins	that	function	as	Cul3	substrate	adaptors.		The	BTB	
domain	binds	to	Cul3.	
Cdk:	 	Cyclin-dependent	kinases	are	responsible	for	cell	cycle	progression.		A	Cdk	is	
active	when	it	is	bound	to	a	cyclin.	
Cdk2:	 	The	Cdk	binding	partner	of	 cyclin	E.	 	Cyclin	/Cdk2	complexes	regulate	 the	
G1/S	transition	and	release	from	quiescence.	
CKI:	 	 Cyclin-dependent	 kinase	 inhibitor.	 	 There	 are	 two	 families	 of	 CKIs:	 	 INK4,	
which	inhibit	Cdk4/6,	and	the	CIP/KIP	family,	which	includes	p21	and	p27.	
Cre:	 	 Cre	 recombinase	 is	 an	 enzyme	 that	 can	 be	 used	 in	 a	 conditional	 knockout	
mouse	model	 to	 recombine	 the	 DNA	 that	 is	 surrounded	 by	 two	 LoxP	 sites	
(floxed).	
	 xi	
Ctb73:	 	A	putative	 substrate	 adaptor	 for	 Cul3,	 Ctb73	 contains	 an	N-terminal	BTB	
domain,	a	central	BACK	domain,	and	a	C-terminal	PHR	domain.			
Cul1:	 	 One	 of	 two	 E3	 ligases	 responsible	 for	 cyclin	 E	 ubiquitination.	 	 	 Cul1	 uses	
substrate	adaptors	with	two	subunits:		The	Skp1	linker	protein	and	an	F-box	
protein.	
Cul3	Δ403-459:	 	A	Cul3	mutation	that	results	in	the	skipping	of	exon	9	of	the	Cul3	
protein.		This	mutation	causes	FHHt	in	humans.	
Cul3:	 	 An	 E3	 ubiquitin	 ligase	 that	 targets	many	 substrate,	 including	 cyclin	 E,	 for	
ubiquitination.	 	 Cul3	 uses	 BTB-domain	 containing	 proteins	 as	 substrate	
adaptors.	
Cul3K712R:		Cul3K712R	is	inactive	because	it	cannot	be	neddylated.	
Cul3Δ51-67:	 	 This	 Cul3	 mutant	 lacks	 the	 region	 near	 its	 N-terminus	 that	 is	
responsible	for	binding	BTB	proteins	(substrate	adaptors).	
Cul5:		Cul5	is	an	E3	ligase	that	uses	B/C	box	or	VHL	proteins	and	substrate	adaptors.	
Cyclin	 E:	 	 Cyclin	 E	 controls	 the	 G1/S	 transition	 by	 binding	 and	 activating	 Cdk2.		
Cyclin	 E/Cdk2	 complexes	 phosphorylate	 themselves	 in	 addition	 to	 many	
other	substrates	including	the	Rb	protein.		Eukaryotes	contain	two	cyclin	E	
proteins,	cyclin	E1	and	cyclin	E2,	which	are	products	of	two	different	genes.	
Cyclin	homology	domain:	 	This	domain	is	responsible	for	cyclin	E’s	ability	to	bind	
Cdk2	and	is	found	in	the	central	part	of	cyclin	E’s	structure.		
Cyclins:		A	class	of	proteins	responsible	for	binding	and	activating	Cdks,	resulting	in	
cell	cycle	progression.	
	 xii	
Dynamitin/p50:	 	A	subunit	of	the	dynactin	complex.	 	This	complex	is	responsible	
for	 endosomal	 transport.	 	 P50	 links	 the	 microtubule	 binding	 and	 cargo	
binding	portions	of	 the	complex.	 	P50	was	 identified	as	a	Klhl3	 interacting	
protein	and	possible	substrate	(Chapter	3).	
E1	ubiquitin	activating	enzyme:		E1	enzymes	are	responsible	for	activating	the	C-
terminal	 Gly-Gly	 motif	 on	 ubiquitin	 and	 preparing	 it	 for	 attachment	 to	 a	
substrate.	 	 Activation	 of	 ubiquitin	 by	 an	 E1	 occurs	 via	 an	 ATP-dependent	
reaction.	
E2	ubiquitin	conjugating	enzyme:	 	E2	enzymes	work	with	E3	ubiquitin	ligases	in	
order	to	transfer	ubiquitin	to	substrates.	
E2F:	 	A	transcription	factor	involved	in	cell	cycle	regulation.		E2F	is	sequestered	by	
the	 Rb	 protein,	 which	 releases	 E2F	 upon	 sufficient	 phosphorylation	 by	
cyclins	and	Cdks.		Once	E2F	is	free	of	Rb,	it	is	able	to	activate	transcription,	
resulting	in	entry	into	S-phase.	
E3	 ubiquitin	 ligase:	 	 E3	 ligases	 provide	 substrate	 specificity	 to	 the	 ubiquitin	
system.		Cullin	E3s	work	with	an	E2	to	facilitate	ubiquitin	attachment.		HECT	
E3	ligases	and	cullin	ligases	represent	two	classes	of	E3s.	
EEA1:		A	marker	of	early	endosomes.	
ENaC:		A	sodium	channel	located	in	the	nephron.	
F-box:		Cul1	utilizes	substrate	adaptors,	such	as	Fbxw7,	that	contain	F-box	domains	
to	recognize	substrates.	
FAZF:	 	 A	BTB	 protein	 that	 also	 contains	 a	 zinc-finger	 domain.	 	 FAZF	 binds	 LRR5	
(FMOD)	(Chapter	4).	
	 xiii	
Fbxw7:	 	An	F-box	protein	that	functions	as	a	substrate	adaptor	for	Cul1.		Fbxw7	is	
involved	in	Cul1-mediated	ubiquitination	of	cyclin	E.	
FHHt:	 	 Familial	 Hyperkalemic	 Hypertension:	 	 Also	 called	 PHAII	 or	 Gordon’s	
syndrome.		Mutations	in	Cul3	and	Klhl3	cause	this	disease.	
Floxed:	 	 “Flanked	by	LoxP”:	 	This	 is	a	DNA	construct	that	uses	LoxP	sites	to	make	
conditionally	–expressing	mouse	alleles.		Cre	recombinase	can	be	expressed	
in	mice	 that	 carry	 a	 floxed	 allele,	 resulting	 in	 the	 deletion	 of	 the	 selected	
DNA.		The	Cre	LoxP	system	is	useful	for	studying	essential	genes,	as	it	allows	
for	tissue	specific	deletion.	
G0:	 	G0	is	another	name	for	the	quiescent	stage	of	the	cell	cycle.	 	A	cell	arrested	in	
quiescence	is	not	preparing	to	divide,	but	can	re-enter	the	proliferative	cell	
cycle	if	given	the	appropriate	mitogenic	signals.	
G1:		This	is	the	first	growth	phase	that	takes	place	during	interphase	of	the	cell	cycle.		
G1	occurs	prior	to	S-phase.	
G2:		G2	is	the	growth	phase	following	DNA	synthesis	but	prior	to	mitosis.	
Gli:	 	A	family	of	mammalian	transcription	factors	that	are	involved	in	the	hedgehog	
signaling	pathway.		The	Gli	proteins	are	homologues	of	Ci	in	Drosophila.		Gli	
proteins,	as	well	as	Ci,	are	ubiquitinated	by	Cul3.	
GSK3:		A	kinase	that	phosphorylates	cyclin	E.	
Interphase:		Interphase	consists	of	the	G0,	G1,	S,	and	G2	phases	of	the	cell	cycle.	
KCTD13:	 	 KCTD13	 is	 the	 BTB	 substrate	 adaptor	 that	 targets	 RhoA	 for	 Cul3-
mediated	degradation.	
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Keap1:	 	 A	 prominent	 member	 of	 the	 BTB-BACK-Kelch	 family	 of	 proteins,	 Keap1	
targets	the	transcription	factor	Nrf2	for	degradation.	
Kelch	 domain:	 	 A	 common	 substrate-recognition	 domain	 that	 is	 found	 in	 many	
BTB-domain	containing	proteins.		Some	notable	members	of	this	family	are	
Keap1,	which	regulates	Nrf2,	and	Klhl3,	which	is	involved	in	blood	pressure	
regulation.	
Klhl17	 (actinfilin):	 	 A	 BTB-BACK-Kelch	 protein	 that	 is	 thought	 to	 be	 a	 Cul3	
substrate	adaptor.	
Klhl2	 (Mayven):	 	A	BTB-BACK-Kelch	protein	and	Cul3	substrate	adaptor,	Klhl2	 is	
closely	related	to	Klhl3.	
Klhl24:	 	 Klhl24	 is	 a	 BTB-BACK-Kelch	 protein	 and	 Cul3	 substrate	 adaptor	 that	
ubiquitinates	keratin	14.	
Klhl3:	 	A	BTB-BACK-Kelch	protein	 that	has	been	shown	to	cause	FHHt	 in	humans	
when	mutated.		
Klhl3R528H:		A	dominant	mutation	in	Klhl3	that	has	been	associated	with	FHHt.	
LAMP-1:		A	marker	that	can	be	used	to	identity	late	endosomes.	
MATH	 domain:	 	A	secondary	domain	 that	 is	 found	 in	 the	Cul3	 substrate	 adaptor	
SPOP.	
MEI-1:		A	katanin	protein	involved	in	microtubule	dynamics,	MEI-1	is	ubiquitinated	
by	Cul3	and	MEL-26.	
MEL-26:		A	BTB	protein	that	works	with	Cul3	to	ubiquitinate	MEI-1.	
MG132:	 	 A	 proteasome	 inhibitor	 that	 when	 added	 to	 cultured	 cells,	 results	 in	
increased	stability	of	some	ubiquitin-proteasome	system	substrates.	
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Mitosis:	 	The	final	portion	of	the	proliferative	cell	cycle	when	a	cell	completes	cell	
division,	resulting	in	two	daughter	cells.	
MSI2:		A	substrate	of	the	Cul3RhoBTB2	ligase	that	is	associated	with	breast	cancer.	
MUF1	(LRRC41):		An	LRR-domain	containing	protein	that	also	contains	a	B/C/	box,	
making	it	a	possible	Cul5	substrate	adaptor.		MUF1	can	bind	Cdk2	(Chapter	
4).	
Na+/K+	ATPase:		This	transporter	is	found	in	a	variety	of	tissues	and	is	responsible	
for	creating	an	ion	gradient	in	the	cells	of	the	nephron.		The	beta	subunit	of	
this	 transporter	 was	 identified	 as	 a	 potential	 Klhl3-interacting	 protein	
(Chapter	3).	
NCC	 transporter:	 	NCC	 is	 a	 sodium	 chloride	 transporter	 found	 in	 the	DCT	of	 the	
nephron.		Improper	regulation	of	NCC	causes	FHHt	hypertension.	
Nedd8:	 	 Nedd8	 is	 a	 ubiquitin-like	 molecule	 involved	 in	 Cul3	 function.	 	 Cul3	 is	
modified	by	Nedd8	on	K712.	
Nrf2:	 	 Nrf2	 is	 a	 transcription	 factor	 involved	 in	 the	 stress-response.	 	 Nrf2	 is	 a	
substrate	of	the	Keap1	BTB-Kelch	protein	and	Cul3.	
OSR1:		OSR1	is	a	kinase	that	activates	NCC	via	phosphorylation.	
PEST:		A	short	sequence	that	was	identified	in	proteins	with	high	turnover.		Cyclin	E	
has	a	PEST	sequence	located	near	its	C-terminus.	
PHR	domain:		A	secondary	domain	that	is	similar	to	a	kelch	domain.			Several	BTB-
proteins	also	contain	PHR	domains.		Kelch	and	PHR	domains	are	involved	in	
Cul3	substrate	recognition.	
PLZF:		A	zinc-finger	domain	containing	BTB	protein.		PLZF	is	closely	related	to	FAZF.	
	 xvi	
Rb:		The	retinoblastoma	protein	plays	a	crucial	role	in	cell	cycle	progression,	as	it	is	
responsible	for	binding	and	sequestering	the	E2F	transcription	factor,	which	
is	 necessary	 for	 S-phase	 to	 begin.	 Sufficient	 phosphorylation	 of	 Rb	 by	
cyclin/Cdk	pairs	results	in	the	release	of	E2F,	allowing	for	transcription	of	S-
phase	associated	genes	to	begin.			
Rbx1:	 	 The	 “ring-finger”	 protein,	 which	 interacts	 with	 cullin	 ubiquitin	 E3	 ligases	
near	their	C-termini.		Rbx1	is	believed	to	play	a	role	in	E2	binding.	
RCBTB1:	 	RCBTB1	is	a	BTB	protein	that	has	been	associated	with	the	eye	disease	
retinitis	pigmentosa.	
RhoA:	 	RhoA	 is	a	small	GTPase	 that	regulates	many	processes,	 including	 the	actin	
cytoskeleton.		RhoA	is	ubiquitinated	and	degraded	in	a	Cul3KCTD13	dependent	
manner.	
RhoBTB2:	 	 A	member	 of	 the	 RhoBTB	 protein	 family,	 RhoBTB2	 targets	 MSI2	 for	
degradation.	
RhoBTB3:	 	 A	member	 of	 the	 RhoBTB	 protein	 family	 that	 binds	 cyclin	 E.	 	 Others	
have	 suggested	 that	 RhoBTB3	 and	 other	 members	 of	 the	 RhoBTB	 family	
associate	with	MUF1.	
S-phase:		The	cell	cycle	stage	during	which	a	cell	replicates	its	DNA.	
Skp1:		Skp1	forms	part	of	Cul1-based	complexes	as	it	is	responsible	for	linking	Cul1	
with	an	F-box	protein.	
SPAK:		SPAK	is	a	kinase	that	regulates	NCC.		See	OSR1.	
SPOP:		Also	called	Ctb75,	SPOP	is	a	Cul3	substrate	adaptor	(BTB	protein).	
	 xvii	
Substrate	 adaptor:	 	 Substrate	 adaptors	 are	proteins	 that	bind	 to	 cullin-based	E3	
ligases	 in	 order	 to	 recognize	 specific	 substrates	 for	 ubiquitination.	 	 Each	
cullin	ligase	can	associate	with	many	different	substrate	adaptors,	allowing	
each	cullin	to	have	many	substrates.	
UbE2E1:	 	UbE2E1	is	an	E2	ubiquitin	conjugating	enzyme,	which	forms	degradative	
(K48)	ubiquitin	linkages.		UbE2E1	binds	RhoBTB3	(Chapter	2).	
Ubiquitin:	 	 Ubiquitin	 is	 a	 small	 protein	 that	 is	 attached	 to	 target	 proteins,	 often	
resulting	in	their	degradation.	
WNK1:		With	no	lysine	(K)	1:		A	kinase	involved	in	NCC	regulation.		WNK1	can	bind	
and	be	ubiquitinated	by	Klhl3.	
WNK4:		With	no	lysine	(K)	4:		A	kinase	involved	in	NCC	regulation.		WNK4	interacts	
with	and	can	be	ubiquitinated	by	Klhl3.	
Zinc	Finger	domain:		A	DNA-binding	domain	that	is	present	in	some	BTB	proteins,	
for	example	PLZF	and	FAZF.	
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CHAPTER	1:		Introduction	and	Background
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THE	CUL3	UBIQUITIN	LIGASE	
	
Post-translational	 modifications	 of	 proteins	 such	 as	 phosphorylation,	
methylation,	acetylation,	and	ubiquitination	are	essential	 for	a	wide	variety	of	 cell	
signaling	events.		The	ubiquitin	system	is	one	crucial	method	of	cellular	signaling	in	
eukaryotic	cells	 in	which	a	small	protein	called	ubiquitin	(Figure	1.1)	 is	covalently	
attached	to	lysine	residues	on	target	proteins,	also	called	substrates	(Metzger	et	al.	
2012).	 	 Substrates	 can	 be	 either	monoubiquitinated	 (one	molecule	 of	 ubiquitin	 is	
attached)	 or	 polyubiquitinated	 with	 a	 ubiquitin	 chain	 consisting	 of	 multiple	
ubiquitin	molecules	(Hicke	2001).		Histones	are	often	modified	post-translationally	
by	 monoubiquitination	 (Cole	 et	 al.	 2015).	 	 Ubiquitin	 chains	 can	 form	 different	
conformations	(Grice	and	Nathan	2016),	which	are	determined	by	the	specific	lysine	
residues	 on	 the	 ubiquitin	 molecules	 that	 comprise	 the	 chain	 (Figure	 1.2).		
Ubiquitinated	 proteins	 can	 be	 differentiated	 by	 the	 cell	 depending	 upon	 the	 type	
and	 length	 of	 ubiquitin	 chain	 that	 is	 attached.	 	 For	 example,	 K48-linked	 ubiquitin	
chains	signal	the	ubiquitinated	protein	to	be	degraded	by	the	proteasome	whereas	
K63-linked	 chains	 are	 involved	 in	 different	 processes	 (Lim	 and	 Lim	 2011).	 	 The	
attachment	 of	 ubiquitin	 signals	 a	 target	 protein	 to	 undergo	 a	 variety	 of	 cellular	
processes	 including	degradation	by	 the	26S	proteasome	 (Grice	and	Nathan	2016).		
The	ubiquitin	system	relies	upon	a	complex	set	of	biochemical	mechanisms	allowing	
for	proper	substrate	identification	and	ubiquitin	attachment.		Ubiquitin	signaling	is	
essential	for	the	survival	and	proper	function	of	eukaryotic	cells	(Finley	et	al.	1987).	
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The	transfer	of	ubiquitin	to	a	substrate	requires	three	enzymes	(Figure	1.3).		
First,	an	E1,	also	called	an	ubiquitin	activating	enzyme,	attaches	the	C-terminal	Gly	
residue	 of	 ubiquitin	 to	 its	 active	 site	 in	 an	 ATP-dependent	 reaction	 (Haas	 et	 al.	
1982).	 	 Next,	 The	 E1	 transfers	 the	 ubiquitin	 to	 the	 active	 site	 of	 an	 E2	 ubiquitin-
conjugating	enzyme.		Lastly,	the	E2	will	work	with	an	E3	ubiquitin	ligase	to	form	an	
isopeptide	bond	attaching	the	ubiquitin	(via	the	C-terminal	Gly	residue)	to	a	lysine	
residue	 on	 	 	 the	 target	 protein	 (Haas	 and	 Rose	 1982;	 Pickart	 and	 Rose	 1985).	
Ubiquitin	ligases	are	a	diverse	class	of	molecules,	which	is	 important	because	they	
are	 responsible	 for	 providing	 substrate	 specificity	 to	 this	 system	 (Gonen	 et	 al.	
1996).	 Thus,	 ubiquitin	 ligases	 ensure	 that	 the	 appropriate	 target	 protein	 is	
ubiquitinated	at	the	proper	time.			
	 	
4	
	
	
	
	
	
Figure	1.1:	 	Ubiquitin	is	a	small	protein	that	is	attached	to	substrates.		Ubiquitin	is	a	
small	protein,	the	C-terminus	of	which	is	attached	to	substrates	and	other	ubiquitin	
molecules	 via	 lysine	 residues.	 	 Different	 conformations	 of	 chains	 are	 formed	
depending	 upon	 which	 ubiquitin	 lysines	 are	 involved;	 for	 example	 K48-linked	
chains	target	substrates	for	proteasomal	degradation.	
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Figure	1.2:		Examples	of	ubiquitin	chains.		K48-linked	chains	have	a	globular	
shape	and	are	associated	with	degradation	(Left).		K63-linked	chains	have	a	
linear	structure	and	are	associated	will	non-degradative	processes	(Center).		
A	 substrate	 can	 also	 be	 monoubiquitinated,	 which	 is	 necessary	 for	
regulation	of	histone	proteins	(Right).	
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Figure	1.3:		Ubiquitin	attachment	is	a	three-step	process.		Attachment	of	ubiquitin	to	
a	 substrate	 requires	 three	 events:	 	 First,	 an	 E1	 activating	 enzyme	 prepares	 the	
ubiquitin	molecule	for	conjugation.		Next,	the	E1	transfers	the	ubiquitin	to	the	active	
site	Cysteine	on	the	E2	ubiquitin-conjugating	enzyme.		Lastly,	the	E2	will	work	with	
an	E3	ubiquitin	 ligase,	which	provides	substrate	specificity,	 to	attach	the	ubiquitin	
to	the	substrate.	
	
	
There	are	 two	main	classes	of	E3	ubiquitin	 ligases.	 	The	 first	 class	 is	 called	
the	 HECT	 (homologous	 to	 E6-AP	 carboxyl	 terminus)	 ubiquitin	 ligases,	 which	 can	
directly	 catalyze	 the	 transfer	 of	 an	 activated	 ubiquitin	 molecule	 to	 a	 substrate	
(Bernassola	 et	 al.	 2008).	 	 The	 second	 class	 of	 E3	 ligases	 is	 called	 the	 cullin-RING	
(really	 interesting	 new	 gene)	 E3	 ligases	 (Petroski	 and	Deshaies	 2005).	 Unlike	 the	
HECT	E3s,	 these	cullin	scaffolds	do	not	 themselves	catalyze	ubiquitin	 transfer,	but	
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instead	function	to	position	the	substrate	in	close	proximity	to	the	E2,	allowing	for	
the	attachment	of	the	ubiquitin	molecule	(Petroski	and	Deshaies	2005).			
Humans	possess	 eight	 cullin	 proteins	 (Cul1,	 Cul2,	 Cul3,	 Cul4A,	 Cul4B,	 Cul5,	
Cul7,	and	the	APC)	each	of	which	forms	its	own	set	of	E3	ligases	complexes	(Petroski	
and	 Deshaies	 2005).	 	 The	 cullin-based	 ligases	 are	 divided	 into	 several	 subtypes	
including	Cul1-based	(SCF),	Cul2-based,	Cul3-based	etc.	 	The	complexes	formed	by	
these	different	 ligases	have	many	 structural	 similarities,	 but	 each	 type	of	 ligase	 is	
unique	 and	 requires	 a	 different	 set	 of	 substrate	 recognition	 proteins,	 for	 example	
Cul1	uses	 Skp1	and	an	F-box	protein	 to	 recognize	 substrates,	 and	Cul3	uses	BTB-
domain	 containing	 proteins	 to	 bind	 substrates	 (Geyer	 et	 al.	 2003;	 Petroski	 and	
Deshaies	2005).		The	requirement	of	a	second	protein,	or	substrate	adaptor,	to	bind	
a	 substrate,	 allows	 for	 each	 cullin	 to	 have	 a	 diverse	 set	 of	 substrates	 and	 affect	 a	
wide	variety	of	cellular	processes.				Cul1	and	Cul3	have	both	been	shown	to	degrade	
the	 cell	 cycle	 regulator	 cyclin	 E	 and	 form	 SCF	 (Skp1-Cul1-F-box)	 and	 BCR	 (BTB,	
Cul3,	Rbx1)	complexes	respectively	(Clurman	et	al.	1996;	Singer	et	al.	1999;	Petroski	
and	Deshaies	2005).	 	Cul1-based	complexes	have	been	extensively	studied	and	the	
structure	 of	 these	 complexes	 is	 well	 known	 (Figure	 1.4).	 	 The	 structure	 of	 Cul3-
based	complexes	is	not	as	well	understood,	even	though	they	are	crucial	for	cellular	
functioning	and	Cul3	is	an	essential	gene	in	mice	(Singer	et	al.	1999).	
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Figure	 1.4:	 	A	comparison	between	Cul1	and	Cul3-based	complexes.	 Cul1	 (SCF,	 top,	
purple)	 uses	 a	 two-subunit	 substrate	 adaptor	 consisting	 of	 Skp1	 and	 an	 F-box	
protein	 whereas	 Cul3	 (BCR,	 bottom,	 red)	 relies	 upon	 one-subunit	 substrate	
adaptors	 called	 BTB	 proteins,	 which	 contain	 both	 a	 Cul3	 binding	 domain	 and	 a	
substrate	 interaction	 domain.	 	 Both	 Cul1	 and	 Cul3	 bind	 the	 ring-finger	 protein,	
Rbx1,	 and	 associate	 with	 E2	 enzymes	 (green)	 via	 the	 C-terminal	 domain	 of	 the	
cullin.	
	
Both	 Cul1	 and	 Cul3	 possess	 an	 N-terminal	 domain	 which	 interacts	 with	
substrate	adaptors,	a	central	cullin	homology	domain,	and	a	C-terminal	region	that	
is	 modified	 by	 the	 ubiquitin-like	 protein	 Nedd8,	 interacts	 with	 the	 ring	 finger	
protein	Rbx1,	and	interacts	with	the	E2	enzyme	(Hori	et	al.	1999;	Zheng	et	al.	2002;	
Wimuttisuk	and	Singer	2007).	 	Current	understanding	of	cullin	architecture	posits	
that	the	E2	binds	to	Rbx1,	which	is	located	near	the	C-terminus	of	the	cullin	(Kleiger	
et	al.	2009;	Metzger	et	al.	2014).		For	example,	it	has	been	shown	that	the	acidic	tail	
on	the	E2	enzyme	Cdc34	interacts	with	a	basic	region	near	the	Rbx1	binding	site	on	
Cul1	(Kleiger	et	al.	2009).			SCF	modification	of	Cul1	by	Nedd8	increases	SCF	activity	
9	
and	 may	 be	 involved	 in	 recruiting	 the	 E2	 to	 the	 complex,	 demonstrating	 the	
importance	of	Nedd8	modification	for	cullin	functioning	(Kawakami	et	al.	2001).			
In	 order	 to	 recognize	 substrates,	 Cul1	 relies	 upon	 substrate	 adaptors	
comprised	of	Skp1	and	an	F-box	protein.		Skp1	helps	to	associate	the	F-box	protein	
with	the	Cul1	complex,	whereas	the	F-box	protein	is	responsible	for	recognizing	and	
recruiting	phosphorylated	substrates	to	the	complex	(Skowyra	et	al.	1997;	Zheng	et	
al.	2002).		
Cul3	relies	upon	a	class	of	proteins	containing	BTB	(Bric-a-brac,	Tram	track,	
Broad	 Complex)	 domains	 to	 recognize	 substrates	 (Xu	 et	 al.	 2003;	 Pintard	 et	 al.	
2004).		These	proteins	contain	one	or	more	BTB	domains	that	interact	with	Cul3,	as	
well	 as	 a	 secondary	 domain	 such	 as	 a	 Kelch	 domain	 or	 MATH	 domain	 which	 is	
responsible	for	substrate	binding	(Stogios	et	al.	2005).		BTB	proteins	work	with	Cul3	
to	 regulate	 a	 variety	 of	 cellular	 processes.	 	 The	 BTB	 family	 of	 proteins	 has	many	
members	 including	 MEL-26	 which	 ubiquitinates	 the	 katanin	 protein	 MEI-1,	
RhoBTB3	which	 is	believed	 to	ubiquitinate	both	cyclin	E	and	HIFα,	Klhl3	which	 is	
involved	 in	blood	pressure	 regulation	by	ubiquitinating	WNK4,	and	Klhdc5	 (Ctb9)	
which	 ubiquitinates	 the	 microtubule-severing	 protein	 p60/katanin	 (Pintard	 et	 al.	
2003;	Cummings	et	al.	2009;	Johnson	et	al.	2009;	Lu	and	Pfeffer	2013;	Shibata	et	al.	
2013;	Wakabayashi	et	al.	2013;	Zhang	et	al.	2015).		Coordinated	ubiquitination	of	a	
substrate	 by	more	 than	 one	 ligase	 is	 known	 to	 occur.	 	 For	 example,	 the	 cell-cycle	
regulator	Cyclin	E	provides	us	with	an	example	of	a	 substrate	 that	 is	degraded	by	
two	different	cullin-based	E3	ligases,	Cul1	and	Cul3	(Clurman	et	al.	1996;	Singer	et	
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al.	1999).			The	ubiquitination	of	the	Gli	proteins	in	the	hedgehog-signaling	pathway	
is	also	known	to	occur	via	both	Cul1	and	Cul3-dependent	mechanisms	(Jiang	2006).	
CELL	CYCLE	REGULATION:		Basic	mechanisms	controlling	proliferation	
	
The	 cell	 division	 cycle	 is	one	 crucial	process	 in	which	 the	ubiquitin	 system	
has	 long	 been	 known	 to	 play	 an	 essential	 role.	 	 Interphase	 of	 the	 eukaryotic	 cell	
cycle	 is	 divided	 into	 three	 stages.	 	 The	 first	 stage	 is	 a	 growth	 phase	 called	 G1	
(Ohtsubo	 and	Roberts	 1993).	 	 G1	 is	 followed	by	 S	phase	during	which	 the	DNA	 is	
replicated,	which	in	turn	is	followed	by	G2.		The	proliferative	cell	cycle	is	completed	
with	“M	phase”,	 the	phase	during	which	mitosis	occurs	(Pardee	1974).	Eukaryotes	
have	 evolved	 complex	 mechanisms	 to	 ensure	 that	 cells	 replicate	 their	 DNA	 and	
divide	only	when	appropriate.	Mechanisms	to	ensure	the	proper	replication	of	DNA	
are	in	place	throughout	interphase	of	the	cell	cycle,	which	helps	to	ensure	that	the	
genome	is	copied	only	once	and	only	during	S	phase	(Nishitani	and	Lygerou	2002).			
During	S-phase,	DNA	replication	begins	from	pre-determined	locations	on	the	DNA,	
known	as	origins,	which	must	be	properly	labeled	for	replication	to	occur	(Ford	and	
Chevalier	1995).		Origins	are	labeled	either	late	in	M-phase	or	early	in	G1	(Ford	and	
Chevalier	1995).	 	The	 labeling	of	origins	during	this	brief	 temporal	window	is	one	
way	to	decrease	the	chance	that	re-replication	will	occur,	as	it	prevents	the	labeling	
of	more	origins	later	on	during	the	cell	cycle	(Ford	and	Chevalier	1995).		Following	
the	 labeling	of	an	origin	during	G1,	 the	proteins	Cdt1	and	Cdc6	will	associate	with	
the	ORC	 (origin	 recognition	 complex).	 	 The	next	 step	 in	 the	 replication	process	 is	
called	 licensing,	 which	 can	 only	 occur	 during	 G1	 (Nishitani	 and	 Lygerou	 2002).		
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During	this	step,	two	proteins,	Cdt1	and	Cdc6,	 load	the	replication	machinery	onto	
the	origin	in	preparation	for	DNA	replication	(Nishitani	and	Lygerou	2002).	
The	cell	cycle	also	has	a	special	state	referred	to	as	‘G0’	or	‘quiescence’,	during	
which	 the	 cell	 is	 not	 preparing	 to	 divide.	 	 	 Unlike	 senescent	 cells,	 which	 can	 no	
longer	divide,	quiescent	cells	possess	the	ability	to	exit	the	G0	state	and	reenter	the	
cell	 cycle	 if	 given	 the	 proper	molecular	 signals	 (Siddiqi	 and	 Sussman	 2014).	 	 The	
quiescent	state	of	the	cell	cycle	is	imperative	to	the	normal	functioning	of	eukaryotic	
organisms.		At	any	given	time,	a	large	portion	of	the	cells	in	a	multicellular	organism	
are	arrested	in	this	quiescent	state.			Quiescence	is	actively	regulated	by	the	cell	and	
is	 necessary	 to	 prevent	 excessive	 proliferation	 and	 preserve	 the	 integrity	 of	 the	
cell’s	 DNA	 (Cheung	 and	 Rando	 2013).	 	 Abnormal	 release	 from	 quiescence	 can	
results	 in	 unwanted	 proliferation	 and	 can	 be	 harmful	 to	 the	 organism.	 	 Intricate	
processes	regulate	the	cell	cycle	during	all	its	stages	and	are	governed	by	cyclin/Cdk	
(cyclin	dependent	kinase)	protein	complexes.		These	complexes	drive	the	cell	cycle	
forward	via	the	phosphorylation	of	a	wide	variety	of	substrates.	
CELL	CYCLE	REGULATION:		Cyclins	and	Cdks	
	
Cyclins	 are	 essential	 for	 proper	 cell	 cycle	 control.	 	 Mammalian	 cells	 have	
several	different	 cyclins,	 and	each	one	 is	active	at	a	 specific	 time	point	during	 the	
cell	 cycle	 (Figure	 1.5).	 	 Therefore,	 the	 level	 of	 any	 given	 cyclin	 does	 not	 remain	
constant,	but	instead	rises	and	falls	throughout	the	different	stages	of	the	cell	cycle.		
Proper	temporal	regulation	of	cyclin	activity	throughout	the	cell	cycle	 is	necessary	
for	proper	functioning	of	the	cell	and	the	health	of	the	organism	as	a	whole.	
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Figure	1.5:		Cyclins	and	Cdks	regulate	cell-cycle	transitions.		Cyclin	D	and	its	partner	
Cdk4/6	are	responsible	for	 internalizing	an	external	mitogenic	signal.	 	An	external	
stimulus	causes	cyclin	D/Cdk	4/6	to	phosphorylate	target	proteins,	such	as	Rb,	that	
result	 in	 cell	 cycle	 progression	 and	 increase	 cyclin	 E	 levels.	 	 Cyclin	 E/Cdk2	
complexes	 phosphorylate	 substrates	 during	 the	 G1/S	 transition	 resulting	 in	 the	
start	of	S-phase.	 	A	cell	has	passed	the	restriction	point	once	 it	no	 longer	requires	
external	signals	for	cell	cycle	progression	to	occur,	and	cyclins	D	and	E	are	involved	
in	this	process.	 	Cyclin	A/Cdk2	controls	progression	through	S-phase	and	cyclins	A	
and	B	bind	Cdk1,	controlling	progression	through	G2	and	mitosis.	
	
Cyclins	 bind	 to	 and	 activate	 enzymes	 known	 as	 Cyclin	 Dependent	 Kinases	
(Cdks)	 (Koff	 et	 al.	 1991).	 	 When	 bound	 to	 a	 Cdk,	 the	 Cyclin/Cdk	 complex	
phosphorylates	target	proteins	that	are	responsible	for	cell	cycle	progression	(Koff	
et	al.	1992).		Cyclin	E	is	a	mammalian	cyclin	that	binds	to	Cdk2.		The	Cyclin	E/Cdk2	
complex	 is	 responsible	 for	 the	phosphorylation	of	 target	proteins	during	 the	G1/S	
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transition	of	the	cell	cycle	(Figure	1.5).	 	The	cyclin	E	gene	is	one	of	many	cell	cycle	
related	genes	that	 is	regulated	by	the	E2F	transcription	factor	(Swiss	and	Casaccia	
2010).		E2F	binds	to	the	Rb	(retinoblastoma)	pocket	protein,	which	prevents	it	from	
activating	transcription	(Swiss	and	Casaccia	2010).		Sufficient	phosphorylation	of	Rb	
by	cyclin	D	and	Cdk4/6	upon	mitogen	stimulation	during	G1	of	the	cell	cycle	results	
in	release	of	E2F	by	Rb	and	increased	expression	of	E2F	controlled	genes,	including	
cyclin	E	(Resnitzky	et	al.	1994;	Sherr	1994;	Ekholm	and	Reed	2000).		Cyclin	E	then	
binds	 and	 activates	 Cdk2,	 resulting	 in	 the	 phosphorylation	 of	 Rb	 as	well	 as	 other	
substrates	(Koff	et	al.	1991;	Ohtsubo	and	Roberts	1993).		Cyclin	E/Cdk2	substrates	
include	Rb,	 Cdh1,	 cyclin	 E/Cdk2	 autophosphorylation,	 and	 others	 (Won	 and	Reed	
1996;	Abbas	et	al.	2007;	Keck	et	al.	2007).		One	essential	substrate	of	cyclin	E/Cdk2	
is	Cdc6,	which	when	stabilized	upon	phosphorylation	by	cyclin	E/Cdk2,	allows	 for	
the	 formation	 of	 the	 pre-replication	 complex	 prior	 to	 the	 start	 of	 S-phase	 (Ayad	
2005;	Mailand	and	Diffley	2005).	
G1	 contains	 a	point	known	as	 the	 “Restriction	point”	 at	which	 time	 the	 cell	
has	committed	to	duplicating	its	DNA	and	will	continue	on	into	S-phase	even	if	the	
external	 mitogenic	 stimuli	 are	 removed	 (Pardee	 1974;	 Blagosklonny	 and	 Pardee	
2002).	 	 Cyclin/Cdk	 activity	 contributes	 to	 the	 cell’s	 ability	 to	 reach	 this	 point	
(Blagosklonny	and	Pardee	2002).				This	mechanism	plays	an	important	role	in	both	
the	entry	into	S-phase	and	release	from	quiescence.	
Eukaryotes	contain	two	cyclin	E	proteins,	cyclin	E1	and	cyclin	E2,	which	are	
products	of	two	different	genes,	CCNE1	and	CCNE2	(Sherr	and	Roberts	1999;	Geng	
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et	al.	2003;	Perez-Neut	et	al.	2015).	 	Both	cyclin	E	proteins	bind	and	activate	Cdk2	
(Perez-Neut	et	al.	2015).	 	Cyclin	E	 is	significant	as	 its	overexpression	 is	associated	
with	 increased	 proliferation	 and	 release	 from	 quiescence	 as	 well	 as	 aneuploidy,	
polyploidy,	and	delayed	progression	through	mitosis	(Spruck	et	al.	1999;	Keck	et	al.	
2007).	 	 Overexpression	 of	 cyclin	 E	 in	 cancer	 cells	 is	 associated	 with	 increased	
tumorigenesis	 and	 poor	 clinical	 prognosis	 (Said	 and	Medina	 1995)	 .	 	 In	 contrast,	
mouse	fibroblasts	that	lack	both	cyclin	E	genes,	cyclin	E1	and	cyclin	E2,	are	unable	
to	exit	from	the	quiescent	state	but	loss	of	cyclin	E	has	little	effect	on	cells	that	are	
already	proliferating	(Geng	et	al.	2003).		
As	 cyclin	 E	 plays	 a	 significant	 role	 in	 cell	 cycle	 progression,	 it	 stands	 to	
reason	that	it	is	a	highly	modified,	highly	regulated	protein.		Cyclin	E1	and	cyclin	E2	
are	regulated	by	different	mechanisms	(Perez-Neut	et	al.	2015).	 	The	remainder	of	
this	 section	 discusses	 regulation	 of	 cyclin	 E1.	 	 Cyclin	 E1	 is	 regulated	 via	
phosphorylation,	 both	 auto	 phosphorylation	 when	 bound	 to	 Cdk2	 and	
phosphorylation	by	different	kinases	such	as	GSK3	(Clurman	et	al.	1996;	Welcker	et	
al.	2003).		Cyclin	E	is	also	regulated	in	a	ubiquitin-dependent	manner,	resulting	in	its	
degradation	by	the	26S	proteasome	(Clurman	et	al.	1996).		Lastly,	activity	of	cyclins	
and	 Cdks	 is	 regulated	 via	 a	 class	 of	 proteins	 called	 cyclin	 dependent	 kinase	
inhibitors	or	CKIs	(Besson	et	al.	2008).		There	are	two	types	of	CKIs:		The	first	type	
includes	 the	 INK4	 proteins,	 which	 exclusively	 regulate	 Cdks	 4	 and	 6	 (Sherr	 and	
Roberts	1999).	 	The	second	class,	which	regulates	cyclin	E	and	Cdk2	in	addition	to	
others,	includes	the	proteins	p27,	p21,	and	p57	(Sherr	and	Roberts	1999).		Proteins	
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like	p21	and	p27	inhibit	cyclin/Cdk	activity	by	binding	to	various	cyclins	and	Cdks	
(Sherr	and	Roberts	1999).			
Additionally,	 research	 has	 demonstrated	 that	 in	 several	 cancers,	 including	
breast,	 ovarian,	 melanoma,	 and	 others,	 cyclin	 E1	 can	 be	 proteolytically	 cleaved	
resulting	in	truncated	low	molecular	weight	(LMW)	cyclin	E	proteins,	which	mainly	
lack	 their	 N-termini.	 These	 LMW	 cyclin	 E	 are	 able	 to	 activate	 Cdk2	 variants	 are	
associated	 with	 tumorigenesis	 and	 poor	 prognosis	 in	 cancer	 patients	 (Said	 and	
Medina	1995;	Harwell	et	al.	2000;	Porter	et	al.	2001).	
CELL	CYCLE	REGULATION:	Mechanisms	controlling	cyclin	E	abundance	
	
Cells	maintain	proper	levels	of	Cyclin	E	through	a	combination	of	production	
via	 1)	 tight	 transcriptional	 regulation,	 ensuring	 that	 it	 is	 made	 only	 during	 the	
correct	 temporal	 window	 and	 2)	 degradation	 (Clurman	 et	 al.	 1996;	 Singer	 et	 al.	
1999).	 	This	degradation	is	also	stringently	regulated	and	is	frequently	initiated	by	
the	addition	of	ubiquitin.		The	covalent	attachment	of	ubiquitin	to	cyclin	E	results	in	
degradation	by	the	26S	proteasome.		
Two	ubiquitin	ligase	pathways	are	responsible	for	signaling	the	degradation	
of	Cyclin	E.		The	first	is	the	Cul1	(Cullin1)	ubiquitin	ligase,	which	functions	as	part	of	
a	 complex	 that	 recognizes	 a	 phosphorylated	Threonine	 residue	 (T395	 in	 humans,	
T393	in	mice)	on	Cyclin	E	(Clurman	et	al.	1996;	Koepp	et	al.	2001;	Strohmaier	et	al.	
2001;	 Loeb	 et	 al.	 2005).	 	 After	 recognizing	 Cyclin	 E,	 the	 Cul1	 complex	 can	
ubiquitinate	it	for	degradation	by	the	proteasome.		In	addition	to	Cul1,	the	E3	ligase	
Cullin3	(Cul3)	also	functions	in	the	degradation	of	cyclin	E	when	it	is	not	bound	to	
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Cdk2	(Singer	et	al.	1999).	 	The	mechanism	by	which	Cul3	degrades	cyclin	E	 is	not	
well	understood.		Previous	work	from	our	lab	which	utilized	a	condition	knockout	of	
Cul3	 has	 shown	 that	 Cul3	 is	 necessary	 for	 the	 degradation	 of	 cyclin	 E	 and	
maintenance	of	quiescence	in	the	murine	liver	(McEvoy	et	al.	2007).		
CUL3	AND	DISEASE:		Cancer	
	
Cul3	 is	an	essential	gene,	as	ablation	of	Cul3	 in	mice	resulted	 in	embryonic	
lethality	(Singer	et	al.	1999).	 	As	Cul3	is	necessary	for	cellular	functioning,	it	 is	not	
surprising	 to	 learn	 that	 Cul3	 has	 been	 associated	 with	 several	 human	 diseases,	
including	cancer	(Genschik	et	al.	2013).	 	Cancer	 is	a	complicated	disease	 involving	
many	cellular	and	physiological	pathways	 including	 those	 involved	 in	cell	division	
and	 responses	 to	 stress.	 	 Cancer	 develops	 when	 a	 cell	 undergoes	 DNA	 mutation	
which	results	in	transformative	changes	involving	a	variety	of	cellular	pathways	that	
are	meant	 to	control	proliferation,	 resulting	 in	a	cancerous	cell	 that	can	grow	and	
metastasize	 (Penkert	 et	 al.	 2016).	 	 	 Determining	 the	 exact	 role(s)	 Cul3	 plays	 in	
cancer	 development	 poses	 a	 difficult	 task	 as	 Cul3	 regulates	 dozens	 of	 substrates,	
many	of	which	remain	unknown.		Here,	some	of	the	possible	roles	of	Cul3	in	cancer	
are	summarized.		
	One	well-studied	substrate	of	 the	Cul3	 ligase	 is	Nrf2,	a	 transcription	 factor	
involved	in	the	oxidative	stress	response,	which	is	a	substrate	of	Cul3	and	the	Keap1	
BTB	protein	(Itoh	et	al.	1999;	Cullinan	et	al.	2004;	Kobayashi	et	al.	2004;	Zhang	et	al.	
2004;	 Furukawa	 and	 Xiong	 2005).	 	 The	 involvement	 of	 the	 Nrf2-Keap1-Cul3	
pathway	 in	 many	 diseases	 including	 cancer	 has	 been	 extensively	 reviewed	
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(Leinonen	et	al.	2015;	Holmstrom	et	al.	2016;	Kim	and	Keum	2016;	Sparaneo	et	al.	
2016).			In	short,	the	BTB	protein	Keap1	and	other	mechanisms	tightly	regulate	Nrf2	
when	 the	 cell	 is	 not	 under	 stress,	 but	 upon	 stimulation	 by	 stress	 induced	by	ROS	
(reactive	oxygen	species),	a	structural	modification	of	Keap1	occurs	which	reduces	
degradation	 of	 Nrf2	 allowing	 it	 to	 activate	 transcription	 of	 Nrf2-controlled	 genes	
(Harder	 et	 al.	 2015).	 	 Nrf2	 plays	 a	 complicated	 role	 in	 cancer	 as	 Nrf2	 helps	 to	
prevent	 the	development	of	 cancer	 in	healthy	 cells,	 but	 some	 cancerous	 cells	 also	
have	 elevated	 Nrf2	 activity	 which	 is	 associated	 with	 resistance	 to	 chemotherapy	
(Harder	 et	 al.	 2015).	 	 Nrf2	may	 be	 the	most	 studied	 Cul3	 substrate,	 and	 it	 alone	
provides	Cul3	with	a	definitive	role	in	cancer	biology.	
Another	 well-studied	 Cul3	 substrate	 involved	 in	 cancer	 is	 the	 cell	 cycle	
regulator	 cyclin	 E.	 	 Like	 Nrf2,	 cyclin	 E	 levels	 are	 tightly	 maintained	 by	 Cul3	 and	
other	 mechanisms	 in	 most	 cells	 (Singer	 et	 al.	 1999;	 McEvoy	 et	 al.	 2007).	 	 Over-
expression	 of	 cyclin	 E	 is	 associated	 with	 tumorigenesis	 and	 truncated	 cyclin	 E	
variants	 are	 also	 associated	 with	 tumorigenesis	 and	 cancer	 (Scuderi	 et	 al.	 1996;	
Porter	and	Keyomarsi	2000;	Porter	et	al.	2001).			The	regulation	of	cyclin	E	by	Cul3	
will	be	 further	analyzed	 in	chapter	 two.	 	There	are	many	other	processes	 that	are	
regulated	by	Cul3	that	also	have	demonstrated	involvement	in	cancer.		For	instance,	
it	has	recently	been	revealed	that	the	substrate	adaptor	RhoBTB2	is	responsible	for	
degrading	 the	 oncogenic	 protein	 MSI2	 in	 breast	 cancer	 (Choi	 et	 al.	 2016),	 and	
mutations	 in	 the	 BTB	 protein	 SPOP	 have	 been	 demonstrated	 in	 prostate	 cancer	
(Mani	2014).		The	involvement	of	Cul3	and	BTB	proteins	in	cancer	has	been	recently	
reviewed	(Genschik	et	al.	2013;	Chen	and	Chen	2016).	
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CUL3	AND	DISEASE:		FHHt	hypertension:	
	
Familial	 hyperkalemic	 hypertension	 (FHHt),	 also	 known	 as	 Gordon’s	
syndrome	 or	 PHAII,	 is	 an	 inherited	 form	 of	 hypertension	 also	 characterized	 by	
hyperkalemia	 that	 can	 be	 treated	 with	 thiazide	 diuretics	 (O'Shaughnessy	 2015).		
Genetic	 studies	have	 identified	mutations	 in	 two	 components	of	 a	ubiquitin	 ligase	
complex,	the	cullin	scaffold	protein	Cul3,	and	the	BTB	domain	containing	substrate	
adaptor	protein	Klhl3,	that	cause	this	disease	(Boyden	et	al.	2012;	Louis-Dit-Picard	
et	al.	2012).		Mutations	in	the	kinases	WNK1	and	WNK4	were	previously	known	to	
cause	 FHHt,	 which	 is	 known	 to	 result	 from	 misregulation	 of	 the	 NCC	 sodium	
chloride	cotransporter	located	in	the	distal	convoluted	tubule	(DCT)	of	the	nephron	
of	the	kidney	(O'Shaughnessy	2015).			
WNK1	 and	WNK4	 are	 kinases	 that	 are	 involved	 in	 regulation	 of	NCC.	 	 The	
WNK	 kinases	 regulate	 the	 activity	 of	 NCC	 and	 its	 expression	 at	 the	 membrane	
surface	 by	 phosphorylating	 substrates	 including	 the	 SPAK	 kinase,	 which	 is	
responsible	 for	directly	phosphorylating	NCC	(Yang	et	al.	2003;	Hoorn	and	Ellison	
2012;	 Chavez-Canales	 et	 al.	 2014).	 	 Recently,	 WNK4	 has	 been	 identified	 as	 a	
substrate	of	the	ubiquitin	ligase	complex	formed	by	Cul3	and	Klhl3	(Ohta	et	al.	2013;	
Shibata	et	al.	2013;	Wakabayashi	et	al.	2013).		Degradation	of	WNK4	by	the	Cul3Klhl3	
(nomenclature:	 	 Cul3	 scaffold	 containing	 the	 Klhl3	 BTB	 protein)	 ubiquitin	 ligase	
complex	 can	 partially	 explain	 the	 role	 of	 Cul3	 in	 NCC	 regulation,	 as	 WNK4	 is	
necessary	 for	 regulation	 of	 SPAK	 and	 also	 NCC	 degradation	 by	 the	 lysosome	
(Golbang	 et	 al.	 2006;	 Hoorn	 and	 Ellison	 2012).	 	 However,	 patients	 with	 Cul3	
mutations	have	a	more	 severe	disease	phenotype	and	develop	hypertension	at	 an	
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earlier	 age	 in	 comparison	 to	 patients	 with	 mutations	 in	 Klhl3,	 WNK4,	 or	
WNK1(Boyden	 et	 al.	 2012).	 	 This	 led	 to	 the	 hypothesis	 that	 Cul3	 regulates	 ion	
balance	 and	 blood	 pressure	 by	 one	 or	 more	 different	 mechanisms	 besides	 the	
degradation	of	WNK4,	an	idea	that	will	be	explored	further	in	chapter	three.	
The	Cul3	mutations	 that	 cause	 this	disease	 result	 in	 the	 skipping	of	 exon	9	
(encoding	amino	acids	403-459)	of	the	Cul3	protein.		These	mutations	are	dominant	
and	 some,	 including	 the	 Cul3	 mutation,	 are	 believed	 to	 be	 de	 novo	 mutations	
(Boyden	 et	 al.	 2012).	 	 Previous	 researchers	 have	 hypothesized	 that	 the	 Cul3	
mutation	is	a	dominant	negative	(Boyden	et	al.	2012).		However,	we	speculated	that	
this	idea	was	unlikely	since	Cul3	has	been	previously	shown	to	be	essential	for	both	
embryonic	development	and	cell	 survival	 (Singer	et	al.	1999;	McEvoy	et	al.	2007).		
We	 have	 since	 demonstrated	 that	 the	 hypertension	 mutant,	 Cul3Δ403-459,	 is	 a	
functional	ubiquitin	 ligase	 capable	of	ubiquitinating	 substrates	 as	well	 as	 the	BTB	
protein	Klhl3	(McCormick	et	al.	2014).			
CUL3	AND	DISEASE:	Neuronal,	eye,	and	skin	conditions	
	
Besides	hypertension	and	cancer,	Cul3	has	also	been	implicated	in	eye,	skin,	
and	neurological	conditions.	 	Recent	work	has	shown	that	Cul3	uses	 the	substrate	
adaptor	 Klhl24	 to	 ubiquitinate	 keratin14	 and	 that	 dominant	 mutations	 in	 Klhl24	
result	 in	 an	 increase	 in	 keratin	 degradation	 and	 skin	 fragility	 (Lin	 et	 al.	 2016).		
Additionally,	 recent	 research	 has	 shown	 that	 regulation	 of	 RhoA	 by	 Cul3	 and	 the	
substrate	 adaptor	 KCTD13	 is	 necessary	 for	 brain	 development	 (Lin	 et	 al.	 2015).		
Mutations	in	components	of	Cul3	complexes,	including	mutations	in	Cul3	itself,	have	
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been	 associated	with	 autism,	 although	 a	mechanism	 by	which	 Cul3	might	 lead	 to	
autism	has	not	been	proposed	(Codina-Sola	et	al.	2015;	Lin	et	al.	2015;	Wang	et	al.	
2016).	 	 Another	 BTB	 protein,	 RCBTB1,	 has	 been	 associated	with	 retinopathy	 and	
retinitis	 pigmentosa	 (Coppieters	 et	 al.	 2016;	 Wu	 et	 al.	 2016).	 	 	 Together,	 these	
findings	 indicate	 that	 Cul3	 is	 essential	 for	 proper	 cellular	 and	 bodily	 functions	 in	
humans.	 	 Further	 study	 that	 seeks	 to	 determine	 the	 mechanisms	 by	 which	 Cul3	
functions	as	well	as	the	identity	of	more	Cul3	substrates	will	be	necessary	in	order	
to	understand	a	vast	array	of	human	diseases.		
SIGNIFICANCE	
	
In	this	chapter,	I	have	given	a	brief	overview	of	the	Cul3	ubiquitin	ligase	and	
its	involvement	in	the	degradation	of	cyclin	E	as	well	as	its	role	in	a	variety	of	other	
cellular	pathways	and	human	disease.		In	the	upcoming	chapters,	I	will	provide	new	
insights	 into	 the	 role	 of	 Cul3	 in	 cells	 including	 its	 involvement	 in	 cyclin	 E	
destruction.		The	data	presented	in	the	next	chapter	will	demonstrate	that	the	lysine	
residue	on	cyclin	E	that	Cul3	ubiquitinates	is	located	near	the	N-terminus	of	cyclin	E.				
This	 detail	 provides	 insight	 into	 the	 role	 of	 Cul3	 in	 cancer	 and	 tumorigenesis	 as	
cyclin	E	lacking	its	N-terminus	is	associated	with	cancer.		Chapter	three	will	further	
discuss	the	role	of	Cul3	and	Klhl3	in	hypertension.		Lastly,	chapter	four	will	describe	
interactions	 between	 LRR	 (leucine	 rich	 repeat)-domain	 containing	 proteins	 and	
Cul3	complexes	as	well	as	some	other	potential	future	directions	for	these	projects.	
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CHAPTER	2:		The	N-terminus	of	Cyclin	E	is	Required	for	Cul3-mediated	
Degradation	
	 	
30	
INTRODUCTION	AND	BACKGROUND:		
	
Cyclin	E	 and	 its	 binding	partner	Cdk2	 regulate	 the	 transition	 from	G1	 to	 S-
phase	as	well	as	release	from	quiescence	in	mammalian	cells	(Koff	et	al.	1991;	Geng	
et	 al.	 2003).	 	 Thus,	 it	 is	 not	 surprising	 that	 cell	 cycle	 errors	 are	 associated	 with	
alterations	to	cyclin	E	function	and/or	abundance;	fibroblasts	lacking	both	cyclin	E	
genes,	 cyclin	E1	 and	 cyclin	E2,	 are	 unable	 to	 release	 from	quiescence	 (Geng	 et	 al.	
2003).	 	 In	 contrast,	 overexpression	 of	 cyclin	 E	 is	 associated	 with	 cancer	 and	
tumorigenesis	(Said	and	Medina	1995).		Analysis	of	the	cyclin	E	protein	has	revealed	
several	 functional	 domains	 including	 a	 central	 cyclin	 homology	 domain	 which	
interacts	with	Cdk2,	a	unique	N-terminal	 region,	and	a	C-terminal	PEST	sequence,	
which	 is	 commonly	 found	 in	 proteins	 that	 get	 degraded	 by	 the	 ubiquitin	 system	
(Rogers	et	al.	1986;	Rogers	and	Rechsteiner	1986;	Richardson	et	al.	1993;	Honda	et	
al.	2005;	Rath	and	Senapati	2014).	In	certain	cancers,	including	breast,	ovarian	and	
melanoma,	 cyclin	E	 is	 known	 to	be	 cleaved	by	proteases	 resulting	 in	N-terminally	
truncated	 low	 molecular	 weight	 (LMW)	 forms	 ranging	 in	 size	 from	 33	 to	 45	
kilodaltons	 (Scuderi	 et	 al.	 1996;	Harwell	 et	 al.	 2000;	 Porter	 and	Keyomarsi	 2000;	
Porter	et	al.	2001;	Wang	et	al.	2003;	Libertini	et	al.	2005).	 	LMW	cyclin	E	activates	
Cdk2	and	demonstrates	increased	cyclin	E/Cdk2	activity	(Porter	et	al.	2001).		These	
forms	 of	 cyclin	 E	 are	 associated	 with	 poor	 clinical	 prognosis	 in	 cancer	 patients	
(Harwell	et	al.	2000;	Porter	et	al.	2001;	Duong	et	al.	2012).			
Cyclin	 E	 expression	 is	 restricted	 to	 the	 G1/S	 transition	 by	 two	 distinct	 E3	
ubiquitin	 ligase	 complexes	which	 are	 responsible	 for	 the	 degradation	 of	 cyclin	 E:	
Cul1	 and	 Cul3	 (Clurman	 et	 al.	 1996;	 Singer	 et	 al.	 1999;	 Strohmaier	 et	 al.	 2001;	
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Welcker	et	al.	2003).		Both	Cul1	and	Cul3	are	members	of	the	cullin-RING	family	of	
ubiquitin	 ligases.	 	 Cul1	 or	 SCF	 (Skp1,	 Cul1,	 Fbxw7)	 based	 ligases	 use	 Fbxw7	 as	 a	
substrate	adaptor	to	recognize	cyclin	E	(Koepp	et	al.	2001;	Strohmaier	et	al.	2001;	
Hao	et	al.	2007).		Cul1	mediated-degradation	requires	phosphorylation	of	cyclin	E	at	
T77	and	T395	in	order	for	ubiquitination	of	cyclin	E	to	occur	(Clurman	et	al.	1996;	
Welcker	 et	 al.	 2003;	 Loeb	 et	 al.	 2005;	 Minella	 et	 al.	 2008).	 	 Cul1-mediated	
degradation	of	cyclin	E	occurs	about	four	hours	following	release	from	a	thymidine	
block	(S-phase)	(Bhaskaran	et	al.	2013).		
In	 contrast	 to	 the	 Cul1	 pathway,	 the	mechanistic	 details	 of	 Cul3	mediated	
destruction	of	cyclin	E	remain	largely	uncharacterized.	 	Similar	to	Cul1	complexes,	
Cul3	ubiquitin	ligase	complexes	consist	of	a	substrate	adaptor	(BTB	protein)	which	
binds	 near	 the	 Cul3	 N-terminus	 to	 recruit	 substrates,	 and	 C-terminal	 region	 that	
binds	 to	 the	RING	 finger	protein	Rbx1	(Tyers	and	 Jorgensen	2000;	 Jin	and	Harper	
2002;	 Duda	 et	 al.	 2008),	 which	 in	 return	 recruits	 an	 E2	 ubiquitin	 conjugating	
enzyme	(Petroski	and	Deshaies	2005).	 	Previous	studies	 from	our	 lab	have	shown	
that	Cul3	degrades	cyclin	E	that	is	not	bound	to	Cdk2	and	regulation	of	cyclin	E	by	
Cul3	 is	 necessary	 for	 the	 maintenance	 of	 quiescence	 in	 liver	 (Singer	 et	 al.	 1999;	
McEvoy	et	al.	2007).	 	 	In	addition,	it	has	recently	been	demonstrated	that	Cul3	can	
utilize	 the	 substrate	 adaptor	 RhoBTB3	 to	 ubiquitinate	 cyclin	 E	 (Lu	 and	 Pfeffer	
2013).			
Despite	the	advances,	many	details	regarding	the	mechanism	utilized	by	Cul3	
for	 cyclin	 E	 ubiquitination	 remain	 as	 yet	 unknown,	 including	 the	 location	 of	 the	
degron,	 or	 region	 recognized	 by	 the	 ubiquitin	 ligase,	 that	 Cul3	 uses	 to	 recognize	
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cyclin	 E.	 	Here,	 a	 Cul3	 degron	near	 the	N-terminus	 of	 cyclin	 E	 is	 identified,	 and	 a	
unique	mechanism	for	Cul3-mediated	cyclin	E	destruction	is	proposed.		
RESULTS:	
Cyclin	E	binds	directly	to	Cul3	independently	of	BTB	domain-containing	
proteins		
Cul3	is	believed	to	require	a	BTB	protein	to	bind	cyclin	E,	but	previous	work	
from	our	lab	has	shown	Cul3	can	bind	cyclin	E	in	a	yeast	two-hybrid	screen,	which	
suggests	that	the	proteins	interact	directly	with	each	other	(Singer	et	al.	1999).	 	In	
order	 to	 determine	 the	 nature	 of	 the	 interaction	 between	 Cul3	 and	 cyclin	 E,	 and	
whether	the	two	proteins	interact	directly	with	each	other,	several	Flag-tagged	Cul3	
mutants	were	co-transfected	with	full-length	Myc-tagged	cyclin	E1	and	their	binding	
was	measured	using	immunoprecipitation.		The	mutants	represented	disruptions	of	
the	major	functional	regions	of	Cul3;	the	BTB	domain	interaction	region,	the	Nedd8	
modification	 site,	 and	 the	 gain	 of	 function	 403-459	 deletion	 (Zheng	 et	 al.	 2002;	
Wimuttisuk	 and	 Singer	 2007;	 Boyden	 et	 al.	 2012;	 McCormick	 et	 al.	 2014;	
Wimuttisuk	 et	 al.	 2014).	 Cyclin	 E	 bound	 to	 all	 Cul3	mutants	 tested,	 including	 the	
Cul3Δ51-67	mutant,	 which	 cannot	 bind	 BTB	 proteins	 (Figure	 2.1A	 lane	 3).	 These	
data	 imply	 that	 cyclin	 E	 is	 able	 to	 bind	 directly	 to	 Cul3	without	 the	 aid	 of	 a	 BTB	
protein,	unlike	what	has	been	shown	for	other	Cul3	substrates.		
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Figure	2.1:	 	Cul3	binds	cyclin	E	directly.	A:	 	Myc-cyclin	E	was	co-transfected	in	293	
cells	with	different	 Flag-tagged	Cul3	mutants	 including	Cul3Δ51-67,	which	 cannot	
bind	 BTB	 proteins,	 Cul3Δ403-459,	 which	 causes	 FHHt,	 and	 Cul3K712	 R,	 which	 is	
inactive	 because	 it	 cannot	 be	 neddylated.	 	 Immunoprecipitations	 (IPs)	 were	
performed	using	a	Flag	antibody.		A	western	blot	using	Myc	antibody	was	performed	
to	detect	cyclin	E.		IP	results	are	shown	in	the	top	panel.		B:		Flag-Cul3	or	Flag-Cul3	
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Myc-Cyclin E
S-SPOP
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Δ51-67	was	co-transfected	with	Myc-cyclin	E,	HA-ubiquitin,	and	S-tagged-SPOP.		An	
IP	for	Myc-cyclin	E	was	performed	followed	by	western	blotting	for	to	detect	S-SPOP	
(B,	 top	panel)	 and	 Flag-Cul3	 (B,	 second	panel).	 	 The	 lower	 three	 panels	 show	 the	
original	protein	levels	of	the	lysates	prior	to	immunoprecipitation.			
	
In	order	to	further	delineate	the	interaction	between	Cul3	and	cyclin	E,	Cul3	
and	 cyclin	 E1	 binding	was	 examined	 in	 the	 presence	 of	 SPOP,	 a	 BTB	protein	 that	
does	not	bind	or	participate	in	cyclin	E	degradation	(Kwon	et	al.	2006;	Zhang	et	al.	
2014).	 	We	 found	that	when	cyclin	E1	and	SPOP	are	co-transfected	with	WT	Cul3,	
cyclin	 E	 can	 co-immunoprecipitate	 SPOP,	 but	 cyclin	 E	 was	 not	 able	 to	 co-
immunoprecitpitate	 SPOP	 when	 the	 Cul3	 mutant	 Cul3Δ51-67,	 which	 cannot	 bind	
BTB	domain-containing	proteins,	was	used	(Figure	2.1B	lane	2	compared	to	lane	3).		
This	 shows	us	 that	Cul3	was	 ‘linking’	 cyclin	E	 to	 SPOP	 in	 this	 binding	 assay.	 	 The	
ability	 of	 cyclin	 E	 to	 immunopreciptitate	 SPOP	 only	 when	 it	 is	 bound	 to	 Cul3	 is	
consistent	with	a	direct	interaction	between	cyclin	E1	and	Cul3	and	that	the	binding	
interaction	 occurs	 outside	 of	 the	 region	 associated	 with	 binding	 BTB	 domain-
containing	proteins.	
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	Figure	2.2:		Mutants	of	cyclin	E1.		A:		Cartoon	showing	full	length,	wild-type	cyclin	E	
(top)	and	three	truncation	mutants	throughout	the	protein,	STOP100,	STOP200,	and	
STOP300.		B:		Cartoon	depicting	the	locations	of	point	mutants	and	alanine	scanning	
mutants	 (designated	by	amino	acid	number)	on	cyclin	E.	 	The	cleavage	site	which	
produces	LMW	cyclin	E	is	shown	in	red.	
.	
1 395Cleavage
STOP 300
STOP 200
STOP 100 (Unstable)
27 30 41 48 79 93
1 395
Cleavage
123
A.
B.
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Figure	 2.3:	 	 The	 N-terminus	 of	 cyclin	 E	 interacts	 with	 Cul3.	 	 A:	 	 Upper	 blot,	
immunoprecipitation	(IP)	for	Flag-Cul3	and	blot	 for	Myc-cyclin	E	showing	binding.		
Middle	and	 lower	blots	 show	relative	 levels	of	 transfected	protein	 in	 cell	 extracts.			
B:	Top	blot,	 IP	 for	Flag-Cul3	and	western	blot	 for	Myc-cyclin	E	showing	binding	of	
three	 N-terminally	 located	 alanine	 scanning	 mutants	 (lanes	 4,	 6,	 and	 8)	 in	
comparison	 to	 wild-type	 cyclin	 E	 (lane	 2).	 	 The	 lower	 two	 blots	 show	 levels	 of	
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transfected	 protein	 in	 the	 cell	 extracts.	 	 All	 binding	 assays	 were	 repeated	 a	
minimum	of	two	times.		The	result	shown	in	panel	B	was	repeated	four	times	and	is	
reproducible.	
Mutations	in	the	N-terminal	region	of	cyclin	E	prevent	degradation	by	the	Cul3	
complex		
	
In	 order	 to	 determine	 what	 region	 of	 cyclin	 E1	 binds	 to	 Cul3,	 two	 C-
terminally	 truncated	 cyclin	 E1	 mutants	 were	 analyzed	 for	 binding	 to	 Cul3	 and	
compared	 to	 full-length	 cyclin	 E1.	 	 These	 consisted	 of	 the	 N-terminal	 200	 amino	
acids	 (STOP	 200)	 of	 cyclin	 E	 and	 the	 N-terminal	 300	 amino	 acids	 (STOP	 300)	 of	
cyclin	E	(Figure	2.2).		A	STOP100	truncation	of	cyclin	E1	was	also	transfected,	but	it	
was	 found	 to	 be	 unstable	 and	 therefore	 not	 used	 for	 further	 experimentation	
(Figure	2.2).		Cul3	bound	to	both	cyclin	E1	truncation	mutants	as	well	as	wild	type	
cyclin	E1	 (Figure	2.3A	 compare	 lanes	2	 and	4	 to	 lane	6).	 	 To	 further	pinpoint	 the	
binding	 site,	 we	 examined	 the	 potential	 of	 several	 cyclin	 E1	 alanine-scanning	
mutants	 for	binding	to	Cul3	(Kelly	et	al.	1998).	 	Each	mutant	 in	this	set	contains	a	
charged	amino	acid	sequence	that	has	been	mutated	to	alanines.	Amongst	the	set	of	
mutants,	one	alanine-scanning	mutant	DPDEE→AAAA	(amino	acids	41-45),	which	is	
located	near	 the	N-terminus,	 showed	decreased	binding	 to	Cul3	 (Figure	2.3B	 first	
panel	lane	6	in	comparison	to	lanes	2,	4,	8,	and	10).		
After	determining	that	Cul3	only	requires	the	N-terminal	portion	of	cyclin	E1	
for	binding,	we	sought	to	determine	if	this	region	contains	all	the	necessary	signals	
for	Cul3-mediated	degradation	to	occur.		In	order	to	examine	this,	the	stability	of	the	
different	mutants	was	checked	 in	a	novel	 transfection	assay	utilizing	cells	 that	are	
deficient	for	Cul3.		It	was	observed	that	in	Cul3	hypomorphic	(floxed)	MEFs	(Mouse	
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Embryonic	Fibroblasts),	transfected	cyclin	E	was	more	abundant	than	in	WT	MEFs,	
similar	 to	 the	 endogenous	 levels	 of	 cyclin	 E	 (McEvoy	 et	 al.	 2007).	 	 	 Controls	 that	
were	 not	 Cul3	 substrates	 transfected	 with	 equal	 efficiency	 demonstrating	 the	
specificity	 for	 Cul3	 substrates	 in	 this	 assay.	 	 The	 same	 regulation	 of	 cyclin	 E	was	
observed	 when	 comparing	 WT	 (Cul3	 containing)	 and	 Cul3	 KO	 HEK293	 cells	
(Ibeawuchi	et	al.	2015)	(Figure	2.4A	lanes	1	and	2).	 	We	reasoned	that	if	a	mutant	
cyclin	E,	that	lacked	the	Cul3	degron,	was	transfected	into	these	two	genotypes,	we	
would	 not	 see	 a	 difference	 in	 levels	 of	 cyclin	 E.	 	 Therefore,	 transfected	 cyclin	 E1	
mutants	 that	are	Cul3	substrates	would	be	expected	 to	express	at	higher	 levels	 in	
the	Cul3	KO	cells	in	comparison	to	wild-type	293	cells.		On	the	other	hand,	a	mutant	
that	is	not	degraded	in	a	Cul3-dependent	fashion	would	be	expected	to	show	equal	
levels	of	transfected	protein	in	the	two	cell	types.			
Before	 experimentation	 began,	 two	 controls	 Myc-cyclin	 E1	 and	 lysineless	
cyclin	 E1	 were	 transfected	 into	 the	 two	 cell	 types	 (WT	 and	 Cul3	 KO	 293s).	 	 We	
observed	that	when	transfected	with	equal	amounts	of	WT	cyclin	E1,	the	protein	is	
detected	at	higher	levels	in	the	KO	293	cells	than	the	WT	cells	(Figure	2.4A	compare	
lanes	1	and	2).	 	 In	contrast,	 lysineless	cyclin	E1	was	expressed	evenly	 in	both	cell	
types	(Figure	2.4A	lanes	3	and	4),	indicating	the	utility	of	this	assay	as	a	measure	of	
the	substrate	being	recognized	for	degradation	instead	of	merely	binding.		Next,	the	
stability	 of	 the	 cyclin	 E1	 truncations	 were	 examined	 using	 this	 assay	 and	 we	
observed	that	both	the	STOP	200	and	STOP	300	cyclin	E	truncations	are	both	more	
stable	in	the	KO	cells,	 implying	that	the	degron	recognized	by	Cul3	is	found	within	
the	 first	 half	 of	 the	 cyclin	 E1	 protein	 (Figure	 2.4B	 compare	 lane	 1	 to	 lane	 2	 and	
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compare	lane	3	to	lane	4).	Taken	together,	these	results	demonstrate	that	the	Cul3	
degron	 resides	 in	 the	N-terminal	half	 of	 the	 cyclin,	 in	 contrast	 to	Cul1	 the	degron	
which	 encompasses,	 in	 part,	 T395	 located	 near	 the	 C-terminus	 (Clurman	 et	 al.	
1996).			
	
	
Figure	2.4:	 	Mutations	near	the	N-terminus	of	cyclin	E	result	in	increased	stability.	A:		
Controls	for	a	stability	assay	using	WT	and	Cul3	KO	293	cells	shows	that	cyclin	E,	a	
Cul3	substrate,	 is	more	stable	when	transfected	into	Cul3	KO	cells	(A:	 	Left	panel).		
Lysineless	 cyclin	E,	which	 cannot	be	ubiquitinated,	 is	 shown	as	a	negative	 control	
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(A:	 	 Right	 panel).	 	 B:	Myc-tagged	 STOP	200	 and	 STOP	300	 truncations	 of	 cyclin	E	
were	 transfected	 into	 wild-type	 and	 Cul3	 KO	 293	 cells	 and	 their	 expression	 was	
measured	using	a	Myc	(cyclin	E)	antibody.	 	C:	 	Three	Myc-tagged	alanine	scanning	
mutants,	 DPDEE→AAAAA	 (residues	 41-45,	 lanes	 1	 and	 2),	 KIDR→AAAA	 (amino	
acids	48-51,	lanes	3	and	4)	and	DKED→AAAA	(amino	acids	79-82,	lanes	5	and	6),	in	
addition	 to	 a	 triple	point	mutant,	 cyclin	E	K118R,	K123R,	K125R	 (Panel	C	 lanes	7	
and	8),	were	transfected	into	both	WT	and	Cul3	KO	cells	and	their	abundance	was	
measured	 using	 a	Myc	 (cyclin	 E)	 antibody.	 	 D:	 	 Diagram	 showing	 two	mutants	 in	
which	 portions	 of	 the	 N-terminal	 domain	 have	 been	 deleted.	 	 E:	 	 Expression	 of	
transfected	Myc-cyclin	EΔ31-82	and	Myc-cyclin	EΔ2-86	are	shown	 in	both	 the	WT	
and	KO	cells	(E,	right	panel,	lanes	1	through	4).		Quantification	of	each	western	blot	
(WB)	is	listed	below	each	lane	as	a	percent	relative	to	the	sample	in	the	KO	lane	for	
each	pair	(KO	is	always	100	percent).	 	Transfections	were	repeated	a	minimum	of	
three	times	and	representative	results	are	shown.	
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Figure	2.5:	 	Localization	of	cyclin	E	mutants	resembles	wild-type.	 	Myc-
tagged	 cyclin	 E	 mutants	 were	 transfected	 into	 HeLa	 cells	 and	
localization	 was	 determined	 using	 immunofluorescence.	 	 The	
localization	 of	 several	 mutants	 is	 shown:	 DPDEE→AAAAA	 (row	 2),	
KIDR→AAAA	(row	3),	 and	DKED→AAAA	(row	4).	 	The	 top	 row	shows	
the	localization	of	wild-type	cyclin	E.	
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Lysine	48	on	cyclin	E	serves	as	a	ubiquitination	site	for	Cul3	
	
To	pinpoint	specific	residues	on	cyclin	E	that	may	be	involved	in	degradation,	
cyclin	E	alanine	scanning	mutants	were	 transfected	 into	 the	Cul3	WT	and	KO	293	
cells.	 	 Three	 alanine-scanning	 mutants,	 DPDEE→AAAAA	 (amino	 acids	 41-45),	
KIDR→AAAA	 (amino	 acids	 48-51),	 and	DKED→AAAA	 (amino	 acids	 79-82),	 appear	
more	stable	in	the	wild-type	cells,	which	suggests	that	they	are	less	likely	degraded	
by	Cul3	(Figurer	2.4C).	All	three	of	these	mutants	are	located	near	the	N-terminus	of	
cyclin	 E	 and	 in	 order	 to	 further	 describe	 the	 importance	 of	 this	 region	 for	 Cul3-	
mediated	degradation	 to	 occur,	 two	 constructs	 containing	 deletions	 in	 this	 region	
were	 created	 (Figure	 2.4D).	 	 	 	 The	 first	 construct,	 cyclin	 EΔ31-82,	 is	 missing	 the	
region	containing	all	 three	of	the	stabilized	alanine	scanning	mutants.	 	The	second	
construct,	 cyclin	EΔ2-86,	 resembles	 the	 LMW	cyclin	E	 found	 in	 some	 cancer	 cells,	
and	 is	missing	 the	 entire	N-terminal	 region	 (Figure	2.4D).	 	 Both	 of	 these	mutants	
were	 transfected	 into	 the	 wild-type	 and	 Cul3	 KO	 HEK293	 cells,	 and	 both	
demonstrated	increased	stability	in	the	WT	cells	(Figure	2.4E,	compare	lane	1	to	2,	
and	 lane	 3	 to	 lane	 4),	 suggesting	 that	 this	 region	 may	 be	 necessary	 for	 Cul3-
mediated	degradation	of	cyclin	E	to	occur.			
Sometimes,	 phenotypes	 exhibited	 by	 mutant	 proteins	 can	 be	 explained	 by	
changes	in	the	localization	of	the	protein	within	the	cell.		In	order	to	determine	if	the	
phenotypes	 of	 the	 three	 stable	 alanine-scanning	 mutants	 are	 the	 result	 of	
localization	changes,	HeLa	cells	were	transfected	with	each	construct	and	visualized	
using	immunofluorescent	microscopy.		The	cellular	localization	of	the	three	mutants	
was	found	to	be	predominantly	nuclear,	similar	to	wild-type	cyclin	E,	indicating	that	
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their	increased	stability	was	not	a	result	of	a	change	in	cellular	localization	(Figure	
2.5).		The	DPDEE→AAAAA	(residues	41-45)	mutant	cannot	bind	Cul3	as	well	as	the	
others	(Figure	2.3),	which	provides	an	explanation	for	its	increased	stability	in	our	
assay.	 	 As	 the	 KIDR→AAAA	 (residues	 48-51)	 and	 DKED→AAAA	 (residues	 79-82)	
mutants	both	contain	lysine	residues	and	are	located	near	the	N-terminus	of	cyclin	E	
(Figure	 2.4C).	 	 	 	 The	 increased	 stability	 of	 the	 KIDR	 and	 DKED	 alanine	 scanning	
mutants	 as	well	 as	 the	 deletion	mutants	 imply	 that	 both	 lysine	 residues	 K48	 and	
K80	 are	 potential	 ubiquitination	 sites,	 and	 the	 degron	 that	 is	 recognized	 by	 Cul3	
likely	resides	within	the	N-terminal	portion	of	cyclin	E.			
To	establish	if	ubiquitination	on	K48	or	K80	of	cyclin	E	regulates	its	stability,	
we	determined	 if	 the	KIDR→AAAA	mutant	or	DKED→AAAA	mutant	stabilized	by	a	
mutation	in	ubiquitin	that	prevents	K48	branching,	a	type	of	branching	that	leads	to	
degradation	 (Grice	 and	 Nathan	 2016).	 	 To	 test	 this,	 all	 of	 the	 alanine	 scanning	
mutants	within	the	first	200	amino	acids	of	cyclin	E	were	transfected	into	both	cell	
types	 in	 the	 presence	 or	 absence	 of	 a	mutant	K48R	ubiquitin.	 	We	 observed	 that,	
unlike	WT	cyclin	E	which	was	stabilized	in	WT	cells	by	the	addition	of	the	dominant-
negative	K48R	ubiquitin	mutant	(Figure	2.6	compare	lanes	1	and	2	to	lanes	3	and	4),	
the	 KIDR→AAAA	mutant	was	 unaffected	 indicating	 it	 is	 no	 longer	 a	 substrate	 for	
ubiquitination-dependent	 degradation	 (Figure	 2.6	 lanes13-16).	 	 The	
DPDEE→AAAAA	(Cul3	binding	mutant,	lanes	9-12)	mutant	behaved	similarly	to	the	
KIDR→AAAA	mutant,	which	suggests	that	they	might	comprise	a	Cul3	degron,	which	
consists	of	a	binding	region	(DPDEE)	and	ubiquitination	site	 (K48	on	cyclin	E,	 the	
lysine	contained	 in	the	KIDR	mutant).	 	The	DKED→AAAA	mutant	(Figure	2.6	 lanes	
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17-20)	appears	similarly	to	wild-type	(Figure	2.6	lanes	1-4)	in	this	assay	suggesting	
the	K48	(the	KIDR	lysine)	and	not	K80	(the	DKED	lysine)	is	the	ubiquitination	site	
for	Cul3.	 	 	As	a	second	control,	cyclin	E	T395A,	which	cannot	be	degraded	by	Cul1,	
was	 examined	 and	we	 observed	 that	 it	 is	 a	 substrate	 of	 Cul3	 (Figure	 2.6	 lanes	 5	
through	8).		In	order	to	confirm	that	K48	is	an	ubiquitination	site	on	cyclin	E,	a	point	
mutant,	cyclin	E	K48R,	was	constructed	for	use	in	the	ubiquitination	assay.		Like	the	
KIDR	mutant,	cyclin	E	K48R	appears	relatively	stable	(Figure	2.6	lanes	21-24).		The	
increased	stability	of	the	KIDR	mutant	and	cyclin	E	K48R	suggests	that	K48	on	cyclin	
E	is	indeed	an	ubiquitination	site	utilized	by	Cul3	in	vivo.		Taken	together,	these	data	
suggest	 that	 the	 residues	DPDEE	 (binding	 site)	 and	KIDR	 (ubiquitination	 site)	 are	
part	 of	 a	 degron	 that	 is	 recognized	 by	 Cul3.	
	
Figure	2.6:		K48	is	a	Cul3	ubiquitination	site	on	cyclin	E.	 	Alanine	scanning	and	point	
mutants	 located	 within	 the	 first	 200	 amino	 acids	 of	 the	 cyclin	 E	 protein	 were	
transfected	 in	WT	 and	 KO	 293	 cells	 with	 or	 without	 the	 addition	 of	 an	 S-tagged	
K48R	ubiquitin	construct.		Wild-type	cyclin	E	(lanes	1-4)	and	cyclin	E	T395A,	which	
cannot	be	degraded	by	Cul1	(lanes	5-8),	were	included	as	controls.	 	Three	cyclin	E	
alanine	scanning	mutants	are	shown	here,	DPDEE→AAAAA	(residues	41-45,	lanes	9-
12),	KIDR→AAAA	(residues	48-51,	lanes	13-16),	and	DKED→AAAA	(residues	79-82,	
lanes	17-20).	The	point	mutant	cyclin	E	K48R	is	also	shown	(lanes	21-24).		
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The	N-terminal	domain	of	cyclin	E	is	required	for	degradation	
	
In	order	to	truly	measure	if	cyclin	E	that	lacks	its	N-terminus	is	differentially	
degraded	by	Cul3	compared	to	wild-type	cyclin	E,	it	is	necessary	to	measure	the	rate	
of	degradation	of	these	proteins.	To	ascertain	the	role	of	the	N-terminal	domain	of	
cyclin	 E	 degradation,	 cyclin	 E	 half-lives	 were	measured	 and	 compared	 in	 cells	 of	
both	 genotypes	 (Cul3	WT	 and	 KO).	 	 Cells	 were	 transfected	 with	 full-length	 Myc-
tagged	cyclin	E	or	Myc-tagged	cyclin	E	Δ2-86.			Following	addition	of	cycloheximide	
(CHX)	 the	 cells	were	harvested	every	 two	hours	 for	 ten	hours.	 	We	observed	 that	
WT	cyclin	E	has	a	half-life	of	 about	2	hours	 in	 the	WT	cell	 line	but	a	half-life	of	5	
hours	in	the	KO	cells	demonstrating	that	loss	of	Cul3	reduces	the	half-life	of	cyclin	E	
(Figure	2.7	compare	WT	cyclin	E	(left)	to	cyclin	E	Δ2-86	(right).	 	We	also	observed	
that	cyclin	E	Δ2-86	has	a	5	hour	half-life	and	shows	equal	stability	in	both	WT	and	
Cul3	KO	cells,	demonstrating	the	inability	of	Cul3	to	target	it	for	degradation	(Figure	
2.7,	right	panel,	lanes	1-5	vs.	lanes	6-10).		
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Figure	 2.7:	 	 The	 N-terminal	 domain	 of	 cyclin	 E	 is	 required	 for	 Cul3-mediated	
degradation.	 	Cul3	WT	and	KO	293	cells	were	transfected	with	Myc-tagged	cyclin	E	
(Left)	 or	 Myc-tagged	 cyclin	 EΔ2-86	 (Right).	 	 After	 24	 hours,	 cycloheximide	 was	
added	 and	 cells	 were	 harvested	 at	 the	 indicated	 time	 points.	 	 Half-lives	 were	
determined	 via	 Western	 blots	 (top),	 and	 quantified	 (bottom).	 	 Repetition	 of	 this	
experiment	yields	similar	results.	
	
	Cul3	cannot	degrade	endogenous	LMW	cyclin	E	
	
As	low	molecular	weight	(LMW)	cyclin	E	can	be	found	endogenously	in	some	
cells,	 we	 sought	 to	 determine	 if	 loss	 of	 Cul3	 affects	 the	 presence	 of	 these	 LMW	
forms.		It	has	been	previously	shown	that	the	LMW	cyclin	E	truncations	can	still	be	
degraded	in	a	Cul1-dependent	manner	(Delk	et	al.	2009).	Overall,	the	Cul3	KO	293	
cells	have	more	endogenous	cyclin	E	than	the	wild-type	(Ibeawuchi	et	al.	2015).		We	
observed	that	the	50	kDa	endogenous	cyclin	E	band	increases	upon	inhibition	of	the	
proteasome	in	WT	cells	to	equal	the	amount	of	the	50	kDa	protein	that	is	present	in	
the	KO	cells	prior	to	proteasome	inhibition,	demonstrating	that	the	50	kDa	band	is	a	
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substrate	of	Cul3	in	293	cells	(Figure	2.8	lane	1	vs	lane	3).		Two	LMW	cyclin	E	bands	
are	 also	 detected,	 the	 smallest	 of	 which	 is	 about	 43	 kDa,	 and	 they	 appear	 to	 be	
equally	 expressed	 in	 WT	 and	 KO	 cells	 (Figure	 2.8	 lanes	 1	 and	 3).	 	 The	 relative	
abundance	of	the	LMW	bands	is	elevated	equally	in	both	cell	types	upon	proteasome	
inhibition	(Figure	2.8	lanes	2	and	4),	indicating	that	LMW	cyclin	E	still	targeted	for	
ubiquitin-mediated	proteolysis	equally	in	both	cell	types.		
	
Figure	2.8:	 	LMW	cyclin	E	is	not	degraded	by	Cul3.	 	The	upper	blot	shows	levels	of	
endogenous	 cyclin	 E	 in	 WT	 and	 Cul3	 knockout	 (KO)	 293	 cells.	 	 The	 proteasome	
inhibitor	MG132	has	been	added	to	the	cells	shown	in	lanes	2	and	4.		The	lower	blot	
shows	levels	of	actin	in	the	same	cells.	
	
Cyclin	E2	is	not	a	substrate	of	Cul3	
	
Mammals	contain	 two	cyclin	E	genes,	CCNE1	(cyclin	E1)	and	CCNE2	(cyclin	
E2),	which	produce	different	proteins	(Sherr	and	Roberts	1999;	Geng	et	al.	2003).		
The	 two	 cyclin	 E	 proteins	 share	 high	 homology	 and	many	 structural	 similarities,	
including	 the	 Cdk2	 interacting	 domain	 (Perez-Neut	 et	 al.	 2015).	 	 In	 order	 to	
determine	if	the	observed	degradation	of	cyclin	E	was	specific	to	cyclin	E1,	cyclin	E2	
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was	transfected	into	the	WT	and	KO	293	cells.		Cyclin	E2	is	evenly	expressed	in	both	
cell	 types,	 indicating	that	 it	does	not	get	ubiquitinated	by	Cul3	(Figure	2.9,	 lanes	1	
and	3	compared	to	lanes	2	and	4).			
	
	
Figure	 2.9:	 	Cyclin	E2	 is	 not	a	Cul3	 substrate.	 	 Transfected,	Myc-tagged	 cyclin	 E2,	
shown	here	in	duplicate	is	shown	here	in	WT	(Lanes	1	and	3)	and	Cul3	KO	(lanes	2	
and	4)	HEK	293	cells.	
	
Loss	of	Cul3	results	in	early	accumulation	of	cyclin	E	after	release	from	serum	
starvation	
	
In	order	to	determine	when	loss	of	Cul3	resulted	in	cyclin	E	accumulation	we	
turned	to	the	Cul3	knockout	293	cells.	Previous	work	from	our	lab	has	shown	that	
loss	of	Cul3	in	mouse	embryonic	fibroblasts	(MEFs)	results	in	increased	amounts	of	
cyclin	E	and	a	greater	percentage	of	cells	in	S-phase	(McEvoy	et	al.	2007).	Analysis	
of	Cul3	KO	293	cells	by	flow	cytometry	shows	an	increased	percentage	of	cells	in	S	
phase	when	compared	to	WT	293s	(Figure	2.10).		This	result	shows	that	the	excess	
cyclin	 E	 in	 the	 Cul3	 KO	 293	 cells	 is	 functional	 as	 it	 is	 capable	 of	 initiating	 DNA	
replication.	 	 To	 determine	 at	 which	 point	 during	 the	 cell	 cycle	 the	 Cul3	 KO	 cells	
begin	to	accumulate	excess	cyclin	E,	both	WT	and	KO	cells	were	arrested	in	G1	via	
serum	starvation	and	released.	 	The	KO	cells	enter	S-phase	earlier	than	their	wild-
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from 050217 gel2 myc
Lane             1              2              3           4
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type	counterparts,	as	four	hours	after	release	into	G1,	only	47.1	percent	of	wild-type	
cells	are	in	S-phase	or	G2	but	61.7	percent	of	Cul3	KO	cells	have	reached	this	point	
(Figure	2.11,	WT	cells	are	shown	on	the	left	and	KO	are	shown	on	the	right).			
In	 order	 to	 determine	 if	 the	 increased	 percentage	 of	 cells	 in	 S-phase	 is	 a	
result	 of	 cyclin	 E	 accumulation	 during	 G1,	 we	 utilized	 a	 similar	 serum-starve	 and	
release	experiment.		We	examined	cyclin	E	accumulation	in	Cul3	hypomorphic	MEFs	
(mouse	 embryonic	 fibroblasts)	 after	 serum	 starvation	 and	 release.	 	We	 observed	
cyclin	E	 accumulation	2	 hours	 earlier	 in	 Cul3	hypomorphic	 (floxed)	MEFs	 than	 in	
WT	MEFs	(Figure	2.12	WT	top	row,	Cul3	hypomorphic	flx/flx	bottom	row).		This	is	
consistent	with	a	role	 for	Cul3	 in	regulation	of	cyclin	E	 levels	 in	quiescent	cells,	as	
we	 had	 observed	 in	 an	 animal	 model	 (McEvoy	 et	 al.	 2007),	 and	 indicates	 Cul3	
regulation	 of	 cyclin	 E	 occurs	 in	 a	 different	 temporal	 window	 than	 the	 Cul1	
regulation	of	cyclin	E	which	takes	place	4	hours	after	the	onset	of	DNA	replication	
(Bhaskaran	et	al.	2013).			 	
50	
	
	
Figure	 2.10:	 	The	excess	cyclin	E	 in	Cul3	KO	293	cells	 increases	proliferation.	 	 Flow	
cytometry	analysis	of	proliferating	293	cells	stained	with	propidium	iodide,	which	
labels	the	DNA	allowing	for	the	quantification	of	DNA	content.	WT	cells	are	shown	
on	the	left	and	Cul3	KO	cells	are	shown	on	the	right.		Cells	in	G1	are	shown	in	purple,	
S-phase	 cells	 are	 shown	 in	 yellow,	 and	 G2/M	 cells	 are	 shown	 in	 green.	 	 At	 least	
20,000	cells	were	counted	for	each	experiment.		The	quantification	show	represents	
and	average	of	three	experiments.			
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Figure	 2.11:	 	Cells	lacking	Cul3	enter	S-phase	early.	 	Cells	were	serum-starved	and	
released	into	G1.	 	Cells	were	harvested	at	4-hour	intervals,	stained	with	propidium	
iodide,	 and	 analyzed	 by	 flow	 cytometry.	 	 Quantification	 of	 the	 resulting	 cell	 cycle	
profiles	is	shown	(Right).	
	
Figure	 2.12:	 	 Cyclin	 E	 levels	 increase	 early	 in	 cells	 that	 are	 hypomorphic	 for	 Cul3.		
Western	blot	showing	levels	of	endogenous	cyclin	E	in	mouse	embryonic	fibroblasts	
(MEFs)	that	are	wild-type	(WT,	top	row)	or	deficient	for	Cul3	(flx/flx,	bottom	row).		
Cells	that	had	been	serum-starved	and	released	were	collected	at	two-hour	intervals	
as	indicated.	
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RhoBTB3	interacts	with	UbE2E1	to	facilitate	complex	formation	
The	previous	data	imply	that	cyclin	E	can	bind	Cul3	without	the	assistance	of	
a	 BTB	 domain-containing	 substrate	 adaptor	 such	 as	 RhoBTB3.	 	 We	 therefore	
became	 interested	 in	what	 potential	 role	RhoBTB3	had	 in	 Cul3	mediated	 cyclin	 E	
degradation,	 as	 it	 has	 been	 suggested	 that	 RhoBTB3	 facilitates	 Cul3-mediated	
ubiquitination	of	cyclin	E	(Lu	and	Pfeffer	2013).	 	Like	Cul3,	RhoBTB3	binds	 to	 the	
cyclin	E	STOP	200	and	STOP	300	 truncations	 (Figure	2.13	panel	A	 lanes	2	and	4).		
RhoBTB3	 shows	a	decreased	ability	 to	bind	 the	DPDEE→AAAAA	 (amino	acids	41-
45)	alanine	scanning	mutant	 in	comparison	 to	other	mutants	 tested,	which	 is	also	
similar	to	Cul3	(Figure	2.14	panel	B,	compare	lane	6	to	lanes	2	and	4).	 	 	Binding	of	
RhoBTB3	 to	 the	 DKED→AAAA	 (amino	 acids	 79-82)	 alanine	 scanning	mutant	 also	
appears	reduced	(Figure	2.13	lane	8).	
Since	 RhoBTB3	 is	 not	 essential	 for	 the	 Cul3/cyclin	 E	 interaction,	 we	
speculated	 that	 it	 might	 be	 playing	 another	 role	 in	 the	 active	 complex.	 	 We	
hypothesized	that	since	specific	E2	recruitment	should	be	an	essential	role	 for	the	
E3	ligase	 it	may	be	that	RhoBTB3	is	responsible	 for	recruiting	the	E2	enzyme	that	
ubiquitinates	cyclin	E.		If	BTB	proteins	are	involved	in	E2	selection,	it	would	ensure	
that	 the	 proper	 E2	 is	 recruited	 to	 form	 the	 correct	 ubiquitin	 linkage	 for	 a	 given	
substrate.		To	test	this	hypothesis,	we	examined	the	binding	of	Cul3	and	RhoBTB3	to	
the	E2	 enzyme	UbE2E1	which	 forms	degradative	K48-linked	 chains	 and	has	 been	
shown	to	associate	with	Cul3	(Plafker	et	al.	2009).		We	observed	that	both	Cul3	and	
RhoBTB3	bind	to	UbE2E1	(Figures	2.14	lane	2	and	2.15	lane	2).	We	then	examined	if	
Cul3	binding	 to	UbE2E1	requires	 the	BTB	domain	 interacting	 region	on	Cul3.	 	We	
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observed	that	UbE2E1	cannot	bind	the	Cul3	mutant	that	is	incapable	of	binding	BTB	
proteins,	Cul3Δ51-67	(Figure	2.15	lane	3).	 	This	 indicates	that	the	interaction	with	
the	 E2	 enzyme	 is	 likely	 not	 entirely	mediated	 by	 RhoBTB3.	 To	 confirm	 that	 Cul3	
does	not	mediate	the	interaction	between	RhoBTB3	and	UbE2E1,	Cul3	KO	293	cells	
were	used	to	analyze	binding	(Ibeawuchi	et	al.	2015).	 	As	can	be	seen	in	lanes	two	
and	five,	RhoBTB3	binds	to	the	E2	enzyme	in	the	absence	of	Cul3	(Figure	2.14	lane	
4)	to	the	same	degree	that	the	two	proteins	bind	in	the	presence	of	Cul3	(Figure	2.14	
lane	2)	indicating	that	Cul3	is	not	required	for	the	BTB	to	interact	with	the	E2	and	
BTB	 proteins	 may	 be	 necessary	 to	 help	 associate	 the	 E2	 enzyme	 with	 Cul3.		
Together	 these	 results	demonstrate	 that	 a	BTB	protein,	 in	 this	 instance	RhoBTB3,	
can	interact	with	an	E2	enzyme	independently	of	Cul3	and	may	enhance	E2	binding	
in	vivo.	
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Figure	 2.13:	 	 RhoBTB3	 interacts	 with	 the	 N	 terminus	 of	 cyclin	 E.	 A:	 	 Upper	 blot,	
immunoprecipitation	results	showing	binding	between	S-tagged	RhoBTB3	and	Myc-
tagged	cyclin	E	truncations.		The	lower	blots	show	levels	of	the	transfected	proteins	
in	the	cell	extracts.		B:		The	upper	blot	shows	immunoprecipitations	results	to	check	
for	binding	between	S-RhoBTB3	and	Myc-cyclin	E	 alanine	 scanning	mutants.	 	 The	
Four	mutants	shown	here	are	27-29	(RSR,	lanes	1	and	2),	30-32	(KRK,	lanes	3	and	
4),	41-45	(DPDEE,	lanes	5	and	6),	and	79-82	(DKED,	lanes	7	and	8).		The	lower	blots	
show	the	expression	of	the	transfected	proteins	in	cell	lysates.	
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Figure	2.14:	 	RhoBTB3	binds	an	E2	enzyme.	 	RhoBTB3	was	co-transfected	with	the	
E2	ubiquitin	conjugating	enzyme	HA-tagged	UbE2E1	in	the	presence	of	endogenous	
Cul3	(WT	cells,	 lanes	one	and	 two)	and	absence	of	Cul3	(KO	cells,	 lanes	 three	and	
four).		Immunopreciptations	(IPs)	were	used	to	check	binding.	
	
Figure	 2.15:	 	Cul3	 requires	a	BTB	protein	 to	 interact	with	UbE2E1.	 	 Flag-WT	 Cul3	
(lane	2)	 and	Flag-Cul3Δ51-67,	which	 cannot	bind	BTB	proteins,	 (lane	3)	were	 co-
transfected	with	 the	HA-tagged	 E2	 enzyme	UbE2E1.	 	 Immunoprecipitations	 using	
Flag	 antibody	 were	 conducted	 to	 check	 for	 binding.	 	 The	 top	 row	 shows	 the	 IP	
results	while	the	bottom	two	rows	show	the	protein	expression	in	the	cell	extracts.	
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DISCUSSION:	
	
Cyclin	E	protein	 accumulates	 in	 late	G1,	 peaks	 in	 early	 S-phase	 and	 rapidly	
disappears.	 	 Increased	 levels	 of	 cyclin	 E	 are	 associated	with	 cell	 cycle	 errors	 and	
tumorigenesis	and	loss	of	cyclin	E	in	MEFs	results	in	the	inability	of	the	cells	to	exit	
from	 quiescence	 (Said	 and	 Medina	 1995;	 Geng	 et	 al.	 2003).	 	 Cyclin	 E	 undergoes	
several	 post-translational	 modifications	 in	 cells	 including	 phosphorylation	 and	
ubiquitination	resulting	in	its	degradation	by	the	proteasome.		Research	has	shown	
that	cyclin	E	can	be	proteolytically	cleaved	resulting	in	truncated	forms	of	the	cyclin,	
many	of	which	lack	portions	of	the	protein	near	the	N-terminus	(Porter	et	al.	2001;	
Wang	et	al.	2003).		These	LMW	forms	of	cyclin	E	are	associated	with	poor	prognosis	
in	cancer	patients	and	overexpression	of	the	LMW	cyclin	E	has	also	been	shown	to	
cause	increased	cell	cycle	errors	and	chromosome	instability	in	cell	culture	models	
compared	to	full	length	cyclin	E	(Bagheri-Yarmand	et	al.	2010).		Others	have	shown	
that	the	LMW	forms	of	cyclin	E	have	an	increased	ability	to	activate	Cdk2,	resulting	
in	an	increase	of	Cdk2	kinase	activity	(Porter	et	al.	2001;	Wingate	et	al.	2005).		It	has	
also	 been	 demonstrated	 that	 these	 cyclin	 E	 truncations	 can	 be	 degraded	 in	 a	
ubiquitin-dependent	manner	(Delk	et	al.	2009).		
Two	ubiquitin	ligase	pathways,	Cul1	and	Cul3,	are	known	to	degrade	cyclin	E.		
Cul1-mediated	 degradation	 has	 been	 extensively	 investigated	 and	 it	 is	 known	 to	
degrade	cyclin	E	that	is	bound	to	Cdk2	and	require	phosphorylation	of	residues	T77	
and	T395	on	cyclin	E	in	order	to	recognize	it	for	degradation	(Clurman	et	al.	1996;	
Loeb	et	al.	2005;	Minella	et	al.	2008).		In	contrast,	the	Cul3-based	pathway	is	not	as	
well	understood	and	is	known	to	degrade	cyclin	E	that	is	not	bound	to	Cdk2	(Singer	
57	
et	 al.	 1999).	 	 LMW	 cyclin	 E	 containing	 complexes	 have	 been	 shown	 to	 be	 more	
poorly	inhibited	by	the	cyclin-dependent	kinase	inhibitors	(CKIs)	p21	and	p27	(Akli	
et	al.	2004;	Wingate	et	al.	2005).		It	has	been	proposed	that	the	LMW	cyclin	E	may	be	
capable	 of	 sequestering	 the	 CKIs	 and	 therefore	 preventing	 them	 from	 interacting	
with	 full	 length	 cyclin	 E,	 which	 is	 believed	 to	 be	 more	 susceptible	 to	 inhibition,	
ultimately	resulting	in	the	increased	Cdk2	activity	that	is	associated	with	the	LMW	
cyclin	E	(Wingate	et	al.	2005).	 	Our	data	 implies	that	decreased	inhibition	of	LMW	
cyclin	E	by	p27	and	p21	may	only	provide	a	partial	explanation	for	the	accumulation	
of	LMW	cyclin	E	and	a	secondary	Cul3-based	mechanism	may	also	contribute	to	the	
increased	 activity.	 	 This	 mechanism	 results	 from	 bypassing	 Cul3	 degradation	 of	
cyclin	E	by	cleaving	off	the	N-terminal	degron	of	cyclin	E	making	more	available	to	
interact	with	Cdk2	(Figure	2.16).	
We	show	that	K48	is	a	ubiquitination	site	on	cyclin	E	utilized	by	Cul3	(Figure	
2.6).		This	finding	is	notable	given	what	is	known	about	the	structure	of	the	cyclin	E	
protein	 as	 the	 N-terminus,	 which	 contains	 K48,	 is	 believed	 to	 be	 a	 disordered,	
mostly	hydrophilic	region	(Rath	and	Senapati	2014).	The	structure	of	cyclin	E	bound	
to	Cdk2	has	been	determined	(Honda	et	al.	2005),	but	the	published	structure	only	
includes	 amino	 acids	 81-363	 of	 cyclin	 E	 and	 therefore	 did	 not	 include	 the	 N-
terminus	 of	 the	 cyclin.	 	 Recently,	 advanced	modeling	 techniques	 have	predicted	 a	
structure	for	the	N-terminal	region	of	cyclin	E	which	shows	that	this	portion	of	the	
protein	 is	mostly	disordered	with	 the	notable	exception	of	a	predicted	alpha	helix	
encompassing	the	sequence	“DEEMAKID”	(amino	acids	43-50,	Figure	2.18A)	(Rath	
and	 Senapati	 2014).	 	 Coincidentally,	 the	 alanine	 scanning	 mutants	 in	 this	 region	
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(DPDEE→AAAAA	and	KIDR→AAAA)	exhibited	 the	most	notable	phenotypes	 in	our	
study	as	DPDEE	exhibited	diminished	binding	to	the	Cul3	complex	and	KIDR→AAAA	
cannot	be	degraded	in	a	Cul3-dependent	manner	(Figures	2.3,	2.4	and	2.6).		Our	data	
suggests	that	this	structural	motif	may	form	part	of	the	interface	on	cyclin	E,	which	
is	responsible	for	Cul3	interaction	and	also	functions	as	the	Cul3	degron	on	cyclin	E	
(Figure	2.17A).	 	The	putative	helix	 comprising	 the	Cul3	degron,	 including	 the	K48	
ubiquitination	site,	is	conserved	in	other	mammalian	species	(Figure	2.17B),	which	
is	notable	as	Cul3	also	regulates	cyclin	E	 in	mice	(Singer	et	al.	1999;	McEvoy	et	al.	
2007).		Additionally,	cyclin	E2,	which	cannot	be	degraded	by	Cul3	(Figure	2.9),	does	
not	resemble	cyclin	E1	 in	 the	region	of	 the	newly	proposed	degron	(figure	2.17C).		
The	net	charge	of	 the	region	was	calculated	by	 finding	 the	difference	between	 the	
number	of	basic	residues	and	the	number	of	acidic	residues.	 	Using	this	method,	 it	
can	be	seen	that	cyclin	E1	is	very	acidic	in	this	region	with	a	net	charge	of	negative	
two.	 	 Cyclin	 E2,	 in	 contrast,	 is	 extremely	 basic	 with	 a	 net	 charge	 of	 four	 (Figure	
2.17C).	 	 Additionally,	 a	 Chou-Fasman	 algorithm	 was	 used	 to	 predict	 possible	
structures	of	both	cyclin	E	proteins	in	the	degron	region	(Chou	and	Fasman	1975).		
This	 method	 revealed	 what	 is	 possibly	 a	 helical	 region	 in	 cyclin	 E1	 but	 an	
unstructured	 region	 in	 cyclin	E2	 (Figure	2.17C).	 	Taken	 together,	 this	 information	
suggests	that	the	Cul3	degron	comprises	a	structural	feature	that	is	unique	to	cyclin	
E1.	These	data	demonstrate	the	critical	role	of	 the	Cul3	complex	 in	degradation	of	
cyclin	 E	 by	 providing	 evidence	 that	 suggests	 that	 Cul3’s	 ability	 to	 degrade	 LMW	
cyclin	E	which	 lack	their	N-termini	may	be	 impaired	as	 the	Cul3	degron	 is	 located	
near	the	cyclin	E	N-terminus.		Cul3	uses	a	mechanism	distinct	from	the	Cul1-based	
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pathway	to	recognize	cyclin	E	for	degradation,	as	Cul3	does	not	require	cyclin	E	to	
be	phosphorylated	on	T395	for	degradation	to	occur	(Figure	2.6	lanes	5-8).			
The	 data	 presented	 here	 support	 the	 idea	 that	 LMW	 cyclin	 E	 is	 still	 a	
substrate	of	the	Cul1	ubiquitin	ligase	pathway	since	LMW	cyclin	E	increases	in	the	
Cul3	KO	293	cells	upon	the	addition	of	MG132,	indicating	that	it	is	still	degraded	in	a	
ubiquitin-dependent	manner	(Figure	2.8).	 	 In	addition,	other	 labs	have	also	shown	
that	LMW	cyclin	E	can	still	be	degraded	by	the	ubiquitin	proteasome	system	(Delk	et	
al.	2009).		
It	 has	 been	 suggested	 that	 Cul3	 utilizes	 the	 substrate	 adaptor	 RhoBTB3	 to	
target	cyclin	E	for	degradation	(Lu	and	Pfeffer	2013).	 	Our	work	sheds	light	on	the	
mechanistic	 purpose	 of	 RhoBTB3	 in	 cyclin	 E	 degradation	 as	we	 demonstrate	 that	
RhoBTB3	is	involved	in	the	binding	of	the	E2	ubiquitin	conjugating	enzyme	and	can	
bind	 the	E2	UbE2E1	both	 in	 the	 presence	 and	 absence	 of	 Cul3	 (Figure	 2.1).	 	 This	
finding	is	significant	as	it	suggests	that	Cul3	substrate	adaptors	may	play	a	role	in	E2	
selection,	which	would	help	to	explain	how	Cul3	 is	capable	of	 forming	a	variety	of	
ubiquitin	 chain	 linkages	 as	 different	 E2s	 are	 associated	 with	 this	 process.	 	 The	
revelation	that	Cul3Δ51-67,	which	cannot	bind	BTB	proteins,	is	incapable	of	binding	
UbE2E1	 (Figure	 2.15	 lane	 3	 compared	 to	 lane	 2)	 presents	 a	 second	 piece	 of	
information	in	support	of	this	idea	that	BTB	proteins	are	necessary	for	E2	selection	
to	occur.		These	findings	may	shed	light	on	interactions	between	Cul3,	BTB	proteins,	
and	E2s,	a	finding	which	may	be	applicable	to	other	BTB	proteins	and	substrates.	In	
addition	to	clarifying	the	mechanistic	details	regarding	Cul3-mediated	degradation	
of	 cyclin	 E,	 the	 work	 presented	 here	 also	 identifies	 the	 temporal	 window	 during	
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which	such	degradation	occurs.	 	Previous	work	has	shown	that	loss	of	Cul3	results	
in	 cyclin	 E	 accumulation	 and	 exit	 from	 quiescence	 in	 mice	 (McEvoy	 et	 al.	 2007),	
leading	us	to	hypothesize	that	loss	of	Cul3	results	in	earlier	increases	in	cyclin	E	and	
entry	into	S-phase.		Here,	this	hypothesis	is	supported	as	cells	that	are	hypomorphic	
for	 Cul3	 both	 enter	 the	 cell	 cycle	 earlier	 than	 their	 WT	 counterparts	 and	 show	
increased	 levels	 of	 cyclin	 E	 earlier	 than	 wild-type	 cells	 following	 release	 from	
quiescence	(Figure	2.11	and	2.12).	 	These	data	suggest	that	Cul3	is	responsible	for	
maintaining	 levels	of	cyclin	E	earlier	 in	 the	cell	 cycle	and	preceding	 the	start	of	S-
phase,	 which	 is	 again	 in	 contrast	 to	 the	 Cul1	 degradation	 pathway	 that	 degrades	
cyclin	 E	 later	 during	 S-phase	 (Bhaskaran	 et	 al.	 2013).	 	 Taken	 together,	 our	 data	
suggests	 that	 during	 G1,	 Cul3	 functions	 to	 suppress	 levels	 of	 cyclin	 E	 via	
ubiquitination	of	its	N-terminal	domain	(Figure	2.18).			Lack	of	cyclin	E	regulation	by	
Cul3	 during	 G1	 might	 contribute	 to	 the	 increased	 cyclin	 E/Cdk2	 activity	 that	 is	
observed	in	LMW	cyclin	E	containing	cancer	cells	(Figures	2.16	and	2.18).	
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Figure	2.16:	 	LMW	cyclin	E	cannot	be	degraded	by	Cul3.	 	 	This	model	demonstrates	
Cul3’s	 role	 in	 degradation	 of	 full-length	 cyclin	 E	 (Left)	 and	 contrasts	 it	 with	
improper	regulation	of	LMW	cyclin	E	(Right).	 	Full	 length	cyclin	E	 is	ubiquitinated	
and	degraded	via	Cul3	during	G1,	 leaving	some	cyclin	E	available	 to	activate	Cdk2.		
However,	 in	 cells	 containing	 LMW	 cyclin	 E	 which	 lacks	 its	 N-terminal	 domain,	
proper	degradation	of	LMW	cyclin	E	by	Cul3	might	not	occur,	which	might	result	in	
increased	activation	of	Cdk2.	
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Figure	 2.17:	 	 Cyclin	 E1	 contains	 a	 putative	 Cul3	 degron	 that	 is	 conserved	 in	 other	
mammals	but	lacking	in	cyclin	E2.		A:		Others	have	proposed	a	helix	located	in	the	N-
terminal	 region	 of	 cyclin	 E1	 (Rath	 and	 Senapati,	 2014).	 	 The	 proposed	 helix	 (A,	
shown	 in	blue)	overlaps	 the	DPDEE	 (Cul3	binding)	and	KIDR	 (ubiquitination	 site)	
alanine	scanning	mutants	(shown	in	red),	suggesting	that	the	Cul3	degron	is	part	of	
a	structural	feature	on	cyclin	E.	 	B:	 	The	Cul3	degron	is	highly	conserved	in	mouse	
(Mus	musculus)	and	rat	(Rattus	norvegicus)	cyclin	E1	(outlined	in	red).		C:			Sequence	
comparison	of	the	degron	region	in	cyclin	E1	(bottom)	to	the	same	region	in	cyclin	
E2	 (top).	 	 Chou-Fasman	 analysis	 of	 the	 amino	 acid	 sequences	 suggests	 that	 the	
structures	differ	between	cyclin	E1	and	cyclin	E2.	 	Additionally,	the	Cul3	degron	in	
cyclin	E1	is	acidic,	with	a	net	charge	of	minus	two	(difference	between	the	number	
of	acidic	residues	and	the	number	of	basic	residues).		The	same	region	in	cyclin	E2	is	
extremely	basic	with	a	net	charge	of	plus	four.	
	
Figure	2.18:		Cul3	degrades	cyclin	E	during	G1.	 	Our	data	is	consistent	with	a	model	
where	 Cul3	 is	 responsible	 for	 maintaining	 cyclin	 E	 levels	 during	 G1	 in	 order	 to	
prevent	 early	 entrance	 into	 S-phase.	 	 Cul1	 is	 known	 to	 degrade	 cyclin	 E	 after	 S-
phase	 has	 begun,	 so	 therefore	 the	 two	 ligases	work	 to	 degrade	 the	 cyclin	 at	 two	
different	points	during	the	cell	cycle.	
nnnnnnnnnnnnnnnnnnnnnnn
E2-TQDVKKRREEVTKKHQYEIRNCW
E1-TVFLQDPDEEMAKIDRTARDQCG
hhhhhtttthhhhhhhhhhhhhh
h=helix
t=turn
n=no structure
Cyclin E1 net charge: -2 (Acidic)
Cyclin E2 net charge: +4 (Basic)
C.
MPRERRERDAKERDTMKEDGGAEFSARSRKRKANVTVFLQDPDEEMAKIDRTARDQCGSQPWDNNAVCADPCSLIPTPDKED...
1 80
TVFLQDPDEEMAKIDRTARDQCG
AVFLQDPDEEIAKIDKTVKSEDS
AVFLQDPDEEIAKIDKTVKSQDS
Human cyclin E1
Mouse cyclin E1
Rat cyclin E1
A.
B.
G1 G2S M
Cul3-/- Cul3+/+
Cul3 Cul1
cyclin E
	
63	
	
MATERIALS	AND	METHODS	
	
Cell	culture	and	transfections:		Cells	(HEK	293,	HeLa,	and	MEFs)	were	maintained	
in	 DMEM	 supplemented	 with	 ten	 percent	 fetal	 bovine	 serum	 and	
penicillin/streptomycin.		HEK	293	and	HeLa	cells	were	split	1:20	for	transfection	in	
6cm	 dishes	 the	 night	 before	 transfection.	 	 Transfections	 were	 completed	 using	
calcium	phosphate	to	precipitate	the	DNA	onto	the	cells.		For	immunoprecipitations	
and	expression	 level	 assays,	 cells	were	harvested	48	hours	post	 transfection.	 	 For	
HeLa	and	293	cells,	between1	and	10	µg	of	plasmid	DNA	was	transfected	into	each	
plate.	 	 For	 experiments	 using	 cycloheximide,	 drug	 was	 added	 24	 hours	 post-
transfection	 at	 a	 final	 concentration	 of	 50	 µg	 per	 milliliter.	 	 Cells	 were	 then	
harvested	at	the	time	points	indicated.		For	experiments	utilizing	MG132,	drug	was	
added	approximately	18	hours	before	harvest	at	a	final	concentration	of	20μM.		All	
transfections	 were	 harvested	 using	 RIPA	 buffer	 and	 then	 sonicated	 before	 being	
used	 for	 immunoprecipitations	or	western	blots.	 	CRISPR	knockout	Cul3	293	cells	
were	a	gift	from	Curt	Sigmund.	
Plasmids:	 	 3x-Flag-Cul3	 was	 used	 for	 all	 Cul3-containing	 transfections.	 	 All	 Cul3	
mutants	 (Cul3	 K712R,	 Cul3Δ51-67,	 and	 Cul3Δ403-459)	were	 expressed	 using	 the	
same	p3x-Flag	vector	as	wild-type	Cul3.		Cyclin	E	mutants	were	expressed	using	the	
CS2+	Myc-tagged	expression	vector,	and	CS2+	S-tagged	and	CS2+HA	tagged	vectors	
were	utilized	for	expression	of	BTB	proteins	and	the	E2	enzyme	UbE2E1.	
Western	 blotting	 and	 immunoprecipitations:	 	 Western	 blots	 and	
immunoprecipitations	were	 conducted	 as	 previously	 described	 (Wimuttisuk	 et	 al.	
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2014).	In	short,	a	sonicated	transfection	lysate	was	added	to	the	desired	antibody	in	
an	Eppendorf	tube	and	brought	to	a	final	volume	of	500μL.		40μL	of	IPA	sepharose	
beads	were	then	added	to	the	mixture,	and	the	IPs	were	placed	on	a	rotator	for	two	
hours	 at	 room	 temperature	 before	 being	 rinsed	with	 RIPA	 buffer,	 heated	 in	 SDS-
loading	buffer,	and	run	on	an	SDS-PAGE	gel.	The	following	antibodies	were	used	for	
immunoprecipitations	 and/or	 western	 blotting:	 	 Monoclonal	 anti-FLAG	 (Sigma,	
F1804-50UG),	monoclonal	anti-Myc	(9E10,	Santa	Cruz),	polyclonal	anti-c-Myc	(A14)	
(Santa	Cruz,	discontinued),	S-peptide	monoclonal	antibody	(6.2)	(Fisher,	Cat#	MA1-
981),	 monoclonal	 anti-HA.11	 (16B12)	 (ThermoFisher),	 polyclonal	 anti-HA	
(ThermoFisher,	Product	#	PA1-985),	polyclonal	anti-β	actin	(ThermoFisher,	Product	
#	 PA1-183),	 polyclonal	 anti-cyclin	 E	 (Singer	 et	 al.	 1999),	 	 polyclonal	 anti-Cul3	
(Singer	et	al.	1999;	McEvoy	et	al.	2007),	and	monoclonal	anti-cyclin	E	(HE12,	Santa	
Cruz	 biotechnology).	 	 Quantification	 of	 the	 western	 blots	 for	 all	 cycloheximide	
experiments	 was	 done	 using	 the	 FluorChem	 SP	 software	 (Alpha	 Innotech)	 and	
graphs	were	generated	using	Microsoft	Excel.	
Immunofluorescence:	 	Hela	cells	were	grown	on	coverslips,	transfected,	followed	
by	 incubation	 in	 four	percent	paraformaldehyde/PBS	at	 room	 temperature	 for	10	
minutes.		Cells	were	then	permeablized	using	a	solution	of	one	percent	Triton	X-100	
with	2mM	EGTA	and	5mM	PIPES,	followed	by	incubation	in	methanol	at	-20	degrees	
for	 10	 minutes.	 	 Cells	 were	 then	 rinsed	 with	 PBS	 and	 stained	 overnight	 with	 a	
polyclonal	 Myc	 antibody	 (A14,	 Santa	 Cruz).	 	 The	 next	 day,	 cells	 were	 rinsed	 and	
stained	with	an	AlexaFluor	488	conjugated	secondary	antibody	(Abcam,	ab150077)	
65	
followed	 by	 DAPI,	 rinsed	 in	 methanol,	 and	 mounted	 on	 coverslips	 for	 viewing.		
Microscopy	was	conducted	using	a	Zeiss	M2	microscope	and	AxioVision	software.		
Flow	 cytometry:	 	 Proliferating	 cells	were	 harvested	when	 they	were	 70	 percent	
confluent.	 	 Cells	 were	 resuspended	 in	 70	 percent	 ethanol	 in	 PBS	 and	 stored	 at	 4	
degrees	 until	 analysis.	 	 Prior	 to	 analysis,	 fixed	 cells	were	 stained	 in	 a	 solution	 of	
propidium	iodide	in	PBS	with	RNAse	A	at	37	degrees	for	a	minimum	of	30	minutes.		
Cells	were	then	strained	and	analyzed	on	a	BD	Accuri	C6	benchtop	flow	cytometer.		
Three	 proliferating	 samples	 of	 each	 genotype	 were	 analyzed	 and	 20,000-50,000	
cells	were	counted	for	each	sample.	 	Analysis	shown	in	 figure	2.10	was	completed	
using	FlowJo	software	(TreeStar).	 	Cell	cycle	analysis	of	the	samples	in	Figure	2.11	
was	completed	by	hand.	
Construction	of	 cyclin	E	mutants:	 	The	majority	of	the	alanine	scanning	mutants	
were	a	kind	gift	from	Jim	Roberts	at	the	Fred	Hutchinson	Cancer	Center	(Kelly	et	al.	
1998).		The	point	mutants	were	made	using	site-directed	mutagenesis	and	all	point	
mutants	 were	 confirmed	 by	 sequencing.	 	 Alanine	 scanning	 mutants	 that	
demonstrated	 a	 phenotype	 were	 also	 re-confirmed	 by	 sequencing.	 	 Truncations	
were	 cloned	 by	 using	 mutagenesis	 to	 generate	 a	 stop	 codon	 at	 the	 designated	
location	 in	 the	 cyclin	 E	 protein.	 	 Both	 deletions	 were	 made	 using	 site-directed	
mutagenesis	 and	were	 also	 confirmed	by	 sequencing.	 	 Forward	primer	 sequences	
for	 mutagenesis	 are	 as	 follows:	 Cyclin	 E	 K80R	 (DKED	 point	 mutant)	 5’-
TCCCCACACCTGACAGAGAAGATGATGACCG,	Cyclin	E	3	 lysine	(K118,	123,	125R)	5’-
AGAGGAAGTCTGGAGAATCATGTTAAACAGGGAAAGGACATACTTAAGGG,	 Cyclin	 E	 Δ	
2-86	 5’-GGACTTGAATTCCATGGTTTACCCAAACTCAA,	 Cyclin	 E	 KIDR	 point	 mutant	
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(K48R)	 5’	 –CGCCGTCCTGTCGATTCTGGCCATTTCTTCAT,	 Cyclin	 EΔ31-82	 5’-
GCTCGCTCCAGGAAGGATGACCGGGTTTAC.	 	 Primer	 sequences	 for	 the	 cyclin	 E	
truncations	 are	 as	 follows:	 	 Cyclin	 E	 STOP	 200	 5’-
TCATCTTTATTTATTTGAGCCAAACTTGAGGAA,	 and	 STOP	 300	 5’-
TTTCCTTATGGTATATGAGCTGCTTCGGCCTGG.	 	 All	 reverse	 primers	 were	 reverse	
complements	of	the	forward	primers.			
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CHAPTER	3:		Identifying	Possible	Roles	of	Cul3	and	Klhl3	in	the	Kidney	
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BACKGROUND:		The	role	of	Cul3	and	Klhl3	in	FHHt	
	
Mutations	in	the	BTB-Kelch	protein	Klhl3	as	well	as	Cul3	have	recently	been	
shown	 to	 cause	 an	 inherited	 form	 of	 hypertension	 called	 Familial	 Hyperkalemic	
Hypertension	(FHHt)	(Boyden	et	al.	2012;	Louis-Dit-Picard	et	al.	2012).		This	form	of	
hypertension	 results	 primarily	 from	 the	 misregulation	 of	 NCC	 sodium	 chloride	
cotransporter	located	on	the	apical	membrane	of	the	distal	convoluted	tubule	of	the	
nephron	 (O'Shaughnessy	 2015).	 	 Klhl3	 can	 affect	 NCC,	 resulting	 in	 disease,	 via	
degradation	of	the	WNK4	kinase,	which	is	responsible	for	controlling	NCC	through	a	
phosphorylation	 pathway	 involving	 the	 SPAK	 and	 OSR1	 kinases	 (summarized	 in	
Figure	3.1)	(McCormick	and	Ellison	2011;	Shibata	et	al.	2013).	 	Mutations	 in	Klhl3	
that	 alter	 its	 ability	 to	 bind	 and	 ubiquitinate	 WNK4	 result	 in	 changes	 in	 NCC	
phosphorylation	 status,	 which	 leads	 to	 the	 disease	 phenotype	 (Ohta	 et	 al.	 2013;	
Shibata	 et	 al.	 2013;	 Wakabayashi	 et	 al.	 2013).	 	 Interestingly,	 the	 FHHt-causing	
mutations	 in	Cul3	and	Klhl3	are	associated	with	a	more	severe	disease	phenotype	
than	the	previously	known	FHHt-causing	mutations	in	WNK4	and	the	related	kinase	
WNK1	 (Boyden	 et	 al.	 2012)	 .	 	 This	 information	 suggests	 that	Klhl3	 and	Cul3	may	
have	additional	unknown	roles	in	this	pathway.		In	order	to	elucidate	Cul3’s	role	in	
FHHt,	two	approaches,	one	focused	on	Cul3	and	one	focused	on	Klhl3,	were	taken:		
First,	 the	 structure	 and	 function	 of	 the	 hypertension-associated	 Cul3	 mutation,	
Cul3Δ403-459,	 was	 studied,	 and	 secondly,	 a	 screen	 was	 performed	 in	 order	 to	
identify	potential	binding	partners	of	Klhl3	in	vivo.		
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Figure	3.1:	 	NCC	regulation.	NCC	is	regulated	via	phosphorylation,	which	requires	
multiple	 kinases	 such	 as	 SPAK,	 OSR1,	 and	 the	 WNK	 kinases.	 	 There	 are	 several	
possible	points	at	which	Cul3	can	regulate	this	pathway:		The	Cul3Klhl3	E3	ligase	has	
been	shown	to	ubiquitinate	WNK4,	but	other	possible	roles	of	Cul3	in	this	process	
remain	unknown.	
	
As	 previous	work	 from	 our	 lab	 has	 demonstrated	 that	 Cul3	 is	 an	 essential	
gene	 as	 its	 loss	 results	 in	 embryonic	 lethality	 in	 mice,	 we	 hypothesized	 that	 the	
newly	discovered	human	Cul3	mutation	 is	 a	 functional	 ubiquitin	 ligase	 capable	 of	
ubiquitinating	 substrates	 and	 therefore	 the	 FHHt-associated	 Cul3	mutant	 is	 not	 a	
loss	 of	 function	 mutant	 (Singer	 et	 al.	 1999).	 	 We	 sought	 to	 determine	 the	
biochemical	properties	of	the	human	Cul3	mutations	as	well	as	the	role	of	the	Cul3	
E3	 ligase	 in	 the	regulation	of	blood	pressure	 (McCormick	et	al.	2014).	 	This	work,	
which	 was	 published	 in	 2014,	 demonstrated	 that	 the	 hypertension-causing	 Cul3	
mutant,	Cul3Δ403-459,	is	a	gain	of	function	mutant	that	has	an	increased	ability	to	
NH2
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NCC
SPAK/OSR
WNK1/4
Cul3
E2
Klhl2/3
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interact	 with	 the	 substrate	 adaptor	 Klhl3	 as	 well	 as	 an	 increased	 ability	 to	
ubiquitinate	 substrates,	 including	 its	 substrate	 adaptor	 Klhl3	 (McCormick	 et	 al.	
2014).		A	kidney-specific	deletion	of	the	Cul3	gene	in	the	DCT	of	mice	revealed	that	
in	 contrast	 to	 the	 human	 mutation,	 loss	 of	 Cul3	 decreases	 blood	 pressure	
(McCormick	et	al.	2014).	 	 	The	kidneys	also	showed	a	marked	increase	in	 levels	of	
WNK4,	 a	 SPAK	 regulating	 kinase	 that	 ultimately	 controls	 NCC	 function,	 which	 is	
consistent	 with	 the	 accepted	 idea	 that	 WNK4	 is	 a	 substrate	 of	 Cul3	 and	 Klhl3	
(McCormick	et	al.	2014).		
One	 interesting	 revelation	 from	 this	 study	 was	 the	 change	 in	 subcellular	
localization	of	the	hypertension-causing	Cul3	mutant	(Figure	3.2).	 	The	localization	
of	wild-type	Cul3	is	predominantly	nuclear,	but	the	mutant	Cul3Δ403-459	is	mostly	
cytoplasmic.	 	 Normally,	 Cul3	 is	 recruited	 to	 different	 locations	 in	 the	 cell	 by	 BTB	
proteins	(Mathew	et	al.	2012),	which	is	demonstrated	here	by	the	shift	of	wild-type	
Cul3	from	the	nucleus	to	the	cytoplasm	in	the	presence	of	Klhl3	(Figure	3.2	bottom	
row)	 (McCormick	 et	 al.	 2014).	 	 This	 change	 in	 localization	 of	 the	 human	 Cul3	
mutation	 indicates	 that	 the	 mutant	 Cul3	 may	 have	 an	 altered	 ability	 to	 degrade	
substrates	 as	 a	 result	 of	 its	 improper	 localization,	 resulting	 in	 changes	 to	
ubiquitination	that	are	substrate-dependent.		Our	lab	has	shown	that	Cul3Δ403-459	
can	 ubiquitinate	 cyclin	 E	 and	 Klhl3	 (McCormick	 et	 al.	 2014),	 but	 others	 have	
suggested	 that	Cul3Δ403-459	actually	has	an	 impaired	ability	 to	degrade	 the	Cul3	
substrate	RhoA	(Ibeawuchi	et	al.	2015).		Future	work	investigating	how	Cul3Δ403-
459	impacts	different	substrates	will	be	necessary	in	order	to	better	determine	the	
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differential	regulation	of	Cul3	substrates	that	might	occur	in	individuals	who	carry	
this	mutation.	
	
	
	
Figure	 3.2:	 	 The	 human	 Cul3	mutant	 localizes	 to	 the	 cytoplasm.	 	 HeLa	 cells	 were	
transfected	with	wild-type	(WT)	Flag-Cul3,	Flag-Cul3Δ403-459,	Myc-Klhl3,	or	both	
Myc-Klhl3	 and	 Flag-Cul3	 and	 stained	 for	 fluorescent	 microscopy.	 	 Flag	 or	 Myc	
antibodies	were	used	to	detect	the	transfected	protein.	 	WT	Cul3	is	predominantly	
nuclear	(top	row)	whereas	the	mutant	is	mainly	localized	to	the	cytoplasm	(second	
row).		Myc-Klhl3	is	a	cytoplasmic	protein	(third	row)	and	is	able	to	recruit	WT	Flag-
Cul3	 to	 the	cytoplasm	(bottom	row).	 	The	same	pattern	can	be	observed	 in	mDCT	
kidney	 cells	 (McCormick	 et	 al.	 2014).	 The	 experiment	 shown	 here	 has	 been	
published	(McCormick	et	al.	2014).	
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RESULTS:			
Identifying	proteins	that	interact	with	Klhl3	
	
As	mutations	in	the	BTB-Kelch	protein	and	putative	Cul3	substrate	adaptor,	
Klhl3,	have	also	been	shown	to	cause	FHHt	(Boyden	et	al.	2012;	Louis-Dit-Picard	et	
al.	2012),	 it	 is	 essential	 to	gain	a	better	understanding	of	Klhl3	and	 its	 role	 in	 the	
cell.	 	 One	 way	 to	 do	 this	 is	 to	 identify	 potential	 Klhl3	 interacting	 partners	 and	
substrates	 in	 the	 cell.	 Several	yeast	 two-hybrid	 screens	were	performed	using	 full	
length	 Klhl3	 (Figure	 3.3).	 	 Klhl3	 was	 cloned	 into	 a	 yeast	 expression	 vector	 and	
transformed	into	yeast.		The	Klhl3-containing	colonies	were	then	screened	against	a	
cDNA	library	to	identify	interacting	proteins.		Yeast	two-hybrid	screens	are	valuable	
for	 identifying	protein-protein	 interactions,	 as	 they	provide	an	 inexpensive	 in	vivo	
system	that	allows	millions	of	proteins	to	be	screened	for	interactions	with	a	single	
‘bait’	protein	of	 interest.	 	Klhl3	was	utilized	as	 ‘bait’	 in	the	appropriate	two-hybrid	
system	to	identify	the	possible	interacting	proteins	listed	below	in	Table	3.1.		
	
	
	
	
BTB BACK KELCH
Figure	3.3:		Klhl3	structure.		Klhl3	is	composed	of	an	N-terminal	BTB	domain	followed	
by	a	BACK	domain	and	C-terminal	Kelch	domain.		The	BTB	domain	is	responsible	for	
binding	 Cul3	while	 the	 Kelch	 domain	 interacts	with	 substrates.	 	 The	 BACK	 domain	
connects	the	BTB	and	Kelch	domains.	
	
76	
Table	3.1:	Potential	binding	partners	of	Klhl3	
Bait:	 Library	Used:	 Number	of	Clones	
screened:	
ID	of	interacting	
partners:	
KLHL3	 Human	Testis		 1.2x106	 Dynamitin	(p50)	
PHLDB3	
Gef10	
PIASx	
KLHL26	
KLHL3	 Human	Fetal	
Liver		
3.0x106	 Dynamitin	(p50)	
KLHL3	 Human	Kidney	 1.7x106	 Dynamitin	(p50)	
KLHL3	
TGFβ	receptor	
TGFβ	receptor	2	
RANBP2	
RANBP9	
MUC20	
ATP1B1	
Foxp1	
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Figure	 3.4:	 	P50/dynamitin	is	a	subunit	of	the	dynactin	
complex.	 	 P50	 interacts	 with	 the	 dynein	 motor.	 P50	
forms	 the	 scaffold,	 which	 connects	 the	 cargo-binding	
arm	 (Arp1,	 green)	 to	 the	 microtubule-binding	
(p150/Glued,	blue)	domain.	 	This	complex	 is	necessary	
for	transport	of	endosomes	within	the	cell.	
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Dynamitin/p50	binds	Klhl3	
	
One	 protein	 of	 interest	 that	 was	 identified	 in	 all	 three	 screens	 was	
p50/dynamitin.	 	 Dynamitin/p50	 is	 a	 subunit	 of	 the	 dynactin	 complex,	 which	 is	
required	 for	 retrograde	 transport	 of	 endocytic	 vesicles	 (Figure	 3.4).	 	 The	
p50/dynamitin	 subunit	 is	 of	 interest	 as	 a	 possible	 Klhl3	 binding	 partner	 as	 p50	
overexpression	 is	 known	 to	 result	 in	 trafficking	 errors	 and	 breakdown	 of	 the	
dynein-dynactin	complex	(Burkhardt	et	al.	1997),	making	p50	a	good	candidate	for	
regulation	by	the	ubiquitin-proteasome	system.	
P50	 was	 cloned	 by	 PCR	 into	 a	 CS+	 vector	 that	 contained	 either	 HA	 and	 S	
epitope	 tag.	 	 These	 vectors	 allow	 the	 protein	 of	 interest	 to	 be	 expressed	 in	
mammalian	 cells	 and	carry	an	epitope	 tag	 for	easy	detection.	 	 Immunofluorescent	
microscopy	 reveals	 that	 transfected	 Klhl3	 and	 p50	 co-localize	 in	 the	 cytoplasm,	
which	 means	 there	 is	 a	 possibility	 that	 a	 biologically	 relevant	 interaction	 might	
occur	 between	 these	 two	 proteins	 (Figure	 3.5).	 	 Co-transfection	 of	 Klhl3	 and	 p50	
followed	by	immunoprecipitation	revealed	the	ability	of	the	two	proteins	to	interact	
in	 mammalian	 cells	 (Figure	 3.6,	 lane	 1	 compared	 to	 lane	 3).	 In	 order	 to	 further	
determine	 the	 significance	 of	 the	 interaction	 between	 p50	 and	Klhl3,	 information	
was	 sought	 in	 the	 literature	 regarding	 the	 staining	 pattern	 of	 the	 endogenous	
proteins.	 	 Endogenous	 Klhl3	 is	 known	 to	 stain	 in	 a	 punctate	 pattern	 in	 293	 cells	
(Louis-Dit-Picard	 et	 al.	 2012),	 which	 can	 be	 characteristic	 of	 actin-associated	
proteins.	 	Endogenous	p50	 is	also	known	 to	stain	 in	a	 similar	cytoplasmic	pattern	
(Burkhardt	 et	 al.	 1997).	 	 Taken	 together,	 this	 information	 suggests	 that	 p50	 and	
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Klhl3	interact	in	vivo	and	it	is	possible	that	Klhl3	is	normally	found	associated	with	
the	dynactin	complex	in	the	cytoplasm.			
To	 further	 elucidate	 the	 interaction	 that	 occurs	 between	 p50	 and	 Klhl3,	 a	
Klhl3	mutant	which	 lacks	 the	 BTB	 (Cul3	 binding,	 refer	 to	 figure	 3.3)	 domain	was	
created.		This	construct	was	utilized	to	determine	if	the	kelch	domain	of	Klhl3,	which	
is	 involved	 in	 substrate	 recognition	 for	 the	 Cul3	 ubiquitin	 ligase	 complex,	 is	 the	
portion	 of	 Klhl3	 that	 is	 responsible	 for	 interacting	with	 p50.	 	 This	 construct	 also	
contains	 the	BACK	domain,	which	 connects	 the	BTB	domain	 to	 the	Kelch	domain.		
Either	wild-type	Klhl3	or	Klhl3ΔBTB	was	co-expressed	with	p50	(Figure	3.6).	 	P50	
binds	 Klhl3ΔBTB	 and	 is	 in	 fact	 stabilized	 in	 its	 presence	 (Figure	 3.6,	 lane	 4	
compared	to	lane	2),	suggesting	that	p50	binds	to	the	substrate	recognition	region	
(kelch	domain)	and	normally	is	degraded	in	a	Cul3-dependent	fashion.	 	This	result	
indicates	that	Klhl3ΔBTB	is	sequestering	p50	and	protecting	it	from	Cul3-mediated	
degradation,	 as	 the	 kelch	 domain	 of	 Klhl3	 retains	 its	 high	 affinity	 for	 p50,	 but	
without	the	BTB	domain	is	unable	to	associate	with	the	Cul3	complex	so	p50	is	not	
degraded.	 	This	result	supports	the	hypothesis	that	p50	is	a	substrate	of	Klhl3	and	
Cul3.	
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Figure	 3.5:	 	P50	and	Klhl3	co-localize	 in	 the	cytoplasm.	 	 Ha-p50	 and	Myc-Klhl3	
were	transfected	into	HeLa	cells	and	stained	using	antibodies	to	HA	and/or	Myc,	
and	 viewed	 using	 immunofluorescent	 microscopy.	 	 The	 localization	 of	 p50	 is	
shown	in	green,	Klhl3	in	red,	and	the	nucleus	(DAPI)	in	blue.	
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Figure	 3.6:	 	 P50	interacts	with	the	substrate	recognition	domain	of	Klhl3.	 	Upper	
blot;	 	 immunoprecipitation	 results	 showing	 binding	 between	 S-tagged	 p50	 and	
either	wild-type	Klhl3	(lanes	2	and	3),	or	Klhl3	lacking	its	BTB	domain	(lanes	4	and	
5).		The	middle	and	lower	blots	show	protein	expression	in	the	cell	extracts.	
	
P50	is	stabilized	in	the	presence	of	an	FHHt-associated	Klhl3	mutant	
	
Several	 mutations	 in	 Klhl3	 have	 been	 shown	 to	 cause	 FHHt	 in	 humans	
(Boyden	et	al.	2012;	Louis-Dit-Picard	et	al.	2012).		A	dominant	mutation	that	results	
in	 hypertension	 is	 Klhl3R528H,	 a	 point	 mutation	 in	 the	 kelch	 domain	 of	 Klhl3	
(Boyden	 et	 al.	 2012).	 	 In	 order	 to	 determine	 if	 this	 mutant	 affects	 p50,	 the	 two	
proteins	were	co-transfected	in	HEK293	cells	(Figure	3.7	lane	2).	 	Our	preliminary	
results	 show	 that	 p50	 appears	 to	 be	 stabilized	 by	 Klhl3R528H	 but	 not	 wild-type	
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Klhl3	 (Figure	 3.7	 lane	 2	 compared	 to	 lanes	 1	 and	 4).	 	 The	 increased	 stability	 is	
comparable	 to	 the	 stability	 that	 results	 when	 p50	 is	 expressed	 with	 Klhl3	 that	
cannot	 bind	 Cul3	 (lacks	 BTB	 domain,	 figure	 3.7	 lane	 3).	 	 P50	 is	 still	 able	 to	 bind	
Klhl3R528H	(Figure	3.7	bottom	row	lane	2).	 	Taken	together,	these	results	suggest	
that	Klhl3-mediated	degradation	might	be	impaired	in	the	presence	of	Klhl3R528H.	
	
Figure	3.7:		A	human	Klhl3	mutant	results	in	p50	stability.		S-tagged	p50	was	
cotransfected	 with	 a	 human	 Klhl3	 mutation,	 Klhl3R528H	 (lane	 2),	 Klhl3	
lacking	its	BTB	domain	(cannot	bind	Cul3,	 lane	3),	or	wild-type	Klhl3	(Lane	
4).	 	P50	 expression	 levels	 in	 the	presence	 of	 each	Klhl3	mutant	 are	 shown	
(top	 panel).	 	 The	 middle	 blot	 shows	 Klhl3	 expression	 and	 the	 lower	 blot	
shows	immunoprecipitation	results.		This	is	a	preliminary	result	as	it	has	not	
yet	been	repeated.	
	
Lane    1                2                 3                4              
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P50	binds	Cul3	
	
As	 previously	 demonstrated	 in	 chapter	 two,	 the	 Cul3	 substrate	 cyclin	 E	 is	
able	to	bind	Cul3	 in	addition	to	a	BTB	substrate	adaptor.	 	 In	order	to	determine	 if	
p50	 also	 possesses	 this	 capability,	 it	 was	 checked	 for	 binding	 with	 a	 set	 of	 Cul3	
mutants.	 	It	was	concluded	that,	similar	to	cyclin	E,	p50	also	has	the	ability	to	bind	
wild-type	 Cul3	 in	 addition	 to	 several	 Cul3	 mutants	 (Figure	 3.8,	 lanes	 2-6).	 	 In	
addition	to	WT	Cul3,	p50	also	binds	Cul3Δ51-67,	a	mutant	that	does	not	bind	BTB	
proteins	 as	 well	 as	 Cul3K712R,	 an	 inactive	 Cul3	 that	 is	 not	 modified	 by	 Nedd8	
(Figure	3.8,	lanes	3	and	5).		These	data	suggest	that	p50	may	be	able	to	interact	with	
Cul3	 independently	 of	 its	 interaction	 with	 Klhl3	 and	 this	 interaction	 is	 not	
dependent	on	neddylation	of	Cul3.		P50	was	also	able	to	bind	the	Cul3	mutant	that	is	
associated	with	hypertension,	Cul3Δ403-459,	indicating	that	the	region	of	Cul3	that	
is	deleted	in	this	mutant	is	not	involved	in	the	interaction	with	p50	(Figure	3.8,	lane	
4),	as	well	as	a	double	mutant	which	contains	both	the	hypertension	mutation	and	
the	BTB	binding	mutation	(Figure	3.8,	lane	6).	
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Figure	 3.8:	 	 P50	 binds	 Cul3	 and	 Cul3	 mutants.	 	 Upper	 blot;	 S-p50	 was	
transfected	 with	 several	 Cul3	 mutants.	 	 Immunoprecipitation	 results	 are	
shown.	 	 The	 lower	 lower	 blots	 show	 expression	 levels	 of	 the	 transfected	
proteins	in	the	cell	lysates.	
	 	
Cul3	and	Klhl3	ubiquitinate	p50/dynamitin	in	vitro	
	
The	 data	 presented	 above	 suggest	 that	 p50/dynamitin	 can	 serve	 as	 a	
substrate	 of	 Cul3	 and	 Klhl3	 in	 vitro	 (Figures	 3.5	 and	 3.9).	 	 In	 order	 to	 further	
investigate	 this	 hypothesis	 and	 determine	 if	 p50	 is	 a	 substrate	 of	 the	 ubiquitin-
proteasome	pathway,	 S-tagged	p50	was	 co-transfected	with	Cul3	 and	Klhl3	 in	 the	
presence	or	absence	of	the	proteasome	inhibitor	MG132.		P50	levels	are	destabilized	
when	Cul3	and	Klhl3	are	present,	but	 its	 levels	are	restored	by	MG132	(Figure	3.9	
lane	3),	demonstrating	that	the	observed	reduction	in	p50	stability	in	the	presence	
of	 Klhl3	 or	 Cul3	 may	 be	 a	 result	 of	 proteasomal	 degradation.	 	 Additionally,	 co-
transfection	 of	 Ubr7,	 a	 mutant	 ubiquitin	 where	 all	 lysines	 have	 been	 mutated	 to	
arginine	 rendering	 it	 unable	 to	 form	 degradative	 ubiquitin	 chains,	 also	 increases	
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steady-state	levels	of	p50	(Figure	3.9	lanes	4	and	5).		Ubiquitin	laddering	of	the	p50	
protein	 can	 also	 be	 observed,	 which	 suggests	 that	 is	 may	 be	 a	 substrate	 of	
ubiquitination	 (Figure	3.9	 lanes	4	 and	5).	 	Taken	 together,	 these	data	 support	 the	
hypothesis	that	p50	is	ubiquitinated	by	Cul3	and	Klhl3	in	vitro.			
	
Figure	 3.9:	 	 P50	 is	 ubiquitinated	 in	 the	 presence	 of	 Cul3	 and	 Klhl3.	 	 S-tagged	
Dynamitin/p50	expression	levels	are	shown	either	alone	(Top	panel,	lane	1)	or	in	
the	presence	of	Cul3	and	Klhl3	(lanes	2	through	5),	with	or	without	the	ubiquitin	
mutant	Ubr7	(lanes	4	and	5)	or	the	proteasome	inhibitor	MG132	(lanes	3	and	5).	
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P50	levels	appear	to	remain	unchanged	in	vivo	
	
In	order	to	determine	if	p50	is	targeted	for	degradation	by	Cul3	in	vivo,	levels	
of	p50	were	compared	 in	Cul3	WT	and	Cul3	KO	293	cells	 (Ibeawuchi	et	al.	2015).		
P50	levels	appear	evenly	expressed	in	the	wild-type	and	Cul3	KO	cells	(Figure	3.10).	
This	 result	 indicates	 that	 if	 p50	 is	 a	 substrate	of	 Cul3,	 ubiquitination	may	 serve	 a	
purpose	besides	degradation,	or	ubiquitination	results	in	degradation	but	only	of	a	
small	pool	of	p50,	which	could	occur	either	in	a	cell	cycle	or	localization-dependent	
manner.	 	 Based	 on	 the	 convincing	 data	 demonstrating	 the	 stabilization	 of	 p50	 by	
transfected	 ubiquitin	 mutants	 or	 the	 addition	 of	 MG132	 (Figure	 3.9),	 the	 latter	
possibility	 seems	 more	 likely,	 as	 p50	 would	 show	 no	 change	 in	 stability	 if	
ubiquitination	by	Cul3	were	non-degradative.			
Cul3-
p50-
actin-
WT Cul3 KO
Figure	3.10:	 	Levels	of	endogenous	p50	are	unaffected	by	loss	of	Cul3.		Levels	
of	endogenous	p50	(middle	panel)	 in	wild-type	and	Cul3	KO	293	cells	were	
determined	via	Western	blotting.	 	 Levels	of	 actin	 in	 the	same	cells	 (bottom	
panel)	are	shown	for	comparison.	
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Transfected	p50	is	destabilized	by	Cul3	
	
To	 further	 support	 the	 hypothesis	 that	 p50	 is	 a	 Cul3	 substrate,	 it	 was	
transfected	 into	 the	 Cul3	 WT	 and	 Cul3	 KO	 293	 cells	 to	 check	 its	 stability	 in	 the	
presence	 and	 absence	 of	 Cul3	 (refer	 to	 the	 assay	 in	 Chapter	 2	 Figure	 2.4).	 	 Like	
cyclin	 E,	 a	 known	Cul3	 substrate,	 p50	 appears	more	 stable	 in	 the	KO	 cells	 that	 it	
does	in	the	wild-type	(Figure	3.11,	top	panel).		This	result	further	supports	a	role	of	
Cul3	in	p50	ubiquitination.			
	
Figure	 3.11:	 	 Transfected	 p50	 is	 more	 stable	 in	 Cul3	 KO	 cells.	 	 Western	 blot	
showing	levels	of	transfected	S-p50	in	Cul3	KO	293	cells	(top	panel,	right	lane)	in	
comparison	 to	 WT	 cells	 (top	 panel,	 left	 lane).	 	 The	 Cul3	 substrate	 cyclin	 E	 is	
shown	as	a	control	(bottom	panel).	
DISCUSSION:	
	
Mutations	 in	Klhl3,	 a	 BTB	protein	 and	 putative	 substrate	 adaptor	 for	 Cul3,	
have	been	shown	to	cause	the	 inherited	 form	of	hypertension	FHHt	(Boyden	et	al.	
2012;	Louis-Dit-Picard	et	al.	2012).		Others	have	shown	that	Klhl3	plays	a	role	in	the	
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ubiquitination	 of	 the	 kinases	 WNK1	 and	 WNK4,	 which	 are	 responsible	 for	
phosphorylating	 the	 SPAK	 kinase,	which	 in	 turn	 regulates	 NCC	 (Yang	 et	 al.	 2003;	
Ohta	 et	 al.	 2013;	 Shibata	 et	 al.	 2013;	 Wakabayashi	 et	 al.	 2013).	 	 In	 order	 to	
determine	 other	 cellular	 processes	 that	 Klhl3	 might	 regulate,	 a	 yeast	 two-hybrid	
screen	was	 performed	 to	 identify	 potential	 binding	 partners	 of	 Klhl3	 (Table	 3.1).		
One	protein	that	this	screen	identified	is	p50/dynamitin,	a	subunit	of	the	dynactin	
complex,	which	 is	 involved	 in	 vesicle	 trafficking	along	 the	 cytoskeleton	 (Table	3.1	
and	Figure	3.4).		The	p50/dynamitin	subunit	of	the	dyanctin	complex	plays	a	role	in	
dynein-dependent	 trafficking	 within	 the	 cell.	 	 The	 work	 presented	 here	
demonstrates	 that	 p50/dynamitin	 binds	 to	 the	 substrate	 recognition	 (Kelch)	
domain	 of	 Klhl3	 and	 also	 to	 Cul3,	 and	 can	 be	 ubiquitinated	 in	 a	 Cul3	 or	 Klhl3-
depenent	 manner.	 	 Taken	 together,	 these	 results	 suggest	 that	 p50	 is	 a	 likely	
substrate	of	 the	Cul3Klhl3	E3	ubiquitin	 ligase	 in	cells	 (Figures	3.6,	3.7,	3.8,	and	3.9).		
These	findings	suggest	the	possibility	that	Klhl3	might	function	as	a	regulator	of	p50	
in	cells,	thereby	suggesting	a	possible	role	for	Klhl3	in	endosomal	trafficking.	
FUTURE	DIRECTIONS:	
	
Taken	together,	these	results	suggest	a	role	for	p50/dynamitin	as	a	substrate	
of	Cul3	and	Klhl3	 in	vitro.	 	However,	 it	remains	unclear	if	p50	is	ubiquitinated	in	a	
Cul3-dependent	manner	in	living	cells	and	organisms.		Future	experimentation	will	
be	necessary	in	order	to	determine	the	role	Klhl3	plays	in	cells	and	to	confirm	the	
status	of	p50	as	a	Cul3	substrate	and	also	show	what	affects	p50	degradation	may	
be	 having	 in	 cells.	 An	 experiment	 that	 would	 be	 illuminating	 would	 be	 to	 knock	
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down	Klhl3	 using	 siRNA	 in	 a	 cell	 line	where	Klhl3	 is	 known	 to	 be	 expressed	 and	
measuring	 if	 there	 are	 any	 effects	 on	 endosomal	 trafficking	 and	 endosome	
maturation	 in	 the	Klhl3	knock-down	cells.	 	Antibodies	 to	early	endosome	markers	
such	as	EEA1	and	late	endosome	markers	such	as	LAMP-1	would	be	useful	for	this	
experiment	(Franken	et	al.	2013).		In	order	to	gather	the	most	convincing	results,	it	
is	 important	 that	 Klhl3	 is	 knocked-down	 for	 this	 experiment,	 as	 Cul3	 has	 already	
been	shown	to	affect	vesicle	trafficking	via	a	different	mechanism(Hubner	and	Peter	
2012;	Huotari	et	al.	2012;	Gschweitl	et	al.	2016).	 	An	effective	siRNA	against	Klhl3	
has	been	developed	for	use	in	this	experiment	(Figure	3.12)	
	
	
	
	
	
	
The	possibility	of	aquaporin	regulation	by	Cul3	
	
One	 notable	 anomaly	 in	 adult	 mice	 that	 have	 had	 Cul3	 deleted	 from	 their	
kidneys	is	depletion	of	the	AQP2	aquaporin	protein	(McCormick	et	al.	2014).		AQP2,	
a	member	of	the	aquaporin	family	of	water	channels,	is	located	on	the	apical	surface	
of	the	renal	collecting	duct,	where	it	functions	in	the	reabsorption	of	water,	helping	
to	maintain	blood	pressure	and	ion	homeostasis	(Takata	et	al.	2008).		Expression	of	
untagged Klhl3
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Figure	 3.12:	 	 An	 siRNA	 targeting	 Klhl3	 effectively	 decreases	 the	
expression	of	transfected	Klhl3	protein.		Different	amounts	of	an	siRNA	
targeting	Klhl3	were	transfected	into	293	cells	with	Klhl3.		This	siRNA	
can	be	used	in	future	experiments	requiring	the	knockdown	of	Klhl3.	
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AQP2	 at	 the	 apical	 membrane	 is	 highly	 regulated	 (Takata	 et	 al.	 2008).	 	 AQP2	 is	
stored	 in	 vesicles	 and	 is	 transported	 to	 the	 membrane	 in	 a	 dynein-mediated	
manner,	which	is	contrary	to	the	usual	direction	of	dynein-mediated	transport	as	a	
result	of	microtubules	that	are	able	to	nucleate	near	the	membrane	in	this	instance	
(Marples	et	al.	1998).	Translocation	of	AQP2	to	the	apical	membrane	occurs	when	
intracellular	 cAMP	 levels	 are	 increased	 upon	 stimulation	 by	 the	 hormone	
vasopressin	 (Klussmann	 et	 al.	 2001;	 Olesen	 and	 Fenton	 2017).	 	 In	 order	 for	
translocation	 to	 occur,	 AQP2	 must	 have	 been	 previously	 phosphorylated	 by	 PKA	
(Nedvetsky	et	al.	2009).	 	 	There	are	several	possible	ways	 in	which	Cul3	might	be	
involved	 in	AQP2	 regulation:	 	1)	AQP2	could	be	a	 substrate	of	Cul3,	2	 and	3)	The	
Cul3	 substrates	 Nrf2	 or	 RhoA,	 which	 are	 believed	 to	 regulate	 AQP2	 might	 be	
involved,	and	4)	Cul3	might	regulate	AQP2	via	trafficking.		These	four	possibilities	as	
well	as	the	literature	supporting	them	will	be	discussed	below.	
When	AQP2	 is	 no	 longer	 needed	 at	 the	membrane,	 it	 undergoes	 clatharin-
mediated	 endocytosis,	 which	 is	 also	 dynein-dependent	 (AQP2	 recycling	 is	
summarized	 in	 Figure	 3.13)	 (Takata	 et	 al.	 2008;	Nedvetsky	 et	 al.	 2009).	 	 AQP2	 is	
known	to	be	ubiquitinated	on	K270,	although	the	E3	ligase	responsible	is	unknown	
(Lee	and	Kwon	2009).	 	Research	has	been	conducted	 in	attempt	 to	determine	 the	
ubiquitin	 ligase	responsible	 for	AQP2	degradation	(Lee	et	al.	2011).	 	Cul3	was	not	
shown	 to	 be	 associated	with	 AQP2	 and	 it	 has	 been	 suggested	 that	 either	 Cul5	 or	
Nedd4	is	responsible	for	AQP2	ubiquitination	(Lee	et	al.	2011).		The	ligase	involved	
remains	to	be	determined	but	ubiquitination	of	AQP2	is	believed	to	be	necessary	for	
its	endocytosis	and	also	exocytosis	via	the	formation	of	a	multivesicular	body	(Lee	
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and	Kwon	2009).		It	remains	a	possibility	that	Cul3	could	be	involved	in	this	process,	
but	 this	 possibility	 seems	 increasingly	 unlikely	 as	 Cul3	was	 not	 found	 associated	
with	AQP2	(Lee	et	al.	2011).		
	
	 	
Figure	 3.13:	 	 Regulation	 of	 AQP2	 expression	 at	 the	 membrane.	 	 This	 model	
illustrates	the	process	by	which	AQP2	is	recycled	or	degraded	within	the	cells	of	
the	nephron.		This	diagram,	has	been	adapted	from	a	review	(Takata	et	al.	2008).	
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	A	possible	 role	 for	Cul3	 in	AQP2	regulation	 in	 the	collecting	duct	has	been	
recently	 described	 via	 the	 Keap1-Nrf2	 pathway	 (Suzuki	 et	 al.	 2017).	 	 Nrf2	 is	 a	
transcription	 factor	 involved	 in	 the	 oxidative	 stress	 response	 and	 it	 is	 tightly	
regulated	 by	 the	 BTB-Kelch	 protein	 Keap1	 (Wakabayashi	 et	 al.	 2003).	 	 Increased	
Nrf2	 activity	 during	murine	 development	 as	 a	 result	 of	 depleted	 Keap1	 has	 been	
shown	 to	 result	 in	 upregulation	 of	 two	 lectins,	 Clec4d	 and	 Clec4n,	 that	 are	
responsible	 for	 the	 glycosylation	 of	 AQP2	 (Suzuki	 et	 al.	 2017).	 	 Increased	
glycosylation	 of	 AQP2	 results	 in	 its	 increased	 excretion	 in	 exosomes	 and	 loss	 of	
AQP2	in	the	collecting	duct,	resulting	in	increased	urine	excretion	as	a	result	of	the	
animals’	inability	to	absorb	water	and	a	diabetic	phenotype	(Suzuki	et	al.	2017).		It	
has	 been	 well	 demonstrated	 that	 Nrf2,	 a	 Cul3	 substrate,	 regulates	 AQP2	 via	 this	
mechanism,	 but	 as	 Cul3	 has	 many	 other	 substrates,	 it	 is	 also	 possible	 that	 other	
Cul3-based	mechanisms	are	also	involved	in	AQP2	regulation.	
A	 second	 known	 regulator	 of	 AQP2	 expression	 at	 the	 apical	 membrane	 is	
RhoA.		RhoA	is	a	member	of	the	Rho	family	of	small	GTPases	and	it	is	known	to	be	
involved	in	the	organization	of	the	actin	cytoskeleton	(Ridley	2001).		RhoA	is	also	a	
known	Cul3	substrate,	and	depletion	of	Cul3	has	been	shown	to	result	in	increased	
formation	 of	 actin	 ‘stress	 fibers’	 in	 cells	 (Chen	 et	 al	 2009).	 	 	 Constitutively	 active	
RhoA	 has	 been	 shown	 to	 result	 in	 the	 formation	 of	 stress	 fibers	 and	 prevent	
translocation	of	AQP2	to	the	apical	membrane	(Klussmann	et	al.	2001;	Tamma	et	al.	
2001).		Therefore,	it	also	remains	a	possibility	that	Cul3	regulates	AQP2	expression	
at	 the	membrane	at	 least	 in	part	 through	Cul3-mediated	 regulation	of	RhoA.	 	 It	 is	
possible	that	increased	RhoA	activity	resulting	from	loss	of	Cul3	results	in	reduced	
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translocation	 of	 AQP2	 to	 the	membrane.	 	 One	 way	 to	 investigate	 this	 hypothesis	
would	be	to	measure	AQP2	abundance	in	exosomes	of	either	Cul3	KO	animals	or	an	
exosome-producing	cell	line	where	either	Cul3	or	Klhl3	has	been	depleted.		
Regulation	 of	 dynactin-mediated	 transport	 by	 Cul3	 provides	 a	 fourth	
possible	 mechanism	 that	 might	 be	 utilized	 by	 Cul3	 to	 regulate	 AQP2	 abundance.		
Further	 investigation	 into	 a	 potential	 role	 for	 Klhl3	 in	 p50/dynamitin	 regulation	
may	help	to	shed	light	on	this	topic.		If	p50	is	indeed	regulated	in	a	Cul3-dependent	
manner,	 then	 impaired	 trafficking	 of	 AQP2-containing	 endosomes	 may	 also	 be	 a	
factor	 that	contributes	 to	 the	reduction	 in	AQP2	that	was	observed	 in	Cul3	kidney	
KO	animals.		Cul3	is	known	to	be	involved	in	other	aspects	of	vesicle	trafficking	and	
endosome	maturation	(Hubner	and	Peter	2012;	Huotari	et	al.	2012;	Gschweitl	et	al.	
2016),	so	regulation	of	p50	may	not	represent	 the	only	point	at	which	Cul3	might	
regulate	 AQP2	 trafficking.	 	 Further	 experimentation	 in	 order	 to	 increase	
understanding	of	the	possible	role	of	Klhl3	in	trafficking	will	be	necessary	in	order	
to	 determine	 if	 Cul3	 is	 regulating	 AQP2	 via	 endosomal	 trafficking.	 	 It	 will	 be	
important	 to	 utilize	 Klhl3	 knockout	 cells	 for	 this	 experiment	 instead	 of	 Cul3	
knockout	cells,	as	Cul3	 is	already	known	to	have	substrates	 involved	 in	 trafficking	
processes	(Hubner	and	Peter	2012;	Gschweitl	et	al.	2016),	and	Klhl3	will	have	fewer	
substrates	 than	 Cul3,	 thereby	 allowing	 for	 a	 clearer	 determination	 of	 which	
pathways	might	be	involved.	
In	 order	 to	 begin	 to	 determine	 which	 of	 these	 four	 mechanisms	 are	
responsible	for	the	loss	of	AQP2	expression	in	the	kidneys	of	adult	Cul3	Kidney	KO	
animals,	 there	 are	 some	 simple	 experiments	 that	 should	 be	 done.	 	 First,	 as	 it	 has	
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been	 shown	 that	Nrf2	 can	 result	 in	decreased	AQP2	expression,	which	 is	 likely	 to	
occur	in	the	Cul3	Pax8	Cre	(Kidney	KO)	animals,	it	will	be	necessary	to	measure	Nrf2	
expression	 both	 in	 kidneys	 of	 adult	 animals	 (WT	 and	 kidney	 KO)	 and	 in	 cells	 or	
embryos	that	are	hypomorphic	or	deleted	for	Cul3	(Cul3flx/flx)	in	order	to	determine	
if	Nrf2	is	being	regulated	by	Cul3.		As	the	effects	of	Nrf2	on	AQP2	are	a	result	of	Nrf2	
levels	 during	 embryonic	 development	 and	 not	 increased	 Nrf2	 levels	 during	
adulthood	 (Suzuki	 et	 al.	 2017),	 	 the	 results	 gleaned	 from	 experiments	with	MEFs	
and	floxed	(hypomorphic	for	Cul3	but	not	Cul3	KO)	Cul3	embryos	will	be	the	most	
informative	as	any	 increase	 in	Nrf2	will	 indicate	whether	or	not	Cul3	 floxed	adult	
animals	 will	 suffer	 from	 abnormal	 AQP2	 regulation	 that	 is	 Nrf2	 dependent.		
Exosome	excretion	in	Cul3	WT	and	KO	animals,	and	possibly	cell	lines,	will	also	be	
necessary	to	confirm	that	the	AQP2	is	being	excreted.	
Next,	 it	will	be	necessary	to	investigate	the	contributions	that	altered	levels	
of	RhoA	may	be	having	on	AQP2	regulation.		This	can	be	accomplished	by	comparing	
levels	 of	 RhoA	 in	 WT	 and	 Cul3	 kidney	 KO	 levels	 by	 western	 blot	 and	 also	
immunofluorescence	to	 look	for	the	 formation	of	actin	stress	 fibers,	which	may	be	
preventing	 AQP2	 from	 reaching	 the	 membrane.	 	 Elucidating	 the	 possible	 role	 of	
Klhl3	 in	p50	 regulation	and	endocytic	 trafficking	as	was	previously	discussed	will	
help	 to	 determine	 if	 Klhl3	 plays	 a	 role	 in	 AQP2	 regulation.	 	 Lastly,	 it	 may	 be	
necessary	 to	 confirm	 that	 Cul3	 is	 not	 the	 E3	 ligase	 responsible	 for	 AQP2	
degradation.		As	other	ligases	have	already	been	implicated	in	this	process	(Lee	and	
Kwon	2009;	Lee	et	al.	2011),	further	experimentation	may	not	be	necessary.	
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Other	identified	proteins	that	may	interact	with	Klhl3	
ATP1β1:	
Another	 protein	 of	 interest	 that	 was	 identified	 in	 the	 Klhl3	 two-hybrid	
screens	is	the	beta	subunit	of	the	Na+/K+	ATPase,	which	is	expressed	in	many	cell	
types	including	the	basolateral	membrane	of	the	DCT	(NCC	and	ENaC	are	found	on	
the	 apical	 surface).	 	 The	 Na+/K+	 ATPase	 is	 responsible	 for	 maintaining	 the	
electrochemical	 gradient	which	 drives	 the	 other	 renal	 ion	 transporters	 (Hamilton	
and	 Devor	 2012).	 	 	 	 ATP1β1	 is	 believed	 to	 be	 ubiquitinated	 and	 degraded	
(Yoshimura	et	al.	2008).	
In	addition	to	its	role	in	renal	function,	this	transporter	and	its	subunits	also	
serve	 other	 purposes	 in	 different	 types	 of	 cells.	 	 ATP1β1	 is	 also	 associated	 with	
cancer,	 as	 it	 plays	 a	 role	 in	 cell	 adhesion	 (Litan	 and	 Langhans	 2015).	 	 Decreased	
expression	of	ATP1β1	 is	 associated	with	poor	prognosis	 in	breast	 cancer	patients	
(Presson	et	al.	2011).		Interestingly,	increased	expression	of	TGFβII,	which	was	also	
identified	as	a	potential	Klhl3	binding	partner,	has	also	been	associated	with	cancer	
(Presson	et	 al.	 2011).	 	 Silencing	of	ATP1β1	 is	 also	 associated	with	 clear	 cell	 renal	
carcinoma	(Selvakumar	et	al.	2014).	
Interestingly,	the	Na+/K+	ATPase	is	also	very	important	in	brain	and	may	be	
associated	with	Down’s	Syndrome	(Lubec	and	Sohn	2003).		ATP1β1	has	been	shown	
to	be	downregulated	 in	 scrapie-infected	mice	 (Kim	et	 al.	 2008)	and	also	has	been	
implicated	in	brain	pathologies	in	humans	(Brignone	et	al.	2011).	ATP1β2	(another	
subunit	 of	 this	 transporter)	 has	 also	 been	 demonstrated	 to	 be	 important	 for	
interactions	between	neurons	and	glial	cells	(Brignone	et	al.	2011).	
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ATP1β1	 is	 a	 good	 candidate	 for	 a	 Cul3	 and	 Klhl3	 substrate	 as	 it	 has	 been	
shown	 by	 others	 that	 it	 can	 be	 degraded	 in	 an	 ubiquitin-dependent	 manner	
(Yoshimura	et	al.	2008).		In	order	to	explore	this	idea	further,	ATP1β1	will	first	need	
to	 be	 cloned	 into	 a	 mammalian	 expression	 vector	 so	 that	 it	 can	 be	 checked	 for	
binding	to	Klhl3	and	Cul3	as	well	as	used	in	 in	vitro	ubiquitination	assays.	 	As	this	
transporter	 has	 been	 shown	 to	 be	 important	 in	 brain	 as	 well	 as	 kidney,	 future	
experiments	may	seek	to	investigate	the	role	of	Klhl3	or	other	BTB-Kelch	proteins	in	
neuronal	development	and	functioning.	
MATERIALS	AND	METHODS	
	
Cell	 culture	 and	 transfections:	 	 Cells	 (mDCT,	 HeLa,	 HEK293)	 were	 grown	 in	
DMEM	supplemented	with	ten	percent	FBS	and	penicillin/streptomycin	as	well	as	l-
Glutamine.	 	 Transfections	were	 conducted	 using	 calcium	 phosphate	 precipitation.		
Between	1	and	10	micrograms	of	DNA	was	used	for	each	transfection	and	cells	were	
seeded	 onto	 6cm	 plates.	 	 Cells	 were	 harvested	 between	 36	 and	 48	 hours	 post-
transfection.	
Yeast	 two-hybrid	screens:	 	The	two	hybrid	screens	were	performed	according	to	
the	 instructions	 from	 the	 Clontech	 Matchmaker	 two-hybrid	 kit	 (testis	 and	 liver	
screens)	 and	 the	Clontech	Yeast	 two	Hybrid	Gold	 system	 (Clontech	Cat	#630489)	
for	the	kidney	screen.		Full	length	Klhl3	was	cloned	into	the	appropriate	bait	vector	
(pGilda	for	Matchmaker	and	pGBK47	for	Matchmaker	Gold).		Human	testis	and	fetal	
liver	pB4AD	cDNA	 libraries	were	purchased	 from	Clontech	and	 screened	with	 the	
pGilda-Klhl3	bait	for	the	Mathcmaker	screens.	 	The	pGBK47-Klhl3	bait	was	used	in	
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the	Matchmaker	Gold	screen	with	a	pACT2	human	kidney	cDNA	library	(Clontech).	
The	sequences	of	both	Klhl3	bait	clones	were	confirmed	by	Sanger	sequencing	prior	
to	 transformation.	 	 The	 bait	 vector	 was	 then	 transformed	 into	 the	 appropriate	
Saccharomyces	 cerevisiae	 strain	 (strain	 EGY48	 for	 the	 ‘Matchmaker’	 screens	 and	
yeast	 strain	 Y2HGold	 for	 the	 ‘Matchmaker	 Gold’	 screens)	 followed	 by	
transformation	 of	 the	 library.	 	 The	 bait	 vectors	 were	 transformed	 using	
electroporation	 and	 all	 library	 transformations	 were	 completed	 using	 a	 lithium	
acetate	 transformation	 procedure.	 The	 efficiency	 of	 each	 library	 transformation	
(number	of	clones	screened,	Table	3.1)	was	determined	by	calculating	a	library	titer.		
Each	library	plasmid	contains	a	unique	cDNA	sequence	fused	to	a	sequence	coding	
for	a	DNA	activation	domain.		When	a	library	plasmid	interacts	with	the	bait	plasmid	
(Klhl3),	then	the	colony	will	grow	on	selective	media	and	turn	blue	in	the	presence	
of	a	beta	galactosidase	indicator.		Using	this	system,	three	screens	were	performed	
using	 human	 cDNA	 libraries;	 Human	 Matchmaker	 Kidney,	 Human	 Fetal	 Liver	
MATCHMAKER	LexA	 cDNA	Library,	 and	Human	Testis	MATCHMAKER	LexA	 cDNA	
library	(Clontech).			
Immunofluorescence:	 	 Immunofluorescence	 was	 performed	 as	 previously	
described	 in	Chapter	 two	as	well	 as	previous	work	 from	our	 lab	 (Cummings	et	al.	
2009).	
Western	blots	and	Immunoprecipitations:	 	These	were	performed	as	previously	
described	 in	 Chapter	 2	 as	well	 as	 previous	work	 from	 our	 lab	 (Wimuttisuk	 et	 al.	
2014).	
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Cloning	 of	 p50	 and	 Klhl3:	 	 Klhl3	was	 cloned	 into	 the	 yeast	 two-hybrid	 vectors	
pGilda	 and	 pGBKT7	 (Clontech)	 via	 PCR	 from	 a	 mammalian	 expression	 vector	
followed	by	restriction	digests	and	ligation	into	the	appropriate	yeast	 ‘bait’	vector.	
P50	was	cloned	by	PCR	from	a	human	testis	cDNA	library	and	inserted	into	an	HA-
tagged	 CS2+	mammalian	 expression	 vector.	 	 Later,	 p50	was	 also	 sub-cloned	 from	
the	 HA-tagged	 vector	 into	 an	 S-tagged	 expression	 vector	 (CS2+)	 using	 restriction	
digests	followed	by	ligation	into	the	new	vector.			
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The	work	presented	here	highlights	the	multitude	of	cellular	processes	that	
are	 dependent	 on	 Cul3-based	 ubiquitin	 ligase	 complexes.	 	 The	 first	 chapter	
summarizes	what	 is	known	about	 the	Cul3	ubiquitin	 ligase	 including	 its	 structure,	
cellular	 functions,	and	 the	diseases	 in	which	Cul3	 is	known	to	be	 involved.	 	 In	 the	
body	of	this	dissertation	has	contributed	to	a	greater	understanding	of	the	cellular	
processes	 that	 are	 governed	 by	 Cul3.	 	 	 Chapter	 two	 describes	 the	 mechanism	
utilized	by	Cul3	to	target	cyclin	E	for	degradation	while	also	helping	to	establish	a	
role	for	Cul3	in	cancer,	as	low	molecular	weight	cyclin	E	that	cannot	be	degraded	by	
Cul3	is	associated	with	tumorigenesis.		Chapter	three	explains	our	understanding	of	
Cul3’s	 role	 in	 the	 kidney	 where	 it	 is	 involved	 in	 ion	 homeostasis	 and	 the	
maintenance	 of	 blood	 pressure.	 	 These	 findings	 have	 led	 to	 several	 new	 research	
questions	 worthy	 of	 exploration.	 	 This	 final	 chapter	 will	 help	 to	 explain	 the	
significance	 of	 this	 work	 and	 propose	 new	 questions	 and	 ideas	 for	 future	
experiments	relating	to	these	projects.		These	projects	have	led	to	five	new	research	
questions,	which	will	be	addressed	in	this	chapter:	
1. What	 is	 the	nature	 of	 the	 interactions	 between	Cul3,	 Cdk3,	 and	
the	LRR	protein	MUF1?	
2. How	does	loss	of	Cul3	affect	breast	cancer	cells?	
3. What	other	posttranslational	modifications	might	affect	cyclin	E	
in	vivo?	
4. How	do	BTB	proteins	affect	 the	binding	of	E2	enzymes	 to	Cul3-
based	complexes?	
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5. Do	 changes	 in	 Nrf2	 activity	 affect	 regulation	 of	 AQP2	 in	 Cul3	
conditional	knockout	or	Cul3Δ403-459	mice?	
RESEARCH	QUESTION	1:		What	is	the	nature	of	the	interactions	between	Cul3,	
Cdk2,	and	the	LRR	protein	MUF1?	
BACKGROUND:		LRR	proteins	and	Cul3	
	
Cul3	is	a	member	of	the	Cullin-RING	family	of	ubiquitin	ligases,	and	as	such	
has	many	 structural	 similarities	 to	other	members	of	 the	Cullin	 family.	 	 Examples	
include	 modification	 by	 the	 ubiquitin-like	 protein	 Nedd8,	 an	 N-terminal	 domain	
which	interacts	with	substrate	adaptors,	and	a	C-terminal	domain	which	binds	the	
RING	finger	protein,	Rbx1,	which	is	believed	to	be	responsible	 for	 interacting	with	
the	E2	enzyme	to	facilitate	substrate	ubiquitination	(Petroski	and	Deshaies	2005)	.		
Each	cullin	interacts	with	a	different	set	of	substrate	adaptors	in	order	to	recognize	
substrates	 (Petroski	 and	Deshaies	 2005).	 	 For	 example,	 Cul1	 is	 known	 to	 require	
two	substrate	adaptor	proteins:	 	the	Skp1	linker	protein,	which	binds	to	both	Cul1	
and	the	F-box	containing	substrate	adaptor,	for	example	Fbxw7.	 	Unlike	Cul1,	Cul3	
substrate	adaptors	are	only	known	to	consist	of	one	BTB	domain	containing	protein	
(Refer	to	Figure	1.3	in	Chapter	1	for	a	visual	comparison)	(Xu	et	al.	2003).	For	the	
sake	of	clarity,	it	is	helpful	to	note	that	many	of	the	findings	included	in	this	section	
as	background	information	have	been	published	(Wimuttisuk	et	al.	2014).	
In	 order	 to	 increase	 our	 understanding	 of	 the	 Cul3-based	 complex	 and	
identify	proteins	that	might	interact	with	Cul3,	a	proteomics	screen	was	performed.	
This	screen	identified	a	variety	of	potential	Cul3	 interacting	proteins	 including	ten	
proteins	which	contain	leucine-rich	repeat	(LRR)	domains	(Wimuttisuk	et	al.	2014).		
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The	identification	of	many	LRR	proteins	in	the	screen	led	to	the	hypothesis	that	they	
may	play	a	structural	role	in	Cul3-based	complexes	in	a	similar	manner	that	the	LRR	
protein	Skp1	plays	in	Cul1-based	complexes	(Wimuttisuk	et	al.	2014).		The	proteins	
identified	are	 involved	 in	a	variety	of	 cellular	processes,	 from	extracellular	matrix	
construction	 to	 neuronal	 structure	 and	 function.	 	 The	 information	 that	 is	 known	
about	these	ten	proteins	is	summarized	in	the	list	below:	
1. LRR1/LRRC8B/	TA-LRRP:		This	protein	is	a	member	of	the	LRRC8	family.		It	
is	expressed	in	many	tissues	(Kubota	et	al.	2004).			
2. LRR2/PRAME	 family	 member	 8:	 	 Members	 of	 the	 PRAME	 family	 are	
considered	 to	 be	 Cancer	 testis-antigens	 based	 on	 their	 expression	 profiles	
and	can	be	found	in	different	types	of	tumors	(Wadelin	et	al.	2010).			PRAME-
like	 proteins	 can	 be	 expressed	 in	 normal	 tissues	 as	 well	 (Wadelin	 et	 al.	
2010).	
3. LRR3/SALM-1:	This	protein	 is	 found	 in	 axons	and	dendrites	 as	well	 as	 the	
synaptic	membrane	(Morimura	et	al.	2006).			SALM	1	(Synaptic	adhesion	like	
molecule-1)	is	a	member	of	the	SALM/Lrfn	family	of	neuronal	LRR	proteins.			
This	 protein	 has	 been	 shown	 to	 be	 involved	 in	 the	 formation	 homo	 and	
heteromeric	 complexes	 (Nam	 et	 al.	 2011).	 	 Another	 member	 of	 the	 SALM	
family,	SALM5,	may	be	involved	in	autism	as	well	as	schizophrenia	(Nam	et	
al.	2011).		
4. LRR4/Caspase	 recruitment	 domain	 protein	 7:	 	 This	 protein	 contains	 a	
caspase	recruitment	domain	(CARD).		The	CARD	domain	is	a	member	of	the	
death-fold	 superfamily,	 which	 is	 involved	 in	 the	 formation	 of	 signaling	
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complexes	 resulting	 in	 the	activation	of	 caspases	and	kinases	 (Kersse	et	 al.	
2011).	
5. LRR5/Fibromodulin:	 	 Fibromodulin	 is	 a	 component	 of	 the	 extracellular	
matrix.	 	 It	 is	 expressed	 in	 B-cell	 chronic	 lymphocytic	 leukemia	 and	mantle	
cell	lymphoma,	but	not	other	blood	cancers	(Mikaelsson	et	al.	2005).					
6. LRR6	/MHC	 Class	 II	 Transactivator	 (CIITA):	 	 LRR6/CIITA	 regulates	 the	
activation	of	MHC	 II	 and	also	 transcriptionally	 regulates	many	 target	genes	
(Wu	et	al.	2009).	 	This	protein	 is	believed	 to	be	degraded	by	 the	ubiquitin-
proteasome	system,	but	the	E3	ligase	that	may	degrade	it	is	unknown	(Wu	et	
al.	2009).	
7. LRR7/	Reticulon-4	receptor-like	1	precursor,	Nogo66	receptor	homolog	
2,	Nogo66	receptor	(NgR)	related	protein	3:	LRR7	is	related	to	the	Nogo-
66	 receptor,	which	 is	 involved	 in	 axonal	 growth.	 	However,	 LRR7	does	not	
bind	 the	 same	 ligands	 as	 NgR	 and	 its	 function	 is	 unknown	 (Barton	 et	 al.	
2003).			
8. LRR8/Erbin(ErB2	 interacting	 protein):	 	 Erbin	 is	 expressed	 in	 sciatic	
nerves	(Tao	et	al.	2009).		Erbin	is	another	neuronal	LRR	protein	expressed	in	
neurons.		It	has	been	shown	to	be	involved	in	myelination	(Tao	et	al.	2009).	
9. LRR9	/LRRK1	 (Leucine	 rich	 repeat	 kinase	 1):	 	 LRRK1	 is	 a	 homolog	 to	
LRRK2,	 a	 protein	 shown	 to	 be	 involved	 in	 Parkinson’s	 disease.	 	 In	 rats,	
LRRK1	 is	 expressed	 in	 different	 parts	 of	 the	 rat	 body	 and	 nervous	 system	
throughout	development	(Westerlund	et	al.	2008).	
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10. LRR10/Densin-180	:		Densin	180	is	a	scaffolding	protein	found	in	the	post-
synaptic	densities	of	neurons	(Thalhammer	et	al.	2009).		LRR10/Densin-180	
and	LRR8/Erbin	have	many	structural	similarities.		
	
BACKGROUND:		LRR5	(FMOD),	LRR3	(SALM1)	and	Cul3	
	
In	order	to	determine	which,	if	any,	Cul3-dependent	processes	these	proteins	
might	 play	 a	 role,	 they	 were	 cloned	 into	 mammalian	 expression	 vectors	 for	
transfection	into	cells.		Two	LRR	proteins	which	were	of	interest	are	LRR5	(FMOD	or	
fibromodulin)	 and	 LRR3	 (also	 called	 SALM1)	 as	 both	were	 found	 to	 interact	with	
BTB	 domain	 containing	 proteins	 (Wimuttisuk	 et	 al.	 2014).	 	 	 As	 fibromodulin	 is	 a	
component	 of	 the	 extracellular	 matrix	 (ECM),	 we	 sought	 to	 determine	 its	
localization,	 as	 Cul3	 is	 not	 an	 extracellular	 protein.	 	 Immunofluorescence	 of	 HA-
tagged	LRR5	(FMOD)	and	Flag-Cul3	shows	that	 the	two	proteins	can	co-localize	 in	
the	cytoplasm,	indicating	that	it	is	possible	for	FMOD	to	play	a	role	inside	the	cell	in	
addition	to	its	established	role	in	the	ECM	(Figure	4.1,	rows	4	and	5).		A	second	LRR	
protein,	 LRR3,	 can	 also	 co-localize	with	Cul3	 in	 the	 cytoplasm	 (Figure	4.1,	 rows	2	
and	3).		LRR3	(SALM1)	is	a	neuronal	protein	that	is	normally	found	in	neurons	and	
is	 involved	 in	 synapse	 formation	 as	 well	 as	 axonal	 outgrowth	 (Nam	 et	 al.	 2011).		
Cul3	has	been	associated	with	neuronal	functioning	and	several	neuronal	disorders	
(Codina-Sola	 et	 al.	 2015;	 Lin	 et	 al.	 2015;	Wang	 et	 al.	 2016),	 so	 it	 is	 reasonable	 to	
speculate	 that	 Cul3	 and	 LRR3	 (SALM1)	may	 serve	 a	 function	 in	 the	 synapse	 that	
remains	 unknown.	 	 This	 hypothesis	 may	 provide	 a	 useful	 basis	 for	 future	
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experimentation,	but	has	not	been	further	explored.		All	further	information	in	this	
section	 will	 focus	 on	 LRR5	 (fibromodulin)	 and	 seek	 to	 determine	 the	 potential	
interactions	 that	 might	 occur	 between	 LRR5	 and	 the	 Cul3	 complex	 within	 living	
cells.	
	
Figure	4.1:	 	Cul3	localizes	with	LRR	proteins.	 	Transfected	Flag-Cul3	co-localizes	 in	
the	 cytoplasm	 with	 two	 transfected	 HA-tagged	 LRR-domain	 containing	 proteins:		
LRR3	(L3,	second	row)	and	LRR5	(L5,	bottom	row).		Antibodies	to	Flag	(Cul3)	or	HA	
(LRR	proteins)	were	used	for	this	experiment.	
	
BACKGROUND:		LRR5	(FMOD)	interacts	with	the	BTB	protein	FAZF	
	
In	addition	to	their	ability	to	interact	with	Cul3,	LRR3	and	LRR5	can	interact	
with	 BTB-domain	 containing	 proteins	 (Wimuttisuk	 et	 al.	 2014).	 	 To	 elucidate	 the	
mechanism	by	which	the	Cul3	complex	might	 interact	with	LRR5	within	the	cell,	a	
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yeast	two-hybrid	screen	was	performed	where	LRR5	(FMOD)	was	used	as	bait	and	
screened	 agains	 a	 human	 testis	 cDNA	 library	 in	 order	 to	 identify	 potential	 LRR5	
interacting	partners.		The	only	protein	that	was	discovered	in	this	screen	was	FAZF,	
a	BTB	and	zinc-finger	domain	containg	protein	(Wimuttisuk	et	al.	2014).		FAZF	is	a	
transcriptional	 repressor	 that	 is	 involved	 in	 blood	 cell	 development	 and	 Fanconi	
anemia,	 a	 blood	 disorder	 associated	 with	 defects	 in	 hematopogenesis	 and	 bone	
marrow	failure	(Dai	et	al.	2002).	
Structurally,	 FAZF	 is	 closely	 related	 to	 PLZF,	 another	 DNA	 binding	 protein	
that	 contains	 both	 a	 BTB	 domain	 and	 a	 zinc-finger	 domain	 (Hoatlin	 et	 al.	 1999).		
Further	 work	 by	 our	 lab	 revealed	 that	 LRR5	 can	 bind	 FAZF	 but	 not	 PLZF	
(Wimuttisuk	et	al.	2014).		One	structural	difference	between	FAZF	and	PLZF	that	we	
hypothesize	might	be	responsible	for	the	interaction	with	LRR5	is	the	presence	of	a	
proline-rich	 region	 in	 FAZF	 which	 is	 located	 just	 upstream	 of	 the	 BTB	 domain	
(Figure	 4.2)	 (Wimuttisuk	 et	 al.	 2014).	 	 This	 region	 is	 not	 present	 in	 PLZF	
(Wimuttisuk	et	al.	2014).		Analysis	of	other	BTB-domain	containing	proteins	reveals	
proline	rich	regions	near	the	BTB	domain	in	Mayven	(Klhl2),	RhoBTB3,	Ctb73,	SPOP,	
and	actinfilin	(Klhl17).	 	Other	proteins	such	as	PLZF	and	Klhl3	do	not	contain	 this	
region.	 	We	 hypothesize	 that	 this	 proline-rich	 region	 that	 is	 located	 in	 some	BTB	
proteins	may	be	involved	in	interactions	with	LRR-domain	containing	proteins	and	
that	the	LRR	proteins	are	not	Cul3	substrates	and	instead	might	function	as	a	part	of	
the	Cul3	complex,	possibly	as	substrate	adaptors		(Wimuttisuk	et	al.	2014).		Further	
work	will	be	necessary	to	determine	 if	proline-rich	regions	 in	BTB	proteins	play	a	
role	 in	 any	 significant	 interaction	 between	 BTB	 proteins	 and	 	 LRR	 domain	
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containing	proteins.				In	order	to	further	explore	this	idea,	several	BTB	proteins	that	
contain	proline	rich	regions	were	identified	by	searching	the	amino	acid	sequences	
of	 several	 BTB	 proteins	 by	 eye	 (Figure	 4.2).	 	 The	 identification	 of	 these	 proteins	
leads	us	to	hypothesize	that	other	pairs	of	BTB	and	LRR	proteins	might	exist.	 	One	
possible	 pair	 consists	 of	 the	 BTB	 protein	 RhoBTB3	 and	 the	 LRR	 protein	 MUF1.
	
Figure	 4.2:	 	 Proline-rich	 regions	 in	 BTB	 proteins.	 	 Domain	 structures	 of	 several	
different	BTB	proteins	show	BTB	domains	located	near	proline-rich	regions.		Many	
BTB	 proteins	 contain	 a	 proline-rich	 region,	 which	 is	 located	 near	 the	 N-terminal	
portion	of	the	BTB	domain.		Proline-rich	regions	were	identified	by	looking	through	
the	 amino	 acid	 sequence	 of	 each	 protein	 to	 find	 areas	where	 there	 are	 at	 least	 3	
prolines	located	within	a	ten	residue	region.	
	
RESULTS:		Exploring	the	interactions	between	the	LRR	protein	MUF1,	Cul3,	
and	Cdk2	
	
RhoBTB3,	 a	 BTB	 protein	with	 a	 proline-rich	 region	 and	 two	 BTB	 domains	
(Schenkova	et	al.	2012),	 is	a	member	of	 the	RhoBTB	 family	of	proteins	and	also	a	
P BTB BACK PHR
P BTB BACK Kelch
P BTB BACK Kelch
P BTB BTBRhoGTPase
P BTB Zinc Finger
P BTB BACKMATH
Ctb73
Klhl2
(Mayven)
Klhl17
(Actinfilin)
RhoBTB3
FAZF
SPOP
(Ctb75)
Protein name Domain structure (NH2-COOH)
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Cul3	 substrate	 adaptor	 (Schenkova	 et	 al.	 2012;	 Lu	 and	 Pfeffer	 2013;	 Zhang	 et	 al.	
2015).		RhoBTB3	is	of	interest	as	a	potential	interacting	partner	for	LRR	proteins	as	
it	 has	 been	 recently	 demonstrated	 that	 RhoBTB	 family	 members,	 including	
RhoBTB3,	can	interact	with	the	LRR	protein	MUF1(Schenkova	et	al.	2012).	 	MUF1,	
also	 called	 LRRC41,	 is	 a	 nuclear	 protein	 whose	 function	 is	 largely	 unknown	
(Schenkova	et	al.	2012).		MUF1	is	highly	conserved	in	higher	eukaryotes,	but	has	not	
been	the	focus	of	extensive	research.		Others	believe	that	MUF1	may	be	a	substrate	
of	Cul3	and	RhoBTB3	(Schenkova	et	al.	2012).			
MUF1	contains	an	N-terminal	B/C	box	and	is	believed	to	interact	with	Cul5,	
and	 a	 C-terminal	 leucine	 rich	 repeat	 (LRR)	 domain	 (Kamura	 et	 al.	 2001).	 	 The	
presence	 of	 the	 B/C	 box	 suggests	 that	 MUF1	 is	 a	 Cul5	 substrate	 adaptor,	 but	 no	
substrates	of	MUF1	are	known	(Kamura	et	al.	2001).	 	 	As	RhoBTB	family	members	
contain	 proline-rich	 regions	 (Figure	 4.2),	 and	 have	 been	 shown	 to	 associate	with	
MUF1,	we	hypothesized	that	MUF1	and	RhoBTB	proteins	may	interact	 in	a	similar	
way	 as	 LRR5	 and	 FAZF.	 	 In	 order	 to	 investigate	 this	 idea,	 a	 FLAG-tagged	 MUF1	
construct	was	obtained	for	future	experimental	use	(Kamura	et	al.	2001).		
Two	 nuclear-localized	 proteins,	 cyclin	 E	 and	 MUF1,	 have	 been	 shown	 to	
interact	with	the	Golgi-associated	RhoBTB3	(Schenkova	et	al.	2012;	Lu	and	Pfeffer	
2013).	 	 It	has	been	suggested	 that	both	proteins	are	ubiquitinated	by	RhoBTB3	at	
the	Golgi,	which	is	peculiar	since	both	proteins	are	normally	localized	to	the	nucleus	
(Schenkova	et	al.	2012;	Lu	and	Pfeffer	2013).		The	amino	acid	sequences	of	cyclin	E	
and	MUF1	were	compared	in	order	to	identify	any	possible	similarities	between	the	
two	proteins	 (Figure	4.3).	 	Cyclin	E	contains	an	MRAIL	sequence,	which	 is	 located	
111	
within	 the	 cyclin	 homology	 domain,	 and	 also	 has	 the	 sequence	 EEIYP	 further	
downstream.	 	 Both	 of	 these	 sequences	 are	 involved	 in	 cyclin	 E’s	 interaction	with	
Cdk2	 (Honda	 et	 al.	 2005).	 	 	 	 Interestingly,	MUF1	 contains	 the	 sequence	RAIV	 and	
EEIP	 further	 C-terminal,	which	 resembled	 the	 Cdk2	 interaction	 region	 in	 cyclin	 E	
and	 suggested	 that	 MUF1	might	 also	 be	 able	 to	 interact	 with	 Cdk2.	 Additionally,	
MUF1	also	contains	 three	possible	Cdk2	phosphorylation	sites,	which	suggest	 that	
MUF1	may	be	a	substrate	of	Cdk2	(Figure	4.3).		
	
Figure	4.3:	 	Sequences	of	MUF1	and	cyclin	E.	 	MUF1	has	a	B/C	box,	which	interacts	
with	Cul5,	shown	in	red.		The	MRAIL	and	EEYIP	sequences	in	cyclin	E,	which	interact	
with	 Cdk2,	 are	 shown	 in	 yellow.	 	 Similar	 sequences	 in	 MUF1	 are	 also	 shown	 in	
yellow.	 	MUF1	 also	 contains	 several	 possible	 Cdk2	 phosphorylation	 sites	 (green).		
The	regions	shown	in	pink,	located	between	the	RAIL	and	EEIYP	sequences,	appear	
to	differ	between	cyclin	E	and	MUF1.	The	MUF1	LRR	domain	is	shown	in	blue	and	
the	B/C	box	in	red.	
	
MUF1:
Cyclin E:
MKEDGGAEFSARSRKRKANVTVFLQDPDEEMAKIDRTARDQCGSQPWDNNAVCADPCSLIP
TPDKEDDDRVYPNSTCKPRIIAPSRGSPLPVLSWANREEVWKIMLNKEKTYLRDQHFLEQH
PLLQPK
PKLHQFAYVTDGACSGDEILTMELMIMKALKWRLSPLTIVSWLNVYMQVAYL
NDLHEVLLPQYPQQIFIQIAELLDLCVLDVDCLEFPYGILAASALYHFSSSELMQKVSGYQ
WCDIENCVKWMVPFAMVIRETGSSKLKHFRGVADEDAHNIQTHRDSLDLLDKARAKKAMLS
EQNRASPLPSGLLTPPQSGKKQSSGPEMA
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MUF1	binds	Cdk2	
	
The	similarities	between	MUF1	and	cyclin	E	have	led	us	to	wonder	if	MUF1	
might	be	involved	in	cell	cycle	regulation.	 	We	hypothesized	that	MUF1	might	bind	
to	Cdk2.		Binding	between	Cdk2	and	MUF1	was	analyzed	via	immunoprecipitations	
of	 transfected	 protein	 (Figure	 4.4).	 	 The	 results	 show	 that	 MUF1	 binds	 to	 Cdk2,	
indicating	that	Cdk2	and	MUF1	might	bind	in	vivo.	 	Further	work	will	be	necessary	
to	determine	if	and	how	this	binding	affects	the	functioning	of	the	cell.	
Levels	of	MUF1	and	cyclin	E	
	
There	 are	 two	 possible	 explanations	 for	 the	 binding	 between	 MUF1	 and	
Cdk2:	 	First,	 it	 is	possible	 that	MUF1	behaves	similarly	 to	a	cyclin	and	works	with	
Cdk2	to	fulfill	a	function	in	the	cell,	and	second,	MUF1	may	be	a	substrate	of	Cdk2.		
One	or	both	of	these	situations	maybe	true.		There	is	a	third	possibility	that	can	be	
eliminated:	 	 Cdk2	may	 be	 a	 substrate	 of	 the	 Cul5/MUF1	 ubiquitin	 ligase.	 	 This	 is	
extremely	unlikely	as	Cdk2	is	not	degraded	in	a	ubiquitin-dependent	manner	as	it	is	
regulated	 by	 its	 cyclin	 subunits	 which	 are	 rapidly	 degraded	 (Felix	 et	 al.	 1989).		
Therefore,	 it	 is	most	 likely	that	MUF1	acts	as	a	Cdk2	substrate	or	binding	partner.		
As	cyclin	E,	a	known	partner	of	Cdk2,	 is	an	unstable	protein,	 it	 led	us	to	wonder	if	
cyclin	E	and	MUF1	might	compete	for	Cdk2.	 	We	hypothesized	that	co-transfection	
of	 cyclin	 E	 and	MUF1	may	 cause	 changes	 in	 the	 stability	 of	 one	 or	 both	 proteins	
(Figure	4.5)			
The	results	of	this	experiment	show	that	MUF1	and	cyclin	E	both	appear	to	
have	diminished	 levels	when	co-transfected	 in	 the	absence	of	excess	Cdk2	(Figure	
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4.5,	lane	2	compared	to	others).		When	Cdk2	is	co-transfected	and	all	three	proteins	
are	present,	however,	cyclin	E	seems	to	show	increased	stability	and	MUF1	shows	
decreased	stability	(Figure	4.5	lanes	5	and	6).		When	HA-Cul3	is	co-transfected	with	
Flag-MUF1,	 it	 appears	 that	 Flag-MUF1	 levels	 may	 be	 slightly	 elevated,	 which	
sometimes	 also	 seems	 to	 be	 the	 case	 when	 HA-Cdk2	 and	 Flag-MUF1	 are	 co-
transfected	 (Figure	 4.5	 compare	 lanes	 1,	 2,	 and	 3).	 	 Taken	 together,	 these	 results	
indicate	an	interaction	between	MUF1,	cyclin	E,	Cdk2,	and	the	Cul3	complex	maybe	
taking	place	which	is	altering	the	stability	of	MUF1	and	cyclin	E.		As	MUF1	contains	
several	 possible	 Cdk2	 phosphorylation	 sites	 (Figure	 4.3),	 it	 remains	 a	 strong	
possibility	that	MUF1	may	be	a	Cdk2	substrate.		This	interaction	may	be	responsible	
for	 regulating	 levels	 of	 MUF1	 within	 the	 cell.	 	 Further	 experimentation	 will	 be	
necessary	 to	 determine	 if	 this	 is	 the	 case,	 and	 if	 so	 the	 nature	 of	 any	 interaction	
between	MUF1,	cyclin	E,	Cdk2,	or	Cul3	which	may	occur.	
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Figure	4.4:		MUF1	binds	Cdk2.		293	cells	were	transfected	with	CDK2	in	the	presence	
and	absence	of	Flag-MUF1.		The	upper	blot	shows	the	immunoprecipitation	results.		
The	lower	blots	show	protein	expression	in	the	cell	extracts.	
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WB: CDK2
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WB: CDK2
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Figure	 4.5:	 	 Expression	 levels	 of	 transfected	 MUF1	 in	 the	 presence	 of	 different	
proteins.	 	 Co-transfection	 and	 western	 blotting	 for	 Flag-MUF1	 or	 Myc-cyclin	 was	
utilized	 to	 determine	 their	 expression	 levels	 in	 the	 presence	 or	 absence	 of	 each	
other	 as	 well	 as	 HA-tagged	 Cul3	 or	 HA-tagged	 Cdk2.	 	 MUF1	 is	 shown	 in	 the	 top	
panel.		Cul3,	Myc-cyclin	E,	and	HA-Cdk2	are	shown	in	the	three	lower	blots.	
	
DISCUSSION:	
	
Previous	work	from	our	lab	has	identified	LRR-domain	proteins	as	potential	
components	 of	 the	 Cul3	 complex	 which	 might	 serve	 as	 part	 of	 multi-subunit	
substrate	 adaptors,	 similar	 to	 the	 system	 employed	 by	 Cul1-based	 ligases	
(Wimuttisuk	 et	 al.	 2014).	 	 Interactions	 have	 been	 reported	 between	 MUF1	 and	
members	 of	 the	RhoBTB	 family	 including	RhoBTB3	 (Schenkova	 et	 al.	 2012).	 	 It	 is	
possible	that	these	interactions	might	fit	within	our	published	model	suggesting	that	
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LRR	 proteins	 can	 be	 involved	 in	 the	 formation	 of	 Cul3-based	 complexes	 via	 an	
interaction	with	BTB	domain	proteins	(Wimuttisuk	et	al.	2014).	 	 	This	 information	
has	 led	 us	 to	 our	 first	 hypothesis	 that	 MUF1	 might	 interact	 with	 the	 RhoBTB	
proteins	via	their	proline-rich	domains	(Figure	4.6	panel	A).		
Although	 preliminary,	 the	 data	 presented	 here	 regarding	 interactions	
between	MUF1	and	 the	 cyclin-dependent	kinase	Cdk2	 suggest	 that	 it	may	play	 an	
important	 role	 in	 the	 cell	 cycle	 and	merits	 further	 study.	 	 The	 information	 in	 the	
literature	which	demonstrates	the	ability	of	RhoBTB3	and	related	proteins	to	bind	
MUF1	as	well	as	the	data	presented	above	demonstrating	the	ability	of	MUF1	to	bind	
Cdk2	presents	a	second	hypothesis	to	describe	how	MUF1	might	interact	with	Cul3	
and	 possibly	 cyclin	 E:	 MUF1	 might	 be	 a	 substrate	 of	 Cdk2	 (Figure	 4.6	 panel	 B).		
MUF1	 is	 a	 highly	 conserved	 protein	 in	mammals	 (Kamura	 et	 al.	 2001),	 indicating	
that	it	might	be	responsible	for	an	important	but	as	of	yet	unknown	function	within	
the	cell.			
	
There	are	many	potential	future	directions	for	this	project	as	it	is	a	novel	idea	
and	still	in	its	infancy.		Further	study	of	MUF1’s	structure	and	function	will	require	
Cul3
E2
RhoBTB
MUF1
B/C box
CDK2
Cyclin E
MUF1



Figure	 4.6:	 	 Model	 showing	 two	 new	
hypotheses	 regarding	 the	 potential	
involvement	of	MUF1	in	regulation	of	Cul3-
based	complexes.	 (A)	and/or	as	a	possible	
substrate	 of	 Cdk2	 (B).	 	 MUF1	 interacts	
with	 proteins	 in	 the	 RhoBTB	 family,	
indicated	 it	 might	 associate	 with	 Cul3-
basd	complexes	via	its	B/C	box	(A).			Other	
LRR	 proteins	 associate	 with	 Cul3	 in	 this	
way	 (Wimuttisuk,	 2014).	 	 MUF1	 contains	
two	 putative	 Cdk2	 phosphorylation	 sites	
and	may	be	regulated	by	Cdk2	(B).	
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experiments	 to	 investigate	 the	 cellular	 role	of	MUF1.	 	MUF1	 is	 a	poorly	described	
protein	and	much	information	about	MUF1	remains	unknown,	including	its	tertiary	
structure	 and	 topology.	 	 As	 MUF1	 is	 believed	 to	 be	 a	 Cul5	 substrate	 adaptor	
(Kamura	 et	 al.	 2001),	 but	 none	 of	 its	 substrates	 are	 known,	 a	 yeast	 two-hybrid	
screen	using	MUF1	as	bait	would	be	an	effective	way	to	identify	proteins	that	might	
interact	with	MUF1	in	vivo.		It	is	possible	that	a	substrate	for	MUF1	may	be	identified	
by	this	method.	 	Cell	cycle	proteins	such	as	Cdk2	and	cyclin	E	may	be	identified	in	
such	a	screen.	 	 	Deletion	of	MUF1	from	mammalian	cells	would	be	a	second	useful	
method	to	help	to	determine	its	function.	 	This	could	be	accomplished	using	either	
siRNA	 or	 CRISP-R	 technology.	 	 However,	 before	 MUF1	 can	 be	 deleted	 it	 will	 be	
necessary	to	obtain	or	produce	an	antibody	that	can	detect	endogenous	MUF1	and	
determine	which	cell	types	produce	MUF1	protein.	
In	order	 to	address	 the	hypothesis	regarding	the	role	of	MUF1	and	Cdk2,	 it	
will	 be	 important	 to	 identify	 sequences	 in	 MUF1	 that	 facilitate	 binding	 to	 Cdk2.		
Mutants	 of	 the	 RAIV	 and	 EEIP	 sequences	 in	MUF1	may	 be	 useful	 to	 determine	 if	
MUF1	 interacts	with	Cdk2	 in	a	similar	manner	as	cyclin	E.	 	Truncation	mutants	of	
MUF1	 should	be	 cloned	 in	 order	 to	 identify	which	 region	on	MUF1	 interacts	with	
Cdk2.	 	 	As	MUF1	also	contains	several	putative	Cdk2	phosphorylation	sites	(Figure	
4.3,	 shown	 in	 green),	 these	 sites	 should	 be	 mutated	 to	 alanines	 in	 order	 to	
determine	if	MUF1	is	a	substrate	of	Cdk2.		Mutants	can	then	be	transfected	into	cells	
to	be	checked	for	binding	to	Cdk2	and	also	to	help	determine	if	any	of	the	mutants	
have	notable	phenotypes.	 	This	 could	be	accomplished	via	 fluorescent	microscopy	
and	also	transfection	assays	similar	to	those	utilized	with	cyclin	E	in	chapter	two.	
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Our	original	hypothesis,	which	first	 led	me	to	MUF1,	was	that	LRR	proteins	
interact	with	 BTB	 proteins	 via	 a	 proline-rich	 region	 on	 the	 BTB	 protein	which	 is	
located	 N-terminally	 of	 the	 BTB	 domain	 (Figure	 4.2).	 	 RhoBTB	 family	 members	
possess	 such	 a	 region	 and	 have	 been	 shown	 by	 others	 to	 interact	 with	 MUF1	
(Schenkova	 et	 al.	 2012).	 	We	 currently	 possess	 a	 clone	 of	 RhoBTB3	 in	 lab,	 but	 in	
order	 to	 further	 investigate	 this	 idea	 it	 will	 be	 necessary	 to	 clone	 RhoBTB1	 and	
RhoBTB2.		After	cloning	all	three	proteins,	the	proline	rich	region	should	be	mutated	
to	alanines	in	each	protein	and	the	resulting	mutants	should	be	checked	for	binding	
with	 MUF1	 either	 via	 immunoprecipitation	 or	 yeast	 two-hybrid	 screen.	 	 	 These	
experiments	 will	 help	 to	 shed	 light	 on	 MUF1’s	 cellular	 role	 as	 well	 as	 any	
involvement	it	might	have	in	processes	that	are	regulated	by	Cul3.	
RESEARCH	QUESTION	2:		How	does	loss	of	Cul3	affect	breast	cancer	cells?	
	
Chapter	two	demonstrated	that	Cul3	binds	cyclin	E	directly	and	ubiquitinates	
its	N-terminal	domain.	 	This	finding	is	significant	given	the	association	between	N-
terminally	truncated	cyclin	E	variants	and	tumor	progression.		The	next	step	for	this	
project	 will	 be	 to	 determine	 how	 loss	 of	 Cul3	 and	 overexpression	 of	 Cul3	 affects	
breast	cancer	cells	to	determine	how	loss	of	Cul3	might	affect	cancer	progression	in	
humans.	 	 Based	 on	 the	 results	 in	 chapter	 two,	we	 hypothesize	 that	 breast	 cancer	
cells	that	express	LMW	cyclin	E	will	have	similar	amounts	of	LMW	cyclin	E	protein	
in	cells	that	contain	Cul3	and	cells	that	lack	Cul3.		In	order	to	test	this,	human	breast	
cancer	cell	lines	should	be	edited	using	the	CRISPR	Cas-9	system	to	delete	the	Cul3	
gene	 in	 the	 same	manner	 as	 it	 was	 deleted	 in	 the	 293	 cells	 that	were	 utilized	 in	
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Chapter	 two	 (Ibeawuchi	 et	 al.	 2015).	 	 Three	 human	 breast	 cell	 lines	 should	 be	
chosen	for	this	experiment;	one	normal,	one	cancerous	and	producing	LMW	cyclin	E,	
and	the	third	cancerous	but	not	producing	LMW	cyclin	E.		Once	these	three	cell	lines	
have	 been	 produced,	 they	 will	 be	 valuable	 tools	 and	 can	 be	 compared	 to	 their	
counterparts	with	wild-type	levels	of	Cul3.		The	breast	cancer	cell	line	MDA-MB-157	
has	been	used	by	others	for	the	study	of	LMW	cyclin	E,	so	these	cells	would	be	an	
ideal	choice	(Porter	et	al.	2001).		Based	on	our	own	observations	the	breast	cancer	
cell	 lines,	 Sk-br-3,	 MCF7,	 and	 MDA-MB-231	 might	 also	 be	 useful	 for	 these	
experiments	(Cummings	and	Singer,	unpublished	results).	
RESEAERCH	QUESTION	3:		What	other	modifications	may	affect	cyclin	E	in	
vivo?	
	
Continued	work	with	cyclin	E	revealed	the	presence	of	a	band	visible	in	293	
cells	and	detected	with	the	HE12	cyclin	E	antibody,	which	is	double	the	size	of	the	
endogenous	cyclin	E	band	(Figure	4.7).		This	band	appears	to	be	more	prevalent	in	
the	 Cul3	 KO	 293	 cells	 (Figure	 4.7).	 	 Cyclin	 E	 is	 known	 to	 undergo	 several	 post-
translational	 modifications,	 which	 suggests	 the	 possibility	 that	 this	 90	 kDa	 band	
might	result	from	an	unknown	modification.	 	One	modification	that	might	result	in	
such	a	 large	product	 is	modification	by	 the	 transglutaminase	enzyme	TG2.	 	TG2	 is	
known	to	cross-link	glutamine	residues	with	lysine	residues	in	the	same	protein	or	
lysine	residues	with	lysine	residues	in	other	proteins	which	results	in	large	products	
and	has	been	previously	demonstrated	to	modify	pRb,	 the	retinoblastoma	protein,	
upon	 cellular	 stress	 (Oliverio	 et	 al.	 1997;	 Boehm	 et	 al.	 2002;	Mishra	 et	 al.	 2007).		
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Transglutaminase	is	believed	to	play	a	role	in	apoptosis	and	also	cancer	(Mishra	et	
al.	2007).			
The	 cyclin	 E	 product	 that	 we	 observed	 in	 the	 293	 cells	 is	 large,	 so	 we	
hypothesized	that	it	could	be	the	result	of	cyclin	E	modification	by	TG2.	In	order	to	
test	 this,	a	sample	of	Cul3	WT	and	Cul3	KO	293	cells	was	harvested	 in	 lysis	buffer	
and	 then	 incubated	with	varying	amounts	of	TG2	(Figure	4.8).	 	A	western	blot	 for	
cyclin	E	reveals	 that	with	 increasing	amounts	of	TG2,	both	 the	endogenous	50kDa	
and	 90kDa	 cyclin	 E	 bands	 appear	 to	 disappear	 from	 the	 gel,	 whereas	 levels	 of	
endogenous	 cyclin	 A	 remain	 unchanged	 (Figure	 4.8).	 	 This	 result	 indicates	 the	
possibility	that	TG	is	modifying	cyclin	E	but	not	A.	 	 It	 is	possible	that	the	modified	
cyclin	E	resulted	 in	a	product	 too	 large	 in	order	 to	be	observed	 in	 the	ten	percent	
resolving	gel	that	was	used	for	this	experiment.		In	order	to	determine	if	cyclin	E	can	
be	modified	in	a	TG2-dependent	manner,	this	experiment	will	need	to	be	repeated	
and	the	incubated	extracts	will	need	to	be	run	on	a	gradient	gel	in	order	to	identify	
any	large	products	that	might	form.		If	cyclin	E	does	appear	modified	in	this	assay,	it	
will	then	be	necessary	to	determine	if	this	modification	differs	between	the	Cul3	WT	
and	KO	cells.		
Next,	 in	order	 to	determine	 if	 cyclin	E	 can	be	modified	by	 transfected	TG2,	
either	WT	or	KO	293	cells	were	transfected	with	a	Myc-tagged	human	TG2	construct	
in	 the	 presence	 or	 absence	 of	 the	 transglutaminase	 inhibitor	 dansyl	 cadaverine	
(Oliverio	et	al.	1997).	 	The	results	of	 this	experiment	reveal	a	72	kDa	band	that	 is	
detectible	 with	 cyclin	 E	 antibody,	 in	 addition	 to	 a	 smear	 at	 the	 very	 top	 of	 the	
resolving	gel	(Figure	4.9).		It	is	possible	that	this	band	results	from	TG2	modification	
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of	 cyclin	 E,	 but	 this	 experiment	 will	 need	 to	 be	 repeated	 to	 verify	 these	 results.		
Additionally,	the	dansyl	cadaverine	did	not	appear	to	completely	inhibit	TG2	activity	
in	 this	 assay,	 so	 it	will	 be	 necessary	 to	 titrate	 the	 amount	 of	 drug	 that	 should	 be	
added	in	order	to	optimize	TG2	inhibition	(Figure	4.9	lanes	2	and	6).	
The	results	presented	here	are	preliminary	and	these	experiments	will	need	
to	 be	 optimized	 and	 repeated	 in	 order	 to	 determine	 if	 cyclin	 E	 is	 modified	 in	 a	
transglutaminase-dependent	 manner.	 	 Others	 have	 shown	 the	 the	 Rb	 protein	 is	
modified	 by	 transglutaminase	 during	 apoptosis	 (Boehm	 et	 al.	 2002),	 so	 further	
experimentation	suggests	that	cyclin	E	is	a	transglutaminase	substrate,	it	would	be	
necessary	to	determine	if	cyclin	E	is	modified	during	apoptosis	as	well.		
	
	
Figure	 4.7:	 A	 heavy	 cyclin	 E	 band	 is	 present	 in	 Cul3	 KO	 293	 cells.	 	 Western	 blot	
showing	endogenous	levels	of	Cul3	(top)	and	cyclin	E	(bottom)	in	WT	and	KO	293	
cells.		The	cyclin	E	antibody	HE12	was	used	for	this	experiment.	
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Figure	4.8:	 	The	heavy	cyclin	E	band	disappears	after	incubation	in	transglutaminase.		
293	lysates	were	harvested	and	incubated	in	different	amounts	of	transglutaminase	
for	 an	 hour	 followed	 by	 blotting	 for	 endogenous	 cyclin	 E	 (top)	 and	 cyclin	 A	
(bottom).		
WB: HE12
WB: Cyclin A
WT 293___________ Cul3 KO 293______
TG - 2uL 10uL - 2uL 10uL
I added TG to cell lysates and incubated for 15 minutes.  The dilution was prepared according to!
Rob's inscrutions, but instead of only adding 2 uL I also included a lane where 10uL was added.  I !
then blotted for endogenous cyclin E and endogenous cyclin A.  In both cell types, the heavy cyclin E!
band appeared to decrease with increasing amounts of TG.  Since I did not transfer the stacking gel,!
I cannot guarentee that there isn't an extremely large product that was formed.  I also blotted for!
endogenous cyclin A as a control.  No change in cyclin A was observed.
50kDa
90kDa
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Figure	4.9:		The	effects	of	transfected	transglutaminase	on	cyclin	E.		Either	WT	(lanes	
1	through	4)	or	Cul3	KO	(lanes	5	through	8)	293	cells	were	transfected	with	a	myc-
tagged	 transglutaminate	 (TG2)	 construct	 in	 the	 presence	 or	 absence	 of	 the	 TG	
inhibitor	dansyl	cadaverine.		A	western	blot	for	endogenous	cyclin	E	is	shown.			
	
RESEARCH	QUESTION	4:		How	do	BTB	proteins	affect	the	binding	of	E2	
enzymes	to	Cul3-based	complexes?	
	
The	 data	 resented	 in	 chapter	 two	 demonstrated	 that	 RhoBTB3,	 which	 is	
believed	 to	 be	 the	 substrate	 adaptor	 for	 cyclin	 E,	 can	 bind	 the	 E2	 ubiquitin	
conjugating	enzyme	UbE2E1	 in	 the	absence	of	Cul3	 (Figure	2.14).	 	Additionally,	 it	
was	also	shown	that	Cul3Δ51-67,	which	does	not	bind	BTB	proteins,	cannot	interact	
with	UbE2E1	(Figure	2.15).			Together,	these	findings	suggest	that	BTB	proteins	may	
be	involved	in	recruitment	and	binding	of	E2	enzymes	to	the	Cul3	complex.		In	order	
to	determine	 if	 this	 is	 the	 case,	 it	will	 be	necessary	 to	 investigate	 the	 interactions	
between	different	E2s	and	BTB	proteins.	
Lane       1              2          3          4             5           6            7           8       
55kDa
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WB: Cyclin E!
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WT 293 cells                                 Cul3 KO 293 cells
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One	method	that	will	be	necessary	to	explore	these	 interactions	 is	 to	check	
the	 binding	 of	 other	 BTB	 proteins	 that	 are	 known	 to	 result	 in	 the	 degradation	 of	
substrates,	such	as	Klhl3	and	Keap1,	to	UbE2E1,	as	it	is	known	to	make	K48-linked	
(degradative)	 ubiquitin	 chains	 (Plafker	 et	 al.	 2009).	 	 This	 experiment	 can	 be	
conducted	by	co-transfecting	and	immunoprecipitating	the	BTBs	with	the	E2	in	both	
WT	and	Cul3	KO	293	cells	as	demonstrated	with	RhoBTB3	and	UbE2E1	(Chapter	2,	
Figure	2.14).		This	method	would	allow	for	quick	detection	of	interactions	between	
BTB	and	E2	pairs.	
A	 second	method	 to	determine	 interactions	between	E2s	and	BTB	proteins	
would	be	 to	perform	a	yeast	 two-hybrid	screen	 in	which	each	E2	has	been	cloned	
into	 the	 ‘prey’	 library	vector	and	each	BTB	protein	 is	 cloned	 into	 the	 ‘bait’	 vector.		
Once	 the	 constructs	are	 completed,	 they	 can	be	 transformed	 into	S.	cerevisiae	 and	
checked	for	interactions	using	the	Matchmaker	Gold	two-hybrid	system	(Clontech).		
This	 method	 would	 be	 useful	 as	 it	 would	 be	 cost-effective	 and	 allow	 for	 the	
screening	of	many	potential	BTB-E2	pairs	simultaneously.	
Next,	it	will	be	necessary	to	explore	the	interactions	between	wild-type	Cul3	
and	Cul3Δ51-67	with	 the	different	E2	enzymes.	 	This	 can	be	done	easily	by	using	
immunoprecipitations	to	check	binding	between	thee	Cul3	constructs	and	different	
E2	enzymes.		It	would	be	best	to	complete	these	experiments	using	the	Cul3	KO	293	
cells	 in	 order	 to	 eliminate	 the	 endogenous	 Cul3	 from	 the	 binding	 assays.	 	 These	
experiments	 will	 help	 to	 further	 describe	 the	 binding	 between	 BTB	 proteins	 and	
different	E2s	as	well	as	helping	 to	 identify	which	E2s	might	be	utilized	by	Cul3	 to	
facilitate	 ubiquitination	 in	 vivo.	 	 This	 information	 will	 help	 to	 describe	 a	 novel	
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mechanism	 by	which	 BTB	 proteins	 help	 to	 determine	 the	 type	 of	 ubiquitin	 chain	
that	is	attached	to	various	Cul3	substrates.	
RESEARCH	QUESTION	5:		Do	changes	in	Nrf2	activity	affect	regulation	of	AQP2	
in	Cul3	conditional	knockout	or	Cul3Δ403-459	mice?	
	
One	well	 studied	 Cul3	 substrate	 is	 Nrf2	which	 is	 involved	 in	 the	 oxidative	
stress	 response	 (Kim	 and	Keum	2016).	 A	 recent	 study	 utilized	 a	mouse	model	 to	
show	that	Nrf2	is	responsible	for	regulating	AQP2	abundance	in	the	kidney	during	
development	and	increased	Nrf2	activity	during	embryonic	development	results	in	
misregulation	of	AQP2	and	diabetes	in	adult	animals	(Suzuki	et	al.	2017).		This	is	of	
interest	as	we	found	that	when	Cul3	deletion	in	the	kidneys	of	adult	mice	resulted	in	
reduced	AQP2	 levels	 (McCormick	 et	 al.	 2014).	 	 As	 discussed	 in	 chapter	 three,	 the	
animals	in	which	we	deleted	Cul3	were	adults,	so	it	is	unclear	if	Nrf2	played	a	role	in	
the	decreased	AQP2	expression	in	this	instance.	 	In	chapter	three,	possible	roles	of	
Cul3	 in	AQP2	 regulation	were	 discussed,	 including	 the	 effects	 that	 increased	Nrf2	
activity	during	development	might	have	on	AQP2	regulation.		This	section	will	focus	
on	 a	 new,	 two-part,	 research	 question	 related	 to	 this	 topic:	 	 How	 does	 the	
hypertension-causing	Cul3	mutation	(Cul3Δ403-459)	affect	the	levels	and	activity	of	
the	 Cul3	 substrate	 Nrf2	 during	 kidney	 development	 and	 AQP2	 expression	 during	
adulthood?	
In	 order	 to	 answer	 this	 question,	 it	 will	 be	 necessary	 to	 track	 kidney	
development	and	Nrf2	 levels	 in	mouse	embryos	that	are	either	wild-type	for	Cul3,	
deleted	or	hypomorphic	for	Cul3,	or	contain	the	hypertension-associated	mutation.		
Before	 measuring	 the	 effects	 of	 the	 hypertension	 mutation	 (Cul3Δ403-459	 in	
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humans),	it	will	be	necessary	to	track	normal	kidney	development	and	Nrf2	levels	in	
comparison	to	embryos	that	are	deficient	for	Cul3.		This	extra	step	will	be	necessary	
as	the	work	associating	the	misregulation	of	Nrf2	in	kidney	development	was	done	
using	a	Keap1	(BTB	protein)	mouse	model	(Suzuki	et	al.	2017),	so	no	direct	effect	of	
Cul3	Nrf2	in	embryonic	kidneys	has	yet	been	demonstrated.			
We	have	shown	 that	Cul3Δ403-459	 is	 capable	of	binding	BTB	proteins	and	
ubiquitinating	substrates	and	may	be	a	gain-of	function	Cul3	mutant	(McCormick	et	
al.	 2014).	 	 However,	 the	 effects	 of	 Cul3Δ403-459	 on	 individual	 substrates	 in	 vivo	
remain	mostly	unknown.		The	mechanism	by	which	Cul3	and	the	BTB-Kelch	protein	
Keap1	ubiquitinate	Nrf2	has	been	well	described,	providing	a	strong	framework	for	
a	 mechanistic	 comparison	 between	 wild-type	 Cul3	 and	 Cul3Δ403-459.	 	 	 	 A	 Cre-
inducible	 mouse	 model	 for	 the	 Cul3Δ403-459	 (also	 called	 Cul3Δ9)	 has	 been	
developed	 (Agbor	 et	 al.	 2016).	 	 This	 mouse	 model	 could	 be	 used	 to	 induce	
expression	of	Cul3Δ9	in	utero	to	track	kidney	development	in	the	knock-in	mice	in	
comparison	to	wild-type.		Levels	of	Nrf2	could	be	measured	in	order	to	determine	if	
Cul3-mediated	degradation	of	Nrf2	remains	unchanged	during	development	 in	 the	
Cul3Δ9	 animals.	 	 AQP2	 expression	 in	 the	 adult	 animals	 would	 also	 need	 to	 be	
quantified.	 	 If	 successful,	 these	 experiments	 could	 shed	 light	 on	 not	 only	 the	
potential	 role	 of	 Cul3Δ403-459	 in	 AQP2	 regulation	 in	 humans	 but	 also	 help	 to	
describe	the	ability	of	Cul3Δ403-459	to	ubiquitinate	substrates	when	compared	to	
wild-type	 Cul3.	 	 As	 previously	 mentioned,	 it	 will	 be	 necessary	 to	 determine	 the	
effects	of	loss	of	Cul3	on	Nrf2	in	mice	before	conducting	determining	the	effects	of	
the	 Cul3	 Δ403-459	 mutation.	 	 As	 Nrf2	 is	 known	 to	 be	 involved	 in	 a	 variety	 of	
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pathological	conditions	including	cancer	(Harder	et	al.	2015;	Holmstrom	et	al.	2016;	
Kim	and	Keum	2016;	Suzuki	et	al.	2017),	these	results	could	help	to	understand	the	
disease	 phenotype	 that	 is	 present	 in	 individuals	 carrying	 the	 Cul3Δ403-459	
mutation.	 	
FINAL	THOUGHTS	
	
Cul3-based	 E3	 ligase	 complexes	 are	 responsible	 for	 the	 regulation	 of	 a	
variety	of	cellular	pathways,	many	of	which	are	known	to	have	profound	effects	on	
the	proper	function	of	multicellular	organisms.		Moving	forward,	it	will	be	necessary	
to	 further	clarify	 the	role	of	Cul3	 in	 these	processes	 in	order	 to	better	understand	
the	 effects	 that	 Cul3	 has	 on	 human	 physiology.	 	 Chapter	 two	 describes	 a	 degron	
recognized	 by	 Cul3,	which	 is	 located	 in	 the	N-terminal	 region	 of	 cyclin	 E.	 	 Future	
work	 should	 attempt	 to	 locate	 Cul3	 degrons	 in	 other	 substrates	 in	 order	 to	
determine	if	those	degrons	resemble	the	one	found	in	cyclin	E.	
METHODS:	
	
Yeast	two-hybrid	screen:		The	yeast	two	hybrid	screen	was	performed	using	LRR5	
(fibromodulin)	 as	 bait	 with	 the	 Matchmaker	 yeast	 two	 hybrid	 system,	 the	 same	
system	used	for	one	of	the	Klhl3	screens	in	Chapter	three.		The	human	testis	library	
(also	used	for	chapter	3)	was	used	for	this	screen.	
Immunofluorescence:	 	 Immunofluorescence	 was	 performed	 as	 previously	
described	 in	 both	 chapter	 two	 and	 previous	work	 from	 our	 lab	 (Cummings	 et	 al.	
2009).	
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Cell	 culture,	 transfections,	western	 blots	 and	 immunoprecipitations:	 	All	 cell	
culture	 work	 utilizing	 HeLa	 and	 293	 cell	 lines	 was	 performed	 as	 described	 in	
Chapters	 two	and	 three.	 	The	Myc-tagged	TG	construct	was	a	gift	 from	Dr.	Robert	
Sheaff	at	the	University	of	Tulsa.	 	Dansyl-cadaverine	was	added	to	the	appropriate	
cells	(Figure	4.9)	at	a	final	concentration	of	1mM	to	inhibit	TG	activity.		For	cyclin	E	
experiments	 involving	 TG2,	 the	 monoclonal	 cyclin	 E	 antibody	 HE12	 (Santa	 Cruz	
Biotechnology)	was	utilized.	
Transglutaminase	 incubation:	 	 Untransfected	 WT	 and	 Cul3	 KO	 293	 cells	 were	
harvested	 in	 Lysis	 buffer	 and	 sonicated.	 	 Lysates	 were	 then	 incubated	 for	 15	
minutes	in	a	37	degree	water	bath	with	varying	amounts	of	commercial,	food-grade	
transgluaminase	enzyme	at	a	concentration	of	50mg/mL.		Following	incubation,	the	
lysates	 were	 mixed	 with	 sample	 buffer,	 boiled,	 and	 ran	 on	 10	 percent	
polyacrylamide	gels	 for	western	blotting.	 	Western	blots	were	probed	using	either	
the	monoclonal	cyclin	E	antibody	HE-12	(Santa	Cruz	Biotechnology)	or	a	polyclonal	
cyclin	A	antibody	 (H-432,	 Santa	Cruz	Biotechnology).	 	We	would	 like	 to	 thank	Dr.	
Robert	Sheaff	at	University	of	Tulsa	for	the	TG	enzyme	and	protocol.	
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